clarithromycin has been researched along with zithromax in 619 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (0.81) | 18.7374 |
| 1990's | 195 (31.50) | 18.2507 |
| 2000's | 194 (31.34) | 29.6817 |
| 2010's | 182 (29.40) | 24.3611 |
| 2020's | 43 (6.95) | 2.80 |
| Authors | Studies |
|---|---|
| Berger, CM; Froshauer, SA; Hayashi, SF; Hecker, SJ; Jaynes, BH; Jefson, MR; Kamicker, BJ; Lipinski, CA; Lundy, KM; McFarland, JW; Reese, CP; Vu, CB | 1 |
| Agouridas, C; Auger, JM; Benedetti, Y; Bonnefoy, A; Bretin, F; Chantot, JF; D'Ambrières, SG; Denis, A; Dussarat, A; Fromentin, C; Lachaud, S; Laurin, P; Le Martret, O; Loyau, V; Tessot, N | 1 |
| Agouridas, C; Auger, JM; Benedetti, Y; Bonnefoy, A; Bretin, F; Chantot, JF; D'Ambrières, SG; Denis, A; Dussarat, A; Fromentin, C; Lachaud, S; Laurin, P; Le Martret, O; Loyau, V; Pejac, JM; Perron, S; Tessot, N | 1 |
| Agouridas, C; Bonnefoy, A; Bonnet, A; Bretin, F; Denis, A; Fromentin, C; Piltan, G | 1 |
| Alder, J; Brazzale, A; Cao, Z; Chu, DT; Clark, RF; Ewing, P; Flamm, R; Griesgraber, G; Li, L; Ma, Z; Meulbroek, J; Mitten, M; Nemoto, PA; Nilius, AM; Or, YS; Phan, LT; Plattner, JJ; Rupp, MJ; Shortridge, VD; Wang, S; Yong, H; Zhang, S; Zhang, X; Zhong, P | 1 |
| Asaka, T; Kameo, K; Kashimura, M; Morimoto, S; Nishida, A; Sato, M; Sugiyama, H; Suzuki, K; Tanikawa, T | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Appelbaum, PC; Credito, KL; DeWasse, B; Kosowska-Shick, K; McGhee, P; Pankuch, GA | 1 |
| Klugman, KP; Low, DE; Smith, AM; Wolter, N | 1 |
| Aralar, P; Baimukanova, G; Bermudez, LE; Chee, C; Inderlied, C; Kolonoski, P; Motamedi, N; Phan, LT; Wang, G; Young, LS | 1 |
| Kasahara, K; Kita, E; Mikasa, K; Mizuno, F; Nishi, K; Yasuda, Y | 1 |
| Baba, S; Billal, DS; Fujihara, K; Hotomi, M; Nishimura, T; Suzuki, K; Yamanaka, N | 1 |
| Appelbaum, PC; Clark, CL; Ednie, LM; Kosowska-Shick, K | 1 |
| Chiba, N; Hasegawa, K; Iwata, S; Matsubara, K; Morozumi, M; Nakayama, E; Sunakawa, K; Takayanagi, R; Ubukata, K | 1 |
| Campbell, BJ; Edwards, SW; Hart, CA; Martin, HM; Rhodes, JM; Roberts, CL; Subramanian, S | 1 |
| Bailey, M; Chettiath, T; Mankin, AS | 1 |
| Beckius, ML; Fraser, SL; Galloway, RL; Griffith, ME; Hospenthal, DR; Mende, K; Miller, RS; Murray, CK; Pimentel, G; Ressner, RA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Apajalahti, J; Fox, J; Frimodt-Møller, N; Hansen, F; Loidl, G; Nagai, J; Siikanen, O; Takano, M; Vaara, M; Vaara, T | 1 |
| Esteban, J; Fernández-Martínez, AI; Fernández-Roblas, R; Gadea, I; García-Almeida, D; Martín-de-Hijas, NZ | 1 |
| Bohnert, JA; Fähnrich, E; Kern, WV; Schuster, S; Wehmeier, C | 1 |
| Connell, TG; Curtis, N; Ritz, N; Robins-Browne, R; Sievers, A; Tebruegge, M | 1 |
| Cui, L; Hiramatsu, K; Neoh, HM; Shoji, M | 1 |
| Jiang, LJ; Or, YS; Wang, M | 1 |
| Jiao, B; Liu, Z; Lou, H; Ma, S; Wang, H; Xian, R; Zheng, M | 1 |
| Blackman Northwood, J; Coley, MD; Cossins, LR; Creti, R; Del Grosso, M; Farrell, DJ; Pantosti, A | 1 |
| Beeton, ML; Chalker, VJ; Kotecha, S; Maxwell, NC; Spiller, OB | 1 |
| Li, W; Liu, Y; Wang, M; Xu, X; Ye, X; Zhang, H; Zhu, D | 2 |
| Appelbaum, PC; Ednie, LM; Kosowska-Shick, K; McGhee, P | 1 |
| Liu, Z; Ma, C; Ma, R; Ma, S; Shen, X | 1 |
| Chen, XZ; Jin, ZP; Lei, PS; Li, Y; Liu, J; Liu, L; Wang, GQ; Xu, P | 1 |
| Lemaire, S; Tulkens, PM; Van Bambeke, F | 1 |
| Gaillard, JL; Jackson, M; McDonnell, G; Niederweis, M; Skovierová, H; Svetlíková, Z | 1 |
| Hamasuna, R; Jensen, JS; Osada, Y | 1 |
| Appelbaum, PC; Beachel, L; Clark, C; Dewasse, B; Kosowska-Shick, KM; McGhee, P; Nagai, K | 1 |
| Furuie, H; Saisho, Y; Shimada, J; Yoshikawa, T | 1 |
| Li, H; Li, Z; Liu, Z; Lu, Y; Ma, S; Song, L; Zhang, L | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Hakanen, AJ; Huovinen, P; Kotilainen, P; Lehtopolku, M; Nakari, UM; Siitonen, A | 1 |
| Hammerschlag, MR; Kohlhoff, SA; Parker, C; Roblin, PM | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Shakya, T; Wright, GD | 1 |
| Liu, Y; Sun, FJ; Wang, Q; Xia, PY; Xie, LL; Xiong, LR | 1 |
| An, K; Li, XL; Liang, JH; Wang, H; Wang, YY; Xu, YC; Yao, GW | 2 |
| Dal-Ré, R; García-de-Lomas, J; García-Delafuente, C; Iriarte, V; Martín-Herrero, JE; Mazón, A; Pérez-Trallero, E; Robles, P | 1 |
| Cao, J; Ju, Y; Ma, R; Ma, S; Xian, R; Zhang, L | 1 |
| Apajalahti, J; Fox, J; Frimodt-Møller, N; He, H; Li, J; Nation, RL; Poudyal, A; Siikanen, O; Vaara, M; Vaara, T | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Guo, H; He, X; Hu, H; Hu, X; Lu, Y; Luo, M; Pan, Y; Qiu, G; Wu, Z; Xiao, Y; Yang, J; Zhou, D | 1 |
| Chiba, N; Ida, T; Kishii, K; Morozumi, M; Ono, A; Ubukata, K | 1 |
| Bohnert, JA; Karamian, B; Nikaido, H | 1 |
| Biedenbach, DJ; Castanheira, M; Jones, RN | 1 |
| An, K; Dong, LJ; Li, XL; Liang, JH; Wang, H; Xu, YC; Yang, L; Yao, GW | 1 |
| Alihodzić, S; Andreotti, D; Berge, JM; Cipcić Paljetak, H; Derek, M; Dumić, M; Eraković Haber, V; Fajdetić, A; Holmes, DJ; Hutinec, A; Lazarevski, G; Lociuro, S; Marsić, N; Mutak, S; Spaventi, R; Stimac, V; Sunjić, V | 1 |
| Biedenbach, DJ; Hammerschlag, MR; Jones, RN; Kohlhoff, SA; Roblin, PM | 1 |
| Alihodzić, S; Antolović, R; Broskey, JP; Cipcić Paljetak, H; Eraković Haber, V; Holmes, DJ; Hunt, E; Jarvest, RL; Kapić, S | 1 |
| Glen, RC; Lowe, R; Mitchell, JB | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Baldelli, R; Cevenini, R; D'Antuono, A; Delucca, F; Di Francesco, A; Donati, M; Moroni, A; Shurdhi, A | 1 |
| Cui, W; Jiao, B; Ju, Y; Liu, L; Ma, C; Ma, R; Ma, S; Ma, X; Meng, Y; Qi, Y; Shen, X; Wang, H; Zhang, L; Zheng, M | 1 |
| Butković, K; Ćaleta, I; Dukši, M; Hlevnjak, M; Koštrun, S; Kragol, G; Makaruha-Stegić, O; Malnar, I; Mikac, L; Munić, V; Ralić, J; Stepanić, V; Tatić, I; Tavčar, B; Valko, K; Zulfikari, S | 1 |
| Boothroyd, JC; Choi, JY; Fu, H; Harvey, C; Khosla, C; Lee, Y; Ravindran, S; Roush, WR | 1 |
| Cao, J; Cong, C; Hu, Y; Li, X; Liu, C; Ma, S; Wang, H | 1 |
| Alihodžić, S; Berge, J; Brajša, K; Cipčić Paljetak, H; Fajdetić, A; Holmes, DJ; Ilijaš, M; Kapić, S; Palej Jakopović, I; Stimac, V | 1 |
| Bhateja, P; Chakrabarti, A; Das, B; Dullu, J; Hajare, AK; Jadhav, JS; Kumar, R; Pandya, M; Ramkumar, G; Rathy, S; Surase, YB; Venkataramanan, R | 1 |
| Alihodžić, S; Čipčić Paljetak, H; Jakopović, IP; Kragol, G; Krajačić, MB; Pešić, D; Skugor, MM; Stimac, V; Vujasinović, I | 1 |
| Kaneda, Y; Manaka, A; Nanaumi, K; Shimazaki, Y; Sugimoto, T; Sugiyama, H; Suzuki, K; Tanikawa, T; Yamasaki, Y | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| An, K; Cushman, M; Liang, JH; Lv, W; Wang, H; Xu, YC | 1 |
| Li, X; Ma, S; Wang, Y; Yan, M | 1 |
| An, K; Cushman, M; Li, XL; Liang, JH; Lv, W; Wang, H; Xu, YC | 1 |
| Inagaki, H; Kitamura, T; Komoriya, S; Kuroyanagi, J; Miyauchi, RN; Nagamochi, M; Odagiri, T; Sugimoto, Y; Takahashi, H | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Kimmins, S; Mutak, S; Pavlović, D | 1 |
| Jia, L; Ma, R; Ma, S; Venter, H; Yan, M | 1 |
| Alihodžić, S; Dragojević, S; Koštrun, S; Malnar, I; Matanović Škugor, M; Munic Kos, V; Palej Jakopović, I; Ralić, J | 1 |
| Chai, WC; Cong, C; Dong, R; Jia, L; Ma, S; Song, D; Wang, Y; Zhou, Z | 1 |
| Jia, L; Ma, S; Qiang, S; Qin, Y; Shen, Y; Yan, M | 1 |
| Barreca, ML; Cannalire, R; Cecchetti, V; Couto, I; Felicetti, T; Machado, D; Manfroni, G; Massari, S; Sabatini, S; Santos Costa, S; Tabarrini, O; Viveiros, M | 1 |
| Hu, C; Jia, L; Ma, S; Qin, Y; Sheng, J; Wang, Y | 1 |
| Hu, C; Ji, S; Liu, Z; Ma, S; Qiang, S; Qin, Y | 1 |
| Blanco, MJ; Edmondson, Q; Furukawa, A; Handford, MJ; Hewitt, WM; Kelly, CN; Klein, VG; Lokey, RS; Ly, AM; Naylor, MR; Noland, RP; Pye, CR; Ramos, DP; Schwochert, J; Townsend, CE; Turmon, AC | 1 |
| Cushman, M; Fan, BZ; Han, X; Kong, FS; Li, YX; Liang, JH; Lv, W; Ma, CX; Tian, JC | 1 |
| Cushman, M; Fan, BZ; Guo, SY; Kong, FS; Li, XM; Li, YX; Liang, JH; Lv, W; Zhang, J | 1 |
| Bi, F; Liu, Z; Ma, R; Ma, S; Qin, Y; Teng, Y; Zhang, P | 1 |
| Bertrand, D; Fernandes, P; Pereira, D; Watkins, PB | 1 |
| Liu, X; Ma, S; Ma, Y; Qin, Y; Song, D; Teng, Y; Zhang, P | 1 |
| Aldrich, C; Brody, S; Cushman, M; Fan, BZ; Hiasa, H; Liang, JH; Lv, W; Yang, ZY | 1 |
| Bai, B; Bi, F; Ma, S; Qin, Y; Teng, Y | 1 |
| Ma, P; Qin, Y; Teng, Y; Wang, Y; Xu, L; Yang, Y | 1 |
| Neu, HC | 1 |
| Danziger, LH; Piscitelli, SC; Rodvold, KA | 1 |
| Brown, BA; De Rosas, V; Onyi, GO; Wallace, RJ | 1 |
| Bahal, N; Nahata, MC | 1 |
| Havlichek, DH; Stein, GE | 1 |
| Tunkel, AR; Whitman, MS | 1 |
| Hammerschlag, MR; Qumei, KK; Roblin, PM | 1 |
| Hedderich, J; Heim, P; Paulsen, P; Peters, O; Simon, C | 1 |
| Stott, GA | 1 |
| Chin, NX; Gu, JW; Neu, HC | 1 |
| Cynamon, MH; Klemens, SP | 3 |
| Peltier, K | 1 |
| Gelber, RH; Murray, LP; Siu, P; Tsang, M | 1 |
| Felmingham, D; Leakey, A; Ridgway, GL; Robbins, MJ; Sanghrajka, M | 1 |
| Gikas, A; Grosset, J; Perronne, C; Pocidalo, JJ; Truffot-Pernot, C; Vilde, JL | 1 |
| Bébéar, C; Renaudin, H | 1 |
| Chastang, C; Derouin, F | 1 |
| Wise, R | 1 |
| Gross, B; Preac-Mursic, V; Schierz, G; Süss, E; Wilske, B | 1 |
| Eichhorn, A; Hoppe, JE | 1 |
| Chang, HR; Pechère, JC | 1 |
| Barry, AL; Jones, RN; Thornsberry, C | 1 |
| Abruzzo, GK; Bartizal, K; Flattery, AM; Gill, CJ; Jackson, J; Kong, L; Kropp, H; Shankaran, K; Smith, JG; Wilkening, R | 1 |
| Kaye, KM; Zuckerman, JM | 1 |
| Mouton, RP; Sloos, JH; Van Asselt, GJ; Van Boven, CP; Van de Klundert, JA | 1 |
| Appelbaum, PC; Jacobs, MR; Spangler, SK | 2 |
| Barry, AL; Brown, SD; Fuchs, PC | 5 |
| Debets-Ossenkopp, YJ; MacLaren, DM; Namavar, F | 1 |
| Bow, LM; Nicolau, DP; Nightingale, CH; Onyeji, CO; Tessier, PR | 1 |
| Delia, S; Iona, E; Mascellino, MT; Mastroianni, CM; Ponzo, R | 1 |
| Cars, O; Löwdin, E; Odenholt-Tornqvist, I | 1 |
| Currier, JS; Davis, RB; Ives, DV | 1 |
| Nilsen, OG | 1 |
| Fanti, D; Fraioli, P; Magliano, E; Montanari, G; Montemurro, L; Pozzoli, R; Rizzato, G | 1 |
| Schlossberg, D | 1 |
| Goodman, NL; McCraney, SA; Rapp, RP; Shaddick, DJ | 1 |
| Doern, GV; Erwin, ME; Gerlach, EH; Hindler, J; Jones, RN | 1 |
| Hughes, WT; Killmar, JT; Oz, HS | 1 |
| Cynamon, MH; Grossi, MA; Klemens, SP | 1 |
| Irifune, K; Ishida, K; Kaku, M; Mizukane, R; Suyama, N; Takemura, H; Tanaka, H; Tomono, K; Usui, T; Yoshida, R | 1 |
| Heifets, L; Mor, N; Vanderkolk, J | 1 |
| Wolinsky, E | 1 |
| Barza, M; Eisenberg, E | 1 |
| Parent, M | 1 |
| Rodriguez, WJ; Wiedermann, BL | 1 |
| Guglielmo, BJ; Kanatani, MS | 1 |
| Bustos, R; Herrera, N; Marinkovic, K; Prado, V; Romero, J | 1 |
| Benson, CA | 1 |
| Barbour, AG; Dever, LL; Jorgensen, JH | 1 |
| Courdil, M; Escaffre, MC; Lareng, MB; Lefèvre, JC | 1 |
| Fass, RJ | 1 |
| Gage, TW | 1 |
| Holdcroft, C | 1 |
| Vaara, M | 1 |
| Hammerschlag, MR | 2 |
| Eliopoulos, GM; Ferraro, MJ; Malanoski, GJ; Moellering, RC | 1 |
| Ikerd, TR; Koletar, SL | 1 |
| Ellis, W; Fayer, R | 1 |
| Guzmán, CA; Molinari, G; Pesce, A; Schito, GC | 1 |
| Müller, O | 1 |
| Bradbury, F | 1 |
| Baskerville, A; Fitzgeorge, RB; Lever, S | 1 |
| Cimochowski, CR; Faiella, JA; Girard, AE | 1 |
| Cluzel, R; Philippon, A; Soussy, CJ | 1 |
| Pocidalo, JJ; Veber, B | 1 |
| Inderlied, CB; Nash, KA | 2 |
| Young, LS | 1 |
| McCutchan, JA | 1 |
| Apseloff, G; Fluids, G; Kraut, E; LaBoy-Goral, L; Vincent, J | 1 |
| Gaydos, C; Quinn, TC; Welsh, L | 1 |
| Barrett, MS; Jones, RN; Mehaffey, PC; Putnam, SD | 1 |
| Conte, JE; Duncan, S; Golden, J; Lin, E; McKenna, E; Zurlinden, E | 1 |
| Appelbaum, PC; Ednie, LM; Jacobs, MR; Visalli, MA | 1 |
| Carpentier, M; Delmée, M; Glupczynski, Y; Gordts, B; Magerman, K; Simon, A; Surmont, I; Van de Vyvere, M; Van Landuyt, H; Van Nimmen, L; Van Noyen, R | 1 |
| Fujita, J; Hojo, S; Kawanishi, K; Negayama, K; Takahara, J; Xu, G; Yamaji, Y; Yuube, K | 1 |
| McLinn, S; Williams, D | 1 |
| el Menyawi, I; Graninger, W; Parschalk, B; Weihs, A; Wenisch, C; Zedtwitz-Liebenstein, K | 1 |
| Laufen, H; Yeates, RA; Zimmermann, T | 1 |
| Tuominen, RK; Vainio, PJ; Viluksela, M | 1 |
| Furuya, N; Ishii, Y; Matsumoto, T; Matsunaga, T; Miyazaki, S; Nagashima, M; Ohno, A; Tateda, K; Yamaguchi, K | 1 |
| Nightingale, CH; Patel, KB; Quintiliani, R; Russomanno, JH; Tessier, PR; Xuan, D | 1 |
| Citron, DM; Claros, MC; Goldstein, EJ; Hunt Gerardo, S | 1 |
| Abdel-Rahman, SM; Nahata, MC; Wintermeyer, SM | 1 |
| Kapell, K; Meyer, P; Segreti, J | 1 |
| Grayston, JT; Jackson, LA; Kuo, CC; Lee, A | 1 |
| Aoyama, T; Fujii, R; Iwata, S; Sunakawa, K; Takeuchi, Y | 1 |
| Itzhaki, A; Keren, G; Keysary, A; Oron, C; Rubinstein, E | 1 |
| Brown, BA; Griffith, DE; Wallace, RJ | 1 |
| Cammarota, G; Cuoco, L; Fedeli, G; Gasbarrini, G; Montalto, M; Papa, A; Tursi, A; Veneto, G | 1 |
| Bozzola, L; Di Mario, F; Franceschi, M; Leandro, G; Pilotto, A; Scagnelli, M; Soffiati, G; Valerio, G | 1 |
| Nelson, MR; Pozniak, A | 1 |
| Anderson, R; Feldman, C; Theron, AJ | 1 |
| Berg-Candolfi, M; Candolfi, E | 1 |
| Fietta, A; Gialdroni Grassi, G; Merlini, C | 2 |
| Klein, JO | 2 |
| McCracken, GH | 1 |
| Nightingale, CH | 1 |
| Tarlow, MJ | 1 |
| Block, SL | 1 |
| Block, SL; Harris, J; Kolokathis, A; Tarlow, MJ | 1 |
| Engstrand, L; Gustafsson, I; Hultén, K; Rigo, R | 1 |
| Andrews, JM; Boswell, F; Brenwald, NP; Wise, R | 1 |
| Beyer, JM; Flamm, RK; Nilius, AM; Tanaka, SK | 1 |
| Danziger, LH; Gotfried, MH; Rodvold, KA; Servi, RJ | 1 |
| Brookings, E; Gray, B; Swiatlo, E; Waites, K | 1 |
| Hoppe, JE; Tschirner, T | 1 |
| Brandt, CM; Miro, JM; Patel, R; Rouse, MS; Steckelberg, JM; Wilson, WR | 1 |
| Barbarini, D; Bono, L; Carretto, E; Marone, P; Telecco, S | 1 |
| Appelbaum, PC; Jacobs, MR; Visalli, MA | 2 |
| Brettle, RP | 1 |
| Appelbaum, PC; Ednie, LM; Jacobs, MR | 2 |
| Muszynski, MJ; Rajyaguru, JM | 1 |
| Chen, C; Danziger, LH; Martin, SJ; Pendland, SL; Schreckenberger, PC | 1 |
| Dautzenberg, B | 1 |
| Cohn, DL | 1 |
| Iino, S; Iwasawa, H; Nakashio, S; Shimada, J | 1 |
| Fujioka, T; Hasegawa, M; Kobayashi, I; Nasu, M; Nishida, M; Saika, T | 1 |
| Burdine, R; Champney, WS | 2 |
| Anderson, R; Cole, PJ; Feldman, C; Ramafi, G; Theron, AJ; Wilson, R | 1 |
| Bermudez, LE; Kolonoski, P; Petrofsky, M; Young, LS | 1 |
| Laufen, H; Schumacher, T; Yeates, RA; Zimmermann, T | 1 |
| Holmberg, SD; Loveless, MO; Moorman, AC; Navin, TR; Palella, FJ; Von Bargen, JC; Ward, DJ | 1 |
| Bukstein, D; Hahn, DL; Luskin, A; Zeitz, H | 1 |
| Abbasciano, V; Caselli, M; Ruina, M; Sartori, S; Trevisani, L; Verdianelli, G | 1 |
| Amsden, GW; Kashuba, AD | 1 |
| Leri, O; Losi, T; Mastropasqua, M; Perinelli, P; Tubili, S | 1 |
| Arnold, B; Stout, JE; Yu, VL | 1 |
| Mizutani, S | 1 |
| Bryskier, A; Hoppe, JE | 1 |
| Rossoni, G; Scaglione, F | 1 |
| Citron, DM; Goldstein, EJ; Hudspeth, M; Hunt Gerardo, S; Merriam, CV | 1 |
| Appelbaum, PC; Jacobs, MR; Lin, G; Spangler, SK | 1 |
| Inoue, K; Matsuo, H; Sakamoto, Y; Sakata, K; Shibazaki, M; Tanaka, K | 1 |
| Kobayashi, H; Kobayashi, O; Ota, M; Watanabe, H | 1 |
| Hara, N; Nakanishi, Y; Takano, K; Takayama, K; Tsuruta, N; Wakamatsu, K; Yanami, J | 1 |
| Inoue, K; Matsuo, H; Nishi, Y; Sakamoto, Y; Sakata, K; Shibazaki, M | 1 |
| Gunawan, J; Mangunnegoro, H; Soepandi, P; Yunus, F | 1 |
| Bayoumi, AM; Redelmeier, DA | 1 |
| Alder, JD; Ewing, PJ; Jarvis, K; Mitten, M; Nilius, AM; Oleksijew, A; Paige, L; Tanaka, SK; Tovcimak, A | 1 |
| Barg, N | 1 |
| Apseloff, G; Foulds, G; LaBoy-Goral, L; Vincent, J; Willavize, S | 1 |
| Counihan, M; Duan, SX; Durol, AL; Graf, JA; Greenblatt, DJ; Harmatz, JS; Mertzanis, P; Shader, RI; von Moltke, LL; Wright, CE | 1 |
| Bouchillon, S; Johnson, J; Pontani, D; Washton, H | 1 |
| Evans, TG; Heifets, L; Huycke, M; Kauffman, C; Rimland, D; Ward, TT | 1 |
| Bryan, E; McFarland, J; Sackoff, J; Su, S | 1 |
| Berry, V; Knott, SJ; Thorburn, CE; Woodnutt, G | 1 |
| Hogan, PA; Sheehan, DJ | 1 |
| Lacy, MK; Nicolau, DP; Nightingale, CH; Owens, RC; Quintiliani, R; Xu, X | 1 |
| Blandino, G; Carbone, M; Ciliberti, FA; Cusumano, V; De Sarro, A; De Sarro, GB; Fera, MT; Riggio, G | 1 |
| Esposito, S; Principi, N | 1 |
| Muller, O; O'Doherty, B | 1 |
| Calhoun, J; Mader, JT; Shirtliff, ME | 1 |
| Ong, EL | 1 |
| Cheybani, K; Estrada, R; Laine, L; Neil, G; Smith, S; Trujillo, M; Yeramian, P | 1 |
| Amsden, GW | 2 |
| Araujo, FG; Khan, AA; Remington, JS; Slifer, TR | 1 |
| Amsden, GW; Garey, KW; Godo, PG; Nafziger, AN; Peloquin, CA | 1 |
| Bergman, KL; Fey, PD; Olsen, KM; Peddicord, TE; Rupp, ME | 1 |
| Carbon, C; Poole, MD | 1 |
| Alvarez-Elcoro, S; Enzler, MJ | 1 |
| Holloway, WJ; Stark, K; Steele-Moore, L | 1 |
| Dart, JK; Horgan, SE; Matheson, MM; McLOUGHLIN-Borlace, L | 1 |
| Neiger, R; Schmassmann, A; Seiler, G | 1 |
| Hill, SL; Johnson, MM; Piddock, LJ | 1 |
| Appelbaum, PC; Credito, KL; Ednie, LM; Jacobs, MR | 1 |
| Bucher, HC; Craig, BA; Gafni, A; Pfluger, D; Sendi, PP | 1 |
| Bui, KQ; Li, C; McNabb, J; Nicolau, DP; Nightingale, CH | 1 |
| Moore, PA | 1 |
| Furuta, T; Yoshida, H | 1 |
| Frimpong, EK; Honda, T; Voravuthikunchai, SP; Yoh, M | 1 |
| Citron, DM; Goldstein, EJ; Merriam, CV; Tyrrell, K; Warren, Y | 1 |
| Carnuccio, R; D'Acquisto, F; Di Rosa, M; Ialenti, A; Ianaro, A; Iuvone, T; Maffia, P; Rombolà, L; Sautebin, L | 1 |
| Burgess, DS; Hastings, RW; Horan, JL | 1 |
| Ivandić, A; Pezerović, D; Stimac, D; Takac, B; Vcev, A; Vceva, A | 1 |
| Inoue, K; Kimura, K; Mizukoshi, T; Nishi, Y; Sakamoto, Y; Sakata, K; Shibazaki, M | 1 |
| Goss, TF; Najib, MM; Stein, GE | 1 |
| Zuckerman, JM | 2 |
| Bermudez, LE; Miltner, EC | 1 |
| Craven, DE; Freedberg, KA; Losina, E; Paltiel, AD; Scharfstein, JA; Seage, GR; Weinstein, MC | 1 |
| Hanada, E; Iga, T; Kotaki, H; Ohtani, H; Sato, H; Sawada, Y; Taninaka, C | 1 |
| Westphal, JF | 1 |
| D'Aprile, M; Kuper, JI | 1 |
| Cohen, MS; Gilligan, P; Kelley, MA; Weber, DJ | 1 |
| Benner, R; Bissett, J; Boulos, M; Cahn, P; Dickenson, G; Dunne, M; Fessel, J; Green, S; Hicks, C; Keiser, P; Kumar, P; Lewi, D; Mogyros, M; O'Connor, M; Schneider, MM; Tilles, J; White, AC | 1 |
| Amábile-Cuevas, CF; Hermida-Escobedo, C; Vivar, R | 1 |
| Denys, GA; Kays, MB | 1 |
| Dan, M; Rosenberg, S; Samra, Z; Soffer, Y | 1 |
| Schooley, S; Stein, GE | 1 |
| Craft, JC; Gooch III, WM; Kaplan, EL; Notario, GF | 1 |
| Benson, C | 1 |
| Cheng, B | 1 |
| Prescott, LM | 1 |
| Currier, J | 1 |
| Torres, G | 1 |
| Schouten, JT; Whittemore, S | 1 |
| Griffith, DE; Kurdowska, A; Noble, JM | 1 |
| Almer, L; Beyer, J; Bui, MH; Flamm, RK; Hensey-Rudloff, D; Ma, Z; Nilius, AM; Or, YS | 1 |
| Ishii, H; Ishimatsu, Y; Iwashita, T; Kaida, H; Kawano, S; Monden, J; Nagata, T; Sukuwa, C | 1 |
| Bouvet, A; Broc, V; Merad, B; Rostane, H; Schlegel, L | 1 |
| Fujikawa, T; Matsumoto, T; Miyazaki, S; Tateda, K; Yamaguchi, K | 1 |
| Adali, MK; Karasalihoglu, AR; Koten, M; Uzun, C; Yagiz, R; Yorulmaz, F | 1 |
| Appelbaum, PC; Bryskier, A; Davies, TA; Ednie, LM; Jacobs, MR; Nagai, K; Palavecino, E | 1 |
| Barthélemy, P; Caekaert, A; Fléjou, JF; Laurent, J; Mégraud, F | 1 |
| Alarcón, T; Baquero, M; Carbó, J; García-Samaniego, J; Iñiguez, A; López-Brea, M; Toro, C | 1 |
| Antinori, S; Cascio, A; Colomba, C; Paterson, DL; Titone, L | 1 |
| Hammerschlag, MR; Kutlin, A; Roblin, PM | 1 |
| Ishii, Y; Kobayashi, T; Matsumoto, T; Miyazaki, S; Tateda, K; Yamaguchi, K | 1 |
| Gaylor, AS; Reilly, JC | 1 |
| Amsden, GW; Kuye, O; Wei, GC | 1 |
| Bathgate, T; King, A; Phillips, I | 1 |
| Anatoliotaki, M; Anatoliotakis, N; Apostolakou, H; Kontoyiannis, DP; Maraki, S; Margioris, AN; Samonis, G; Tselentis, Y | 1 |
| Chimura, T | 1 |
| Florijn, A; Hoepelman, IM; Krijnen, RM; Matute, AJ; Rozenberg-Arska, M; Schurink, CA | 1 |
| Brown-Elliott, BA; Couch, L; Girard, WM; Griffith, DE; Mann, L; Wallace, RJ; Wilson, RW; Yakrus, MA; Zhang, Y | 1 |
| Blondeau, JM | 1 |
| Sugiyama, Y | 1 |
| Fukuno, Y; Hayashi, S; Kawashima, M; Nagata, M; Tominaga, M; yatsunami, J | 1 |
| Appelbaum, PC; Bozdogan, B; Clark, C; Dewasse, B; Jacobs, MR; Peric, M | 1 |
| Kanai, H; Maizumi, N; Tamura, Y; Tsutsui, T | 1 |
| Biertz, J; Breithardt, G; Bruns, HJ; Eckardt, L; Fabritz, L; Fleischer, D; Haverkamp, W; Kirchhof, P; Milberg, P; Ramtin, S; Reinsch, N | 1 |
| Coyle, W; Dunteman, T; Nemec, R; Sullivan, B | 1 |
| Barsić, B; Cajić, V; Krhen, I; Mareković, I; Markovinović, L; Roglić, S; Schönwald, S; Skerk, V; Vince, A; Zeljko, Z | 1 |
| Eiros, JM; Mayo, A; Pastor, E | 1 |
| Freudenstein, J; Hauke, W; Henneicke-Von Zepelin, HH; Köhler, G | 1 |
| Doern, GV; Ernst, EJ; Hoffman, HL; Klepser, ME; Petzold, CR; Sa'adah, LM | 1 |
| Aralar, P; Brown-Elliott, BA; Conville, PS; Hall, G; Inderlied, C; Plaunt, M; Wallace, RJ; Williams-Bouyer, N; Witebsky, FG; Woods, GL | 1 |
| Cabria, F; Esteban, J; Fernández-Roblas, R; Gadea, I; Rollan, E; Santos-O'Connor, FG; Soriano, F; Torres, MV | 1 |
| Appelbaum, PC; Bozdogan, B; Jacobs, MR; Peric, M | 1 |
| Katouno, Y; Kobayashi, Y; Sugita, K; Uchida, H | 1 |
| Abe, S; Inoue, S; Nakamura, H; Otake, K; Sada, M; Takeda, H | 1 |
| Hamdan, II | 1 |
| Malcolm, C; Marrie, TJ | 1 |
| Cascio, A; Colomba, C | 1 |
| Giguère, S; Jacks, SS; Nguyen, A | 1 |
| Kusaba, N; Yoshida, H | 1 |
| García, E; González, J; Marco, F; Marcos, MA; Martínez, JA; Mensa, J; Sánchez, F; Soriano, A; Torres, A | 1 |
| Friedman, H; Yamaguchi, H; Yamamoto, M; Yamamoto, Y; Yasuda, K | 1 |
| Ito, K; Itoh, T; Kanamitsu, S; Ogihara, K | 1 |
| Schöni, MH | 1 |
| Itoh, Y; Kikuchi, K; Nakanishi, K; Nakao, S; Ohsaki, Y; Osanai, S; Saito, K; Sato, M; Tachibana, M; Takahashi, T; Toyoshima, E | 1 |
| Fujiki, Y; Iyobe, S; Okubo, T; Sagai, H | 1 |
| Hasegawa, M; Kobayashi, I; Matsuzaki, K; Sato, Y; Shikano, M; Watabe, E; Yamanaka, N; Yoshimori, K | 1 |
| Allen, M; Callaghan, R | 1 |
| Muhlestein, JB | 1 |
| Nishi, Y; Sakamoto, Y; Sakata, N; Shibasaki, M; Shimono, N | 1 |
| Inoue, K; Kumakura, S; Tsutsui, T; Uchida, M | 1 |
| Baysallar, M; Doğanci, L; Gür, D; Senses, Z | 1 |
| Martínez-Vázquez, C; Rodríguez-Suárez, JR; Sabrià, M; Segura, F; Sopena, N; Valencia, A | 1 |
| Colombo, A; De Vecchi, E; Drago, L; Gismondo, MR; Nicola, L | 1 |
| Kadota, J; Kishi, K; Mizunoe, S; Nagai, H; Nasu, M; Tokimatsu, I | 2 |
| Scheinfeld, NS; Torres, O; Tutrone, WD; Weinberg, JM | 1 |
| Ishii, H; Ishimatsu, Y; Iwashita, T; Kadota, J; Kaida, H; Kohno, S; Mukae, H; Nagata, T; Shikuwa, C | 1 |
| Buxbaum, A; Gattringer, R; Georgopoulos, A; Graninger, W; Lagler, H; Sauermann, R; Stich, K | 1 |
| Ajiboye, P; Cua, A; Hammerschlag, MR; Kutlin, A; Riska, PF; Roblin, PM | 1 |
| Ioannidis, J; Wilkinson, D | 3 |
| Collet, JP; LeLorier, J; Quach, C | 1 |
| Brunner, H; Hoffmann, T | 1 |
| Giese, MJ; Holland, GN; Kuehne, JJ; Mondino, BJ; Ramaswamy, A; Rayner, SA; Taban, R; Yu, AL; Yu, F | 1 |
| Appelbaum, PC; Bozdogan, B; Clark, CL; Credito, KL; Ednie, LM; Jacobs, MR; Kelly, LM; Kosowska, K; Lin, G; Matic, V; McGhee, P; Pankuch, GA; Smith, K | 1 |
| Appelbaum, PC; Clark, C; Credito, K; Dewasse, B; Hoellman, D; Jacobs, MR; Kosowska, K; Lin, G; McGhee, P; Pankuch, GA | 1 |
| Bermudez, LE; Carter, G; Young, LS | 1 |
| Barker, PM; Gillie, DJ; Rubin, BK; Schechter, MS | 1 |
| Altunaiji, S; Curtis, N; Kukuruzovic, R; Massie, J | 2 |
| Srinivasan, R; Yeo, TH | 1 |
| Amsden, GW; De Salvo, MC; Dunne, MW; Lainez-Ventosilla, A; Swanson, RN | 1 |
| García Vázquez, E; Marcos, MA; Martínez, JA; Mensa, J; Ortega, M; Puig, J; Torres, A | 1 |
| Armstrong, EP; Malone, DC; Ramachandran, S; Skrepnek, GH | 1 |
| Zar, HJ | 1 |
| Bosnar, M; Eraković, V; Kelnerić, Z; Munić, V; Parnham, MJ | 1 |
| De Vecchi, E; Drago, L; Legnani, D; Nicola, L; Prenna, M; Ripa, S | 1 |
| Berthold, F; Ebeling, O; Handrick, W; Schwede, I; Wogawa, B | 1 |
| Bonmarin, I; Deutsch, P; Floret, D; Gaudelus, J; Grimprel, E; Guérin, N; Guiso, N; Morer, I | 1 |
| Giger, W; Göbel, A; Joss, A; McArdell, CS; Thomsen, A | 1 |
| Foster, GH; Rubin, BK; Shinkai, M | 1 |
| Hiramatsu, K; Kadota, J; Kishi, T; Mizunoe, T; Nagai, H; Nasu, M; Tokimatsu, K | 1 |
| Rubin, BK; Shinkai, M | 1 |
| Burt, H; Galetin, A; Gibbons, L; Houston, JB | 1 |
| Breen, JD; De Salvo, MC; Drehobl, MA; Lewis, DE | 1 |
| De Vecchi, E; Drago, L; Gismondo, MR; Legnani, D; Nicola, L | 1 |
| Moran, J; Murphy, TV; Tiwari, T | 1 |
| Cofré Guerra, J | 1 |
| Appelbaum, PC; Bogdanovich, T; Bozdogan, B | 1 |
| Fujii, R; Fukui, A; Sunada, H; Tsuji, E; Uchida, T | 1 |
| Anzueto, A; Choudhri, S; Haverstock, D; Kureishi, A; Niederman, MS; Perroncel, R; Sethi, S | 1 |
| Blasi, F; Tarsia, P | 1 |
| Mikamo, H; Tamaya, T; Tanaka, K; Watanabe, K | 1 |
| Ellis, MC; Ellis, MW; Griffith, ME; Hawley, JS; Hospenthal, DR; McCall, S; Moon, JE; Murray, CK; Rivard, RG | 1 |
| Petrini, B | 1 |
| Chen, BM; Chen, X; Deng, FL; Liang, YZ; Liu, SG; Zhou, P | 1 |
| Komori, K; Nakada, N; Suzuki, Y; Tanaka, H; Yasojima, M | 1 |
| Høgh, B; Pontoppidan, PE | 1 |
| Egawa, S; Endo, K; Hosobe, T; Kiyota, H; Kobayashi, I; Onodera, S; Suzuki, H; Takahashi, T | 1 |
| Boswinkel, M; Sloet van Oldruitenborgh-Oosterbaan, MM | 1 |
| Halling, SM; Jensen, AE | 1 |
| De Vecchi, E; Drago, L; Nicola, L; Zucchetti, E | 1 |
| Goić-Barisić, I; Jukić, I; Punda-Polić, V; Simunić, M; Tonkić, A; Tonkić, M | 1 |
| Doern, GV | 1 |
| Hoban, DJ; Zhanel, GG | 1 |
| Ito, S; Murakami, H; Nasu, R; Ohtani, H; Sawada, Y; Tsujimoto, M | 1 |
| Dancer, SJ | 1 |
| Coenen, S; Goossens, H; Lammens, C; Malhotra-Kumar, S; Van Herck, K | 1 |
| Ishii, H; Ishimoto, H; Kohno, S; Mizuta, Y; Mukae, H; Nagata, T; Nakayama, S; Sakamoto, N; Shirai, R; Sugiyama, K; Yanagihara, K | 1 |
| Blasi, F; de Caprariis, PJ; Feldman, C; Garbino, J; Hoepelman, IM; Hogan, P; Tamm, M; Todisco, T | 1 |
| Giguère, S; Lee, EA; Suarez-Mier, G | 1 |
| Gagnon, C; García-Ac, A; Ghosh, D; Lajeunesse, A; Sauvé, S; Segura, PA | 1 |
| Aoki, A; Inoue, M; Iyobe, S; Kobayashi, T; Nakada, Y; Okitsu, N; Sagai, H; Toriya, M; Yano, H | 1 |
| Adelman, MH; Chiou, CC; Klugman, KP; Lavin, B; Paladino, JA; Patel, M; Schentag, JJ; Wilton, GJ; Yu, VL | 1 |
| Cuzic, S; Erakovic-Haber, V; Glojnaric, I; Parnham, MJ | 1 |
| Fujita, J; Haranaga, S; Hibiya, K; Higa, F; Tateyama, M | 1 |
| Izumikawa, K; Kakeya, H; Kamihira, S; Kohno, S; Morinaga, Y; Nakamura, S; Seki, M; Yamada, Y; Yamamoto, Y; Yanagihara, K | 1 |
| De Vecchi, E; Drago, L; Larosa, M; Nicola, L | 1 |
| Martini, B | 1 |
| Eisenblätter, M; Hahn, H; Klaus, C; Lode, H; Orawa, H; Pletz, MW; Wagner, J | 1 |
| McIntyre, P; Wood, N | 1 |
| Larkin, JM | 1 |
| Davis, CB; Dawson, PA; Garver, E; Han, C; Hugger, ED; Rao, A; Shearn, SP | 1 |
| Astegiano, M; Berrutti, M; Fadda, M; Fagoonee, S; Morgando, A; Pellicano, R; Repici, A; Rizzetto, M; Saracco, G; Smedile, A | 1 |
| Amenomori, M; Fujita, H; Imamura, Y; Ishii, H; Ishimoto, H; Kitazaki, T; Kohno, S; Mukae, H; Nakayama, S; Sakamoto, N; Yanagihara, K | 1 |
| Dubrovskaia, NV; Dvoretskiĭ, LI; Filimonova, OIu; Grudinina, SA; Iakovlev, SV; Sidorenko, SV | 1 |
| Aolie, J; El-Khatib, WF; Noreddin, AM; Salem, AH; Zhanel, GG | 1 |
| Noguchi, Y | 1 |
| Barbon, V | 1 |
| Meyer, D; Seifart, HI; van der Bijl, P; van Eyk, AD | 1 |
| Alexander, RE; Grogan, DM | 1 |
| Avolio, M; Camporese, A; De Rosa, R; Modolo, ML; Stano, P | 1 |
| Gomes, T; Juurlink, DN; Mamdani, MM | 1 |
| Bosnar, M; Bosnjak, B; Culic, O; Cuzic, S; Erakovic Haber, V; Glojnaric, I; Hrvacic, B; Marjanovic, N; Parnham, MJ | 1 |
| Izumikawa, K; Kakeya, H; Kamihira, S; Kohno, S; Miyashita, N; Morinaga, Y; Mukae, H; Seki, M; Yamada, Y; Yamamoto, Y; Yanagihara, K | 1 |
| Davis, CB; Dawson, PA; Garver, E; Han, C; Haywood, J; Lan, T; Rao, A | 1 |
| Hu, L; Hu, X; Lu, Z; Wang, D; Zhang, Y | 1 |
| Finley, R; Glass, SK; McEwen, SA; Pearl, DL | 1 |
| Bono, BR; Qamar, F; Zuckerman, JM | 1 |
| Castanheira, M; Jones, RN; Woosley, LN | 1 |
| Chang, CL; Choi, GE; Kang, JE; Kim, JM; Kim, KH; Lee, EY; Tateda, K; Yamaguchi, K | 1 |
| Arnold, F; Griffin, AT; Peyrani, P; Wiemken, T | 1 |
| Duncan, J; Fry, NK; George, RC; Harrison, TG; Vaghji, L | 1 |
| Tang, D; Ying, L | 1 |
| Araki, N; Kamihira, S; Kohno, S; Morinaga, Y; Nakamura, S; Yamada, K; Yamada, Y; Yanagihara, K | 1 |
| Giguère, S; Javsicas, LH; Womble, AY | 1 |
| Khan, DA; Laurie, SA; Ruiz-Huidobro, E; Swamy, N | 1 |
| Bastian, S; Brossier, F; Cambau, E; Gaillard, JL; Jarlier, V; Roux, AL; Veziris, N | 1 |
| Ishii, Y; Kimura, S; Sato, T; Tateda, K; Yamaguchi, K | 1 |
| Gomes, T; Horn, JR; Juurlink, DN; Mamdani, MM; Wright, AJ | 1 |
| Anić-Milić, T; Bogdan, M; Bosnar, M; Culić, O; Eraković Haber, V; Marjanović, N; Michielin, F; Parnham, MJ; Popović-Grle, S; Willé, DR | 1 |
| Cužić, S; Eraković Haber, V; Ivetić Tkalčević, V; Kramarić, MD; Parnham, MJ | 1 |
| Bai, N; Cai, Y; Chai, D; Liang, BB; Liu, Y; Wang, R | 1 |
| Baik, GH; Jung, HC; Kim, GH; Kim, HB; Kim, JM; Kim, JY; Kim, NY; Kim, SJ; Lee, DH; Nam, RH; Song, IS | 1 |
| Dan, M; Rosenberg, S; Samra, Z | 1 |
| Ashley, EA; Lubell, Y; Turner, P; White, NJ | 1 |
| Chono, S; Morimoto, K; Togami, K | 3 |
| Bauters, F; Brusselle, G; Coeman, M; Demedts, I; Deschepper, E; Joos, G; Smeets, P; van Durme, Y | 1 |
| Wang, CP; Xu, XL; Zeng, XH; Zhou, M; Zhou, Y | 1 |
| Amano, K; Azuma, E; Hirayama, M; Ido, M; Ito, M; Iwamoto, S; Komada, Y; Kumamoto, T | 1 |
| Walkey, AJ; Wiener, RS | 1 |
| Alihodžić, S; Belamarić, D; Eraković Haber, V; Lee, M; Malnar, I; Nujić, K; Polančec, D; Schneider, K; Smith, M; Tomašković, L | 1 |
| Itakura, S; Kamiya, S; Kouyama, T; Nagase, T; Omura, S; Sunazuka, T; Takizawa, H; Yamauchi, Y | 1 |
| Adrjanowicz, K; Cal, K; Grzybowska, K; Hawelek, L; Kaminski, K; Paluch, M; Tarnacka, M; Zakowiecki, D | 1 |
| Noto, MJ; Wheeler, AP | 1 |
| Shimizu, S; Shimizu, T | 1 |
| Descours, G; Etienne, J; Floret, D; Gillet, Y; Guillot, S; Guiso, N | 1 |
| Bosnar, M; Bosnjak, B; Cuzic, S; Erakovic Haber, V; Glojnaric, I; Hrvacic, B; Ivetic Tkalcevic, V | 1 |
| Cash, HL; Fujita, J | 1 |
| Hosogaya, N; Imamura, Y; Ishimatu, Y; Izumikawa, K; Kakeya, H; Kohno, S; Miyazaki, T; Morinaga, Y; Nakamura, S; Sakamoto, N; Yamamoto, Y; Yanagihara, K; Yasuoka, A | 1 |
| Alihodžić, S; Bencetić Mihaljević, V; Bosnar, M; Bošnjak, B; Brajša, K; Culić, O; Eraković Haber, V; Glojnarić, I; Hrvačić, B; Jelić, D; Kapić, S; Koštrun, S; Kragol, G; Marušić Ištuk, Z; Padovan, J; Spaventi, R; Tavčar, B; Verbanac, D; Vujasinović, I | 1 |
| Choi, GE; Daley, CL; Hahn, MY; Jeon, K; Jeong, BH; Kim, S; Koh, WJ; Lee, K; Lee, SH; Min, KN; Oh, T; Shin, SJ; Won, CJ | 1 |
| Floto, RA; Stout, JE | 1 |
| Blondeau, JM; Drlica, K; Metzler, K | 1 |
| Bonella, F; Cai, M; Costabel, U; Dai, H; Guzman, J; Sarria, R | 1 |
| Hernández-Díaz, S; Lin, KJ; Louik, C; Mitchell, AA; Yau, WP | 1 |
| Decramer, M; Laekeman, G; Simoens, S | 1 |
| Harada, Y; Hasegawa, H; Izumikawa, K; Kakeya, H; Kohno, S; Migiyama, Y; Morinaga, Y; Nagaoka, K; Nishimura, M; Yamada, K; Yanagihara, K | 1 |
| Grabowski, T; Grześkowiak, E; Karbownik, A; Matuszewski, M; Połom, W; Sobańska, K; Szałek, E; Urjasz, H; Wolc, A | 1 |
| Akaike, H; Kato, A; Kawai, Y; Kawasaki, K; Kondo, E; Kubo, M; Miyashita, N; Nakano, T; Nishizawa, Y; Ogita, S; Ouchi, K; Saito, A; Tanaka, T; Terada, K; Teranishi, H | 1 |
| Kazama, I; Maruyama, Y | 1 |
| Abe, A; Che, XF; Gotoh, A; Inazu, M; Kawaguchi, T; Komatsu, S; Miyazawa, K; Moriya, S; Tomoda, A | 1 |
| Uthman, MM; Uthman, OA; Yahaya, I | 1 |
| Bailey, DG; Fleet, J; Gandhi, S; Garg, AX; Gomes, T; Hwang, YJ; Juurlink, DN; Mamdani, M; Patel, AM; Shariff, S | 1 |
| Ghadir, MR; Iranikhah, A; Sarkeshikian, SS | 1 |
| Donaldson, GC; James, GD; Nazareth, I; Petersen, I; Wedzicha, JA | 1 |
| Berghaus, LJ; Giguère, S; Guldbech, K | 1 |
| Jeong, BH; Jeong, YJ; Kim, HJ; Koh, WJ; Lee, G; Lee, KS; Moon, JW; Woo, S | 1 |
| Herath, SC; Poole, P | 1 |
| Bailey, DG; Fleet, JL; Gandhi, S; Garg, AX; McArthur, E; Rehman, F; Wald, R | 1 |
| Howard, ST | 1 |
| Jalalzadeh, M; Nazarian, M; Vafaeimanesh, J | 1 |
| Brown-Elliott, BA; Griffith, DE; Killingley, J; McNulty, S; Philley, JV; Shepherd, S; Wallace, RJ; Wilson, RW; York, DS | 1 |
| Böttger, EC; Castelberg, C; Maurer, FP; Quiblier, C; Somoskövi, A | 1 |
| Alechaga, E; Boleda, MR; Galceran, MT; Moyano, E; Ventura, F | 1 |
| Mendu, ML; Waikar, SS | 1 |
| Armon, C; Baker, R; Brooks, JT; Buchacz, K; Palella, FJ; Yangco, BG | 1 |
| Harada, Y; Hasegawa, H; Imamura, Y; Izumikawa, K; Kakeya, H; Kaku, N; Kohno, S; Mikamo, H; Miyazaki, T; Morinaga, Y; Nakamura, S; Uno, N; Yamada, K; Yanagihara, K | 1 |
| Alves, SH; Bizzi, K; Ferreiro, L; Jesus, FP; Loreto, ÉS; Ludwig, A; Pilotto, MB; Santurio, JM; Tondolo, JS; Zanette, RA | 1 |
| Patsche, CB; Svensson, E; Wejse, C | 1 |
| Field, SK; Jarand, J | 1 |
| Aksoy, Y; Eyi, YE; Gezer, M; Oztürk, K | 1 |
| Schuhfried, G; Stanek, G | 1 |
| Alves, SH; Loreto, ES; Pilotto, MB; Santurio, JM; Tondolo, JS | 1 |
| Hofmann, T; Scheuch, G; Siekmeier, R | 1 |
| Burkin, M; Galvidis, I; Lapa, G | 1 |
| Chu, N; Duan, H; Huang, H; Lu, Y; Nie, W | 1 |
| Del Mar, CB; Eriksson, L; Farley, R; Spurling, GK | 1 |
| Daley, CL; Huh, HJ; Jeon, K; Jeong, BH; Ki, CS; Kim, SY; Koh, WJ; Lee, KS; Lee, NY; Park, HY; Shin, SJ | 1 |
| Hakimi, P; Khoshnood, A; Reza Mirjalili, M; Salman-Roghani, H | 1 |
| Chan, KA; Chang, CH; Chou, HW; Lai, CL; Lai, MS; Wang, JL | 1 |
| Fraser, LA; Garg, AX; McArthur, E; Naylor, KL; Shariff, SZ | 1 |
| Burgmann, H; Haslacher, H; Hoermann, G; Jutz, S; Kovarik, JJ; Pickl, WF; Poeppl, W; Ratzinger, F; Schmetterer, KG; Steinberger, P | 1 |
| Bai, S; Lu, P; Qin, X; Xue, Y; Yang, B; Zheng, H | 1 |
| Maruyama, F; Masuda, M; Nonaka, L; Suzuki, S | 1 |
| Brusselle, GG | 1 |
| Hauser, G; JajacKnez, A; Salkic, N; Stimac, D; Vukelic, K | 1 |
| Kasai, A; Nishiyama, H; Ogihara, S; Saito, R; Tanimichi, Y; Yamada, K | 1 |
| Feng, PF; Guo, F; Li, BX; Sun, JL; Zhang, R; Zhao, X; Zhi, D | 1 |
| Barni, S; Butti, D; Cianferoni, A; Mori, F; Novembre, E; Pucci, N; Rossi, ME | 1 |
| Ferdman, RM; Markert, ML; Tam, JS; Wang, L; Yin, SM | 1 |
| Eybagi, S; Kazerouni, NP; Naserzadeh, P; Pourahmad, J; Salimi, A; Seydi, E | 1 |
| Brown-Elliott, BA; Chao, AS; Chiu, CH; Griffith, DE; Leu, HS; Lin, CS; Wu, TL; Wu, TS; Yang, CH | 1 |
| Butler-Laporte, G; Menzies, D; Winters, N | 1 |
| Shimizu, T; Suzaki, H | 1 |
| Alves, SH; Azevedo, MI; Driemeier, D; Ferreiro, L; França, RT; Jesus, FP; Lopes, ST; Loreto, ÉS; Ludwig, A; Pilotto, MB; Ribeiro, TC; Santurio, JM; Souza, SO; Tondolo, JS | 1 |
| Bérard, A; Nordeng, H; Sheehy, O; Zhao, JP | 1 |
| Che, XF; Handa, H; Hiramoto, M; Itoi, T; Kazama, H; Kokuba, H; Miyazawa, K; Moriya, S; Mukai, S; Ōmura, S; Sakamoto, S; Sugawara, A; Sunazuka, T; Yokoyama, T | 1 |
| Akaba, T; Akagawa, S; Akashi, S; Hirose, T; Kadota, T; Kawashima, M; Kobayashi, K; Kobayashi, N; Matsui, H; Nagai, H; Ohta, K; Saito, M; Suzuki, J; Tamura, A | 1 |
| Dixon, SN; Garg, AX; Hackam, DG; Jandoc, R; McArthur, E; Nash, DM; Trac, MH | 1 |
| Li, C; Li, X; Liu, G; Wang, M; Wang, Z; Zhou, L | 1 |
| Renaud, J; Sabourin, L; Sumarah, M; Topp, E | 1 |
| Abou-Aisha, K; Akram, FE; El-Azizi, M; El-Tayeb, T | 1 |
| Fujii, R; Ishihara, K; Narita, M; Okuda, K; Shibahara, T; Takano, N | 1 |
| Cambau, E; Guglielmetti, L; Mougari, F; Raskine, L; Sermet-Gaudelus, I; Veziris, N | 1 |
| Abe, A; Hiramoto, M; Hirasawa, K; Hirota, A; Inazu, M; Kazama, H; Miyahara, K; Miyazawa, K; Moriya, S; Takemura, J; Tsukahara, K | 1 |
| Fujii, T; Noguchi, N; Seyama, S; Suzuki, M; Ushio, M; Wajima, T | 1 |
| Cho, J; Han, SK; Lee, CH; Park, J; Yim, JJ | 1 |
| Altman, RB; Fohner, AE; Klein, TE; Sparreboom, A | 1 |
| Giguère, S | 1 |
| Bodík, I; Fáberová, M; Grabic, R; Ivanová, L; Mackuľak, T | 1 |
| Burrow, JA; MacKAY, RJ; Mallicote, MF; Muniz, AL; Sanchez, LC; Stieler Stewart, AL; Westerterp, MS | 1 |
| Aoyagi, H; Ariga, T; Furuyama, H; Hara, K; Hazama, K; Horino, A; Ishiguro, N; Ishizaka, A; Kaiho, M; Kenri, T; Kikuta, H; Koseki, N; Morita, K; Nagano, N; Naito, H; Nakanishi, M; Oba, K; Sasaki, S; Shibata, M; Shida, S; Tabata, Y; Togashi, T; Watanabe, T; Yamanaka, T; Yoshioka, M | 1 |
| Gomes, T; Huang, A; Juurlink, DN; Macdonald, EM; Mamdani, MM; Quinn, KL | 1 |
| Adir, Y; Lavon, O; Schneer, S; Shteinberg, M | 1 |
| Alinejad, AA; Golmohammadi, S; Hassani, G; Mohammadi, AS; Mohseni, SM; Sardar, M; Sarsangi, V; Yazdanbakhsh, AR | 1 |
| Adams, E; Duchateau, T; Paul, P; Sänger-van de Griend, C; Van Schepdael, A | 1 |
| Gergova, RT; Mitov, IG; Muhtarova, AA | 1 |
| Jo, KW; Nam, GB; Shim, TS; Yoon, HY | 1 |
| Hardin, JW; Hyche, S; Magagnoli, J; Sutton, SS | 1 |
| Berghaus, LJ; Giguère, S; Willingham-Lane, JM | 1 |
| Emmanuel, R; Ovais, M; Padmavathy, S; Prakash, P; Saravanan, M; Shinwari, ZK | 1 |
| Alves, SH; Loreto, ES; Oliveira, DC; Santurio, JM; Tondolo, JSM | 1 |
| Fabiánová, K; Jakubů, V; Urbášková, P; Zavadilová, J | 1 |
| Chalmers, JD; Crossingham, I; Evans, DJ; Felix, LM; Kelly, C; Milan, SJ; Relph, N; Spencer, S | 1 |
| Birošová, L; Grabic, R; Kraková, L; Lépesová, K; Mackuľak, T; Medveďová, A; Olejníková, P; Pangallo, D; Tichý, J | 1 |
| Alyabieva, NM; Katosova, LK; Khokhlova, TA; Lazareva, AV; Ponomarenko, OA | 1 |
| Aktan, B; Ersoy, B; Kilic, K; Sakat, MS; Sipal, S | 1 |
| Barr, BS; Carter, CN; Cohen, ND; Elam, J; Erol, E; Giguère, S; Huber, L; Locke, SJ; Phillips, ED; Slovis, NM; Smith, JL | 1 |
| Herath, SC; Maisey, S; Normansell, R; Poole, P | 1 |
| Aydin, ME; Aydin, S; Kilic, H; Ulvi, A | 1 |
| Bykov, K; Gagne, JJ; Glynn, RJ; Mittleman, MA; Schneeweiss, S | 1 |
| Dalcolmo, MP; Daley, CL; Eather, G; Gayoso, R; Hasegawa, N; Jhun, BW; Koh, WJ; Kwak, N; Namkoong, H; Park, J; Thomson, R; van Ingen, J; Yim, JJ; Zweijpfenning, SMH | 1 |
| Crooke, SN; Finn, MG; Oyelere, AK; Raji, I; Schimer, J; Wu, B | 1 |
| de Brouwer, AP; de Jong, A; Hoefsloot, W; Pennings, LJ; Ruth, MM; Schildkraut, JA; van Ingen, J; Wertheim, HF | 1 |
| Adami, ME; Alexiou, N; Giamarellos-Bourboulis, EJ; Gogos, C; Halvatzis, S; Kosmas, V; Koutoukas, P; Kyprianou, A; Kyprianou, M; Kyriakoudi, A; Kyriazopoulou, E; Lada, M; Makina, A; Niederman, MS; Pavlaki, M; Sinapidis, D; Stefos, A; Velissaris, D | 1 |
| Gutiérrez, AV; Kremer, L; Richard, M | 1 |
| Chong, YP; Han, M; Jo, KW; Kim, OH; Kwon, BS; Kwon, YS; Lee, HY; Shim, TS | 1 |
| Chindamporn, A; Chuleerarux, N; Manothummetha, K; Permpalung, N; Plongla, R; Torvorapanit, P; Worasilchai, N | 1 |
| Carter, C; Cruz Penn, MJ; Erol, E; Fortner, J; Locke, S; Saied, A; Smith, J | 1 |
| Giebułtowicz, J; Harnisz, M; Korzeniewska, E; Kucharski, D; Nałęcz-Jawecki, G; Płaza, G | 1 |
| Chambers, ST; Doogue, MP; Gardiner, SJ; Metcalf, SC; Werno, A | 1 |
| Katsukawa, C; Kawahara, R; Kawasaki, Y; Kawatsu, K; Yamaguchi, T | 1 |
| Gibson, PG; Ivey, KL; Rogers, GB; Simpson, JL; Taylor, SL | 1 |
| Carrier, M; Clark, EG; Garg, AX; Harel, Z; Hill, K; Hundemer, GL; Knoll, G; McArthur, E; Rhodes, E; Sood, MM; Sucha, E | 1 |
| Boroumand, B; Hajimirzaei, N; Judi-Chelan, R; Khalili, NP; Pourhosseini, A; Safari, F; Tavakoli, F | 1 |
| Pejčić, AV | 2 |
| Fernández-Piñas, F; González-Pleiter, M; Leganés, F; Marco, E; Pedrouzo-Rodríguez, A; Rosal, R; Verdú, I | 1 |
| Akeda, Y; Arakawa, Y; Miyamoto, K; Onda, M; Shoji, M; Terada, K; Tomono, K; Tsuchiya, T; Yamabe, K | 1 |
| Martingano, D; Mitrofanova, A; Nguyen, A; Nkeih, C; Singh, S | 1 |
| Inoue, Y; Kimura, Y; Kobayashi, T; Kurahara, Y; Minomo, S; Suzuki, K; Tsuji, T; Tsuyuguchi, K; Yoshida, S | 1 |
| Aktas, A; Ataseven, H; Gedikli, MA; Sayin, K; Tuzun, B | 1 |
| Inoue, Y; Kobayashi, T; Suzuki, K; Tsuyuguchi, K; Yoshida, S | 1 |
| Abdelmaksoud, AA; Aref, ZF; Bazeed, SES; Hassan, MH; Mansour, H; Nafady, A; Nafady-Hego, H; Rashad, A; Sayed, MAA; Taya, U | 1 |
| Imai, G; Ooi, HK; Saio, M; Takemori, N | 1 |
| Al-Salloum, J; Gillani, SW; Gulam, SM; Mahmood, RK | 1 |
| Sunaga, T; Yonezawa, R | 1 |
| Arulkumaran, N; Brealey, D; Down, J; Longobardo, A; Satta, G; Singer, M; Snow, TAC | 1 |
| Alharbi, L; Alkhamisi, R; Alradadi, R; Ashy, N; Eljaaly, K | 1 |
| Ma, P; Qin, Y; Sun, M; Yang, Y; Zhang, N | 1 |
| Barceló, D; Borja, Á; de Alda, ML; Larreta, J; López-García, E; Postigo, C; Rodríguez, JG; Solaun, O; Zonja, B | 1 |
| Chhaya, N; Koo, EH; Miller, D; Shaik, N; Tonk, RS; Weiss, M; Zhu, A | 1 |
| Catherine Stanton, I; Hayes, A; Hugo Gaze, W; Kaye Murray, A; May Murray, L; Snape, J; Zhang, L | 1 |
| Crumrine, M; Hewitt, JA; Slay, RM | 1 |
| Cummins, E; Monahan, C; Morris, D; Nag, R | 1 |
| Askari, M; Khezri, M; Zoghi, G | 1 |
| Chen, Y; Cui, S; Ding, Y; Du, Z; Li, P; Ma, Y; Qi, X; Tan, Y; Wang, Y; Wu, L; Yang, L; Zhang, Z | 1 |
| Aoki, A; Inagaki, T; Jinno, H; Nakagawa, T; Ogawa, K; Okamoto, Y; Uchiya, KI; Wajima, T | 1 |
| Álvarez-Rodríguez, E; Arias-Estévez, M; Díaz-Raviña, M; Fernández-Calviño, D; Núñez-Delgado, A; Rodríguez-González, L; Santás-Miguel, V | 1 |
| Chasqueira, MJ; Cruz, C; Fernandes, F; Paixão, P; Rodrigues, L; Santos, R | 1 |
| Jiang, B; Jing, XL; Li, GA; Li, SS; Ling, WC; Sui, SS; Sun, CY; Wang, YL | 1 |
| Higuchi, K; Inoue, K; Kishimoto, H; Kiyomiya, K; Saito, N; Shirasaka, Y; Takada, T; Tomabechi, R; Watai, K | 1 |
93 review(s) available for clarithromycin and zithromax
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Clarithromycin and azithromycin: new macrolide antibiotics.
Topics: Azithromycin; Bacterial Infections; Clarithromycin; Drug Interactions; Drug Labeling; Drug Resistance, Microbial; Erythromycin; Gram-Negative Bacteria; Gram-Positive Bacteria | 1992 |
The new macrolide antibiotics: azithromycin, clarithromycin, dirithromycin, and roxithromycin.
Topics: Anti-Bacterial Agents; Azithromycin; Clarithromycin; Clinical Trials as Topic; Drug Interactions; Erythromycin; Humans; Macrolides; Roxithromycin | 1992 |
The new macrolide antibiotics. Azithromycin and clarithromycin.
Topics: Anti-Bacterial Agents; Azithromycin; Clarithromycin; Clinical Protocols; Clinical Trials as Topic; Drug Resistance, Microbial; Erythromycin; Humans; Respiratory Tract Infections; Sexually Transmitted Diseases; Skin Diseases, Infectious; Therapeutic Equivalency | 1992 |
Azithromycin and clarithromycin: overview and comparison with erythromycin.
Topics: Azithromycin; Bacterial Infections; Clarithromycin; Erythromycin; Gram-Negative Bacterial Infections; Humans; In Vitro Techniques; Mycobacterium Infections, Nontuberculous; Respiratory Tract Infections; Sexually Transmitted Diseases; Skin Diseases, Infectious | 1992 |
New macrolide antibiotics: clarithromycin and azithromycin.
Topics: Azithromycin; Clarithromycin; Erythromycin; Humans; Respiratory Tract Infections; Skin Diseases, Infectious | 1992 |
The new macrolactones: clarithromycin (Biaxin) and azithromycin (Zithromax).
Topics: Azithromycin; Clarithromycin; Drug Interactions; Erythromycin; Humans; Respiratory Tract Infections | 1992 |
Clarithro- and azithromycin--better erythromycins?
Topics: Adult; Azithromycin; Clarithromycin; Erythromycin; Humans | 1991 |
The newer macrolides. Azithromycin and clarithromycin.
Topics: Anti-Bacterial Agents; Azithromycin; Clarithromycin; Drug Resistance, Microbial; Humans; Respiratory Tract Infections | 1995 |
Azithromycin and clarithromycin.
Topics: Azithromycin; Bacterial Infections; Clarithromycin; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests | 1995 |
New macrolide antibiotics: usefulness in infections caused by mycobacteria other than Mycobacterium tuberculosis.
Topics: Anti-Bacterial Agents; Azithromycin; Bacteremia; Clarithromycin; Drug Synergism; Erythromycin; Humans; Microbial Sensitivity Tests; Multicenter Studies as Topic; Mycobacterium Infections, Nontuberculous; Randomized Controlled Trials as Topic | 1994 |
Azithromycin and clarithromycin.
Topics: Animals; Azithromycin; Bacterial Infections; Biological Availability; Clarithromycin; Drug Interactions; Half-Life; Humans; Microbial Sensitivity Tests; Tissue Distribution | 1994 |
The role of newer oral cephalosporins, fluoroquinolones, and macrolides in the treatment of pediatric infections.
Topics: Administration, Oral; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Bacterial Infections; Cefixime; Cefotaxime; Cefpodoxime Proxetil; Cefprozil; Ceftibuten; Ceftizoxime; Cefuroxime; Cephalosporins; Child; Clarithromycin; Fluoroquinolones; Humans | 1994 |
The new macrolides. Azithromycin and clarithromycin.
Topics: Azithromycin; Clarithromycin; Humans | 1994 |
Treatment of disseminated disease due to the Mycobacterium avium complex in patients with AIDS.
Topics: AIDS-Related Opportunistic Infections; Anti-Infective Agents; Azithromycin; Clarithromycin; Clinical Trials as Topic; Colony Count, Microbial; Drug Therapy, Combination; Ethambutol; Gentamicins; Humans; Mycobacterium avium-intracellulare Infection; Prospective Studies; Randomized Controlled Trials as Topic | 1994 |
Azithromycin and clarithromycin.
Topics: Adult; Anti-Bacterial Agents; Azithromycin; Bacterial Infections; Clarithromycin; Erythromycin; Humans; Microbial Sensitivity Tests | 1993 |
[Azithromycin: critical points].
Topics: Anti-Bacterial Agents; Azithromycin; Clarithromycin; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Erythromycin; Gram-Negative Bacteria; Gram-Positive Bacteria; Hydrogen-Ion Concentration; In Vitro Techniques; Macrolides | 1995 |
Treatment and prophylaxis of Mycobacterium avium complex.
Topics: AIDS-Related Opportunistic Infections; Animals; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Clinical Trials as Topic; Humans; Mice; Mycobacterium avium-intracellulare Infection | 1996 |
Dirithromycin: a new macrolide.
Topics: Anti-Bacterial Agents; Azithromycin; Bacteria, Anaerobic; Clarithromycin; Drug Interactions; Erythromycin; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Macrolides; Respiratory Tract Infections | 1996 |
Against the proposition: all patients with advanced HIV disease should be offered rifabutin prophylaxis.
Topics: AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Antibiotic Prophylaxis; Azithromycin; Clarithromycin; Drug Resistance, Microbial; Humans; Mycobacterium avium-intracellulare Infection; Rifabutin; Survival Analysis; Treatment Outcome | 1996 |
History of macrolide use in pediatrics.
Topics: Adolescent; Anti-Bacterial Agents; Azithromycin; Bacterial Infections; Child; Child, Preschool; Clarithromycin; Drug Interactions; Erythromycin; Haemophilus Infections; Haemophilus influenzae; History, 20th Century; Humans; Infant; Infant, Newborn; Microscopy, Electron; Phagocytes; Phagocytosis | 1997 |
Microbiologic activity of the newer macrolide antibiotics.
Topics: Adolescent; Anti-Bacterial Agents; Azithromycin; Child; Child, Preschool; Clarithromycin; Ear, Middle; Erythromycin; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Infant; Infant, Newborn; Microbial Sensitivity Tests; Penicillin Resistance; Respiratory Tract Infections; Streptococcal Infections; Streptococcus pneumoniae | 1997 |
Pharmacokinetics and pharmacodynamics of newer macrolides.
Topics: Adolescent; Anti-Bacterial Agents; Azithromycin; Bacterial Infections; Child; Child, Preschool; Clarithromycin; Ear, Middle; Haemophilus Infections; Humans; Infant; Infant, Newborn; Microbial Sensitivity Tests; Streptococcal Infections; Tissue Distribution | 1997 |
Macrolides in the management of streptococcal pharyngitis/tonsillitis.
Topics: Adolescent; Anti-Bacterial Agents; Azithromycin; Child; Child, Preschool; Clarithromycin; Erythromycin; Humans; Penicillins; Pharyngitis; Streptococcal Infections; Tonsillitis | 1997 |
Causative pathogens, antibiotic resistance and therapeutic considerations in acute otitis media.
Topics: Anti-Bacterial Agents; Azithromycin; beta-Lactam Resistance; Child; Child, Preschool; Clarithromycin; Haemophilus Infections; Haemophilus influenzae; Humans; Infant; Lactams; Moraxella catarrhalis; Neisseriaceae Infections; Otitis Media; Penicillin Resistance; Penicillins; Streptococcal Infections; Streptococcus pneumoniae | 1997 |
Future indications for macrolides.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-Bacterial Agents; Azithromycin; Bacterial Infections; Child; Child, Preschool; Clarithromycin; Community-Acquired Infections; Helicobacter Infections; Humans; Malaria; Mycobacterium avium-intracellulare Infection; Pneumonia, Bacterial | 1997 |
Mycobacterium avium intracellulare infection in patients with HIV or AIDS.
Topics: AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Antibiotic Prophylaxis; Antifungal Agents; Azithromycin; Clarithromycin; Clinical Trials as Topic; Fluconazole; Humans; Immunocompromised Host; Mycobacterium avium-intracellulare Infection; Rifabutin | 1997 |
Rationale for the prevention of disseminated Mycobacterium avium-intracellulare complex disease.
Topics: AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Azithromycin; CD4 Lymphocyte Count; Clarithromycin; HIV Infections; Humans; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Rifabutin | 1997 |
Prevention strategies for Mycobacterium avium-intracellulare complex (MAC) infection. A review of recent studies in patients with AIDS.
Topics: AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Controlled Clinical Trials as Topic; Drug Therapy, Combination; HIV Infections; Humans; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Rifabutin | 1997 |
[Nontuberculous mycobacteriosis; the present status and in the future. Infection with human immunodeficiency virus (HIV) and nontuberculous mycobacteriosis].
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Antibiotics, Antitubercular; Azithromycin; Clarithromycin; Humans; Male; Middle Aged; Mycobacterium avium-intracellulare Infection; Rifabutin | 1998 |
Comparative tolerability of erythromycin and newer macrolide antibacterials in paediatric patients.
Topics: Anti-Bacterial Agents; Azithromycin; Bacterial Infections; Child; Clarithromycin; Drug Hypersensitivity; Drug Interactions; Erythromycin; Humans; Liver Function Tests | 1999 |
Prophylaxis against disseminated Mycobacterium avium complex in AIDS.
Topics: Acquired Immunodeficiency Syndrome; Azithromycin; Clarithromycin; Humans; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection | 1999 |
The role of newer macrolides in the treatment of community-acquired respiratory tract infection. A review of experimental and clinical data.
Topics: Anti-Bacterial Agents; Azithromycin; Clarithromycin; Community-Acquired Infections; Drug Resistance, Microbial; Global Health; Humans; Respiratory Tract Infections | 1999 |
The macrolides: erythromycin, clarithromycin, and azithromycin.
Topics: Adult; Anti-Bacterial Agents; Azithromycin; Child; Clarithromycin; Drug Resistance, Microbial; Erythromycin; Humans; Microbial Sensitivity Tests | 1999 |
Dental therapeutic indications for the newer long-acting macrolide antibiotics.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Azithromycin; Clarithromycin; Cytochrome P-450 Enzyme System; Delayed-Action Preparations; Dental Care for Chronically Ill; Drug Costs; Endocarditis, Bacterial; Erythromycin; Focal Infection, Dental; Humans; Liver; Macrolides; Prodrugs; Tissue Distribution | 1999 |
The newer macrolides: azithromycin and clarithromycin.
Topics: Anti-Bacterial Agents; Azithromycin; Bacterial Infections; Clarithromycin; Drug Resistance, Microbial; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans | 2000 |
Macrolide - induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin.
Topics: Anti-Bacterial Agents; Azithromycin; Clarithromycin; Clinical Trials as Topic; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Erythromycin; Humans; Macrolides; Mixed Function Oxygenases; Substrate Specificity | 2000 |
Drug-Drug interactions of clinical significance in the treatment of patients with Mycobacterium avium complex disease.
Topics: Azithromycin; Clarithromycin; Drug Interactions; HIV Protease Inhibitors; Humans; Mycobacterium avium-intracellulare Infection; Reverse Transcriptase Inhibitors; Rifabutin | 2000 |
Therapy with macrolides in patients with cystic fibrosis.
Topics: Animals; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Clinical Trials as Topic; Cystic Fibrosis; Erythromycin; Humans; Inflammation; Molecular Structure; Pseudomonas aeruginosa | 2002 |
The evolution and role of macrolides in infectious diseases.
Topics: Adult; Anti-Bacterial Agents; Azithromycin; Biological Availability; Child; Clarithromycin; Communicable Diseases; Drug Resistance, Bacterial; Erythromycin; Half-Life; Humans; Metabolic Clearance Rate | 2002 |
[Contribution of Japanese researchers to progress in the field of pulmonary medicine in the last 100 years: New pharmacological action of macrolides].
Topics: Anti-Bacterial Agents; Azithromycin; Bronchiolitis; Chronic Disease; Clarithromycin; Erythromycin; History, 20th Century; Humans; Japan; Lung Neoplasms; Respiratory Tract Infections | 2002 |
[Macrolides in the treatment of children with Mediterranean spotted fever].
Topics: Adolescent; Anti-Bacterial Agents; Azithromycin; Boutonneuse Fever; Child; Child, Preschool; Chloramphenicol; Clarithromycin; Female; Humans; Infant; Italy; Macrolides; Male; Randomized Controlled Trials as Topic; Sicily; Tetracyclines; Treatment Outcome | 2002 |
Macrolide antibiotic therapy in patients with cystic fibrosis.
Topics: Anti-Bacterial Agents; Azithromycin; Clarithromycin; Clinical Trials as Topic; Cystic Fibrosis; Erythromycin; Humans; Randomized Controlled Trials as Topic | 2003 |
Mycobacterium malmoense infection of the knee.
Topics: Azithromycin; Clarithromycin; Drug Therapy, Combination; Female; Humans; Knee Joint; Magnetic Resonance Imaging; Middle Aged; Mycobacterium Infections, Nontuberculous; Myositis; Nontuberculous Mycobacteria; Popliteal Cyst; Rifampin | 2003 |
Antibiotic treatment of atherosclerosis.
Topics: Animals; Anti-Bacterial Agents; Arteriosclerosis; Azithromycin; C-Reactive Protein; Cardiovascular Diseases; Chlamydophila Infections; Chlamydophila pneumoniae; Clarithromycin; Coronary Artery Disease; Coronary Restenosis; Diet, Atherogenic; Fluoroquinolones; Gatifloxacin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Models, Animal; Myocardial Ischemia; Rabbits; Randomized Controlled Trials as Topic; Roxithromycin; Treatment Outcome | 2003 |
Macrolides in dermatology.
Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Azithromycin; Biological Availability; Child; Clarithromycin; Clinical Trials as Topic; Half-Life; Humans; Intestinal Absorption; Macrolides; Respiratory Tract Infections; Skin Diseases, Bacterial | 2004 |
Macrolides and ketolides: azithromycin, clarithromycin, telithromycin.
Topics: Anti-Bacterial Agents; Azithromycin; Bacterial Infections; Clarithromycin; Humans; Ketolides; Macrolides | 2004 |
HIV: opportunistic infections.
Topics: Acyclovir; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Anti-Infective Agents; Antitubercular Agents; Antiviral Agents; Atovaquone; Azithromycin; Chickenpox; Clarithromycin; Cytomegalovirus Infections; Drug Therapy, Combination; Ganciclovir; Herpes Simplex; Humans; Mycobacterium avium-intracellulare Infection; Naphthoquinones; Pneumonia, Pneumocystis; Rifabutin; Toxoplasmosis; Trimethoprim, Sulfamethoxazole Drug Combination; Tuberculosis, Pulmonary; Valacyclovir; Valine | 2003 |
HIV: prevention of opportunistic infections.
Topics: 2-Aminopurine; Acyclovir; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Antifungal Agents; Antiprotozoal Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Antiviral Agents; Atovaquone; Azithromycin; Clarithromycin; Cytomegalovirus Infections; Drug Therapy, Combination; Famciclovir; Herpes Simplex; Herpes Zoster; Humans; Mycobacterium avium-intracellulare Infection; Mycoses; Naphthoquinones; Pneumonia, Pneumocystis; Toxoplasmosis; Trimethoprim, Sulfamethoxazole Drug Combination; Tuberculosis, Pulmonary; Valacyclovir; Valine | 2003 |
Anti-inflammatory effects of macrolides--an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions?
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents; Azithromycin; Chronic Disease; Clarithromycin; Community-Acquired Infections; Erythromycin; Humans; Inflammation; Macrolides; Respiratory Tract Infections | 2005 |
Antibiotics for whooping cough (pertussis).
Topics: Anti-Bacterial Agents; Azithromycin; Bordetella pertussis; Clarithromycin; Contact Tracing; Erythromycin; Erythromycin Estolate; Erythromycin Ethylsuccinate; Humans; Infant; Randomized Controlled Trials as Topic; Trimethoprim, Sulfamethoxazole Drug Combination; Whooping Cough | 2005 |
Are newer macrolides effective in eradicating carriage of pertussis?
Topics: Anti-Bacterial Agents; Azithromycin; Clarithromycin; Humans; Infant; Macrolides; Whooping Cough | 2005 |
Neonatal chlamydial infections: prevention and treatment.
Topics: Anti-Bacterial Agents; Azithromycin; Chlamydia Infections; Clarithromycin; Humans; Infant, Newborn; Ophthalmia Neonatorum; Pneumonia, Bacterial; Roxithromycin | 2005 |
[Action to be taken when facing one or more cases of whooping-cough].
Topics: Adult; Anti-Bacterial Agents; Azithromycin; Child; Clarithromycin; Cross Infection; Drug Combinations; Enzyme-Linked Immunosorbent Assay; France; Humans; Pertussis Vaccine; Polymerase Chain Reaction; Whooping Cough | 2005 |
HIV: prevention of opportunistic infections.
Topics: 2-Aminopurine; Acyclovir; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Anti-HIV Agents; Antifungal Agents; Antitubercular Agents; Antiviral Agents; Azithromycin; Chickenpox; Clarithromycin; Cytomegalovirus Infections; Drug Therapy, Combination; Famciclovir; Ganciclovir; Herpes Simplex; Humans; Mycobacterium avium-intracellulare Infection; Mycoses; Pneumonia, Pneumocystis; Rifabutin; Toxoplasmosis; Trimethoprim, Sulfamethoxazole Drug Combination; Tuberculosis, Pulmonary | 2005 |
Macrolides and airway inflammation in children.
Topics: Anti-Bacterial Agents; Asthma; Azithromycin; Bronchitis; Child; Clarithromycin; Cystic Fibrosis; Drug Resistance; Humans; Inflammation; Macrolides; Respiratory Tract Diseases | 2005 |
[Pertussis chemoprophylaxis: a sterile effort?].
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Azithromycin; Clarithromycin; Drug Administration Schedule; Erythromycin; Humans; Risk Factors; Severity of Illness Index; Whooping Cough | 2006 |
Eradication of H. influenzae in AECB: A pooled analysis of moxifloxacin phase III trials compared with macrolide agents.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; Azithromycin; Bronchitis, Chronic; Chronic Disease; Clarithromycin; Clinical Trials, Phase III as Topic; Double-Blind Method; Female; Fluoroquinolones; Haemophilus Infections; Haemophilus influenzae; Humans; Male; Middle Aged; Moxifloxacin; Multicenter Studies as Topic; Quinolines; Randomized Controlled Trials as Topic; Treatment Outcome | 2006 |
Value of short-course antimicrobial therapy in community-acquired pneumonia.
Topics: Anti-Bacterial Agents; Azithromycin; Clarithromycin; Clinical Trials, Phase III as Topic; Community-Acquired Infections; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Levofloxacin; Male; Microspheres; Ofloxacin; Pneumonia; Time Factors; Treatment Outcome | 2005 |
Mycobacterium abscessus: an emerging rapid-growing potential pathogen.
Topics: Administration, Oral; Amikacin; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Cystic Fibrosis; Drug Resistance, Bacterial; Drug Therapy, Combination; Humans; Microbial Sensitivity Tests; Minocycline; Mycobacterium; Mycobacterium Infections; Respiratory Tract Infections; Skin; Soft Tissue Infections; Species Specificity; Surgical Wound Infection; Tigecycline; Tuberculosis, Cutaneous; Wounds and Injuries | 2006 |
[Antibiotics treatment of whooping cough].
Topics: Anti-Bacterial Agents; Azithromycin; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Erythromycin; Humans; Infant; Meta-Analysis as Topic; Patient Compliance; Trimethoprim, Sulfamethoxazole Drug Combination; Whooping Cough | 2006 |
[Diagnosis and therapy of Rhodococcus equi infection in the horse].
Topics: Actinomycetales Infections; Animals; Animals, Newborn; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Drug Therapy, Combination; Erythromycin; Horse Diseases; Horses; Pneumonia, Bacterial; Rhodococcus equi; Rifampin; Treatment Outcome | 2006 |
Macrolide and ketolide resistance with Streptococcus pneumoniae.
Topics: Anti-Bacterial Agents; Azithromycin; Bacterial Proteins; Clarithromycin; Drug Resistance, Bacterial; Humans; Ketolides; Macrolides; Membrane Proteins; Pneumococcal Infections; Streptococcus pneumoniae | 2006 |
Clinical implications of macrolide resistance in community-acquired respiratory tract infections.
Topics: Anti-Bacterial Agents; Azithromycin; Clarithromycin; Community-Acquired Infections; Drug Resistance, Bacterial; Humans; Ketolides; Macrolides; Microbial Sensitivity Tests; Respiratory Tract Infections; Risk Factors; Streptococcus pneumoniae | 2006 |
Antibiotics for whooping cough (pertussis).
Topics: Anti-Bacterial Agents; Azithromycin; Bordetella pertussis; Clarithromycin; Contact Tracing; Erythromycin; Erythromycin Estolate; Erythromycin Ethylsuccinate; Humans; Infant; Randomized Controlled Trials as Topic; Trimethoprim, Sulfamethoxazole Drug Combination; Whooping Cough | 2007 |
[Overview of respiratory infection caused by nontuberculous mycobacteria].
Topics: Animals; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Female; Humans; Immunocompromised Host; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Tuberculosis, Pulmonary | 2007 |
Pertussis: review of epidemiology, diagnosis, management and prevention.
Topics: Anti-Bacterial Agents; Azithromycin; Bordetella pertussis; Clarithromycin; Developed Countries; Humans; Macrolides; Pertussis Vaccine; Polymerase Chain Reaction; Whooping Cough | 2008 |
Lyme disease in children and pregnant women.
Topics: Adult; Amoxicillin; Azithromycin; Ceftriaxone; Cefuroxime; Child; Child, Preschool; Clarithromycin; Contraindications; Doxycycline; Female; Humans; Infectious Disease Transmission, Vertical; Lyme Disease; Male; Pregnancy; Pregnancy Complications, Infectious | 2008 |
[Pharyngeal Neisseria gonorrhoeae and Chlamydia trachomatis infections].
Topics: Anti-Bacterial Agents; Azithromycin; Bacteriological Techniques; Cephalosporins; Chlamydia Infections; Chlamydia trachomatis; Clarithromycin; Drug Therapy, Combination; Female; Gonorrhea; Humans; Male; Neisseria gonorrhoeae; Nucleic Acid Amplification Techniques; Ofloxacin; Pharyngitis; Pregnancy; Pregnancy Complications, Infectious; Sexual Behavior | 2009 |
Long-acting erythromycins: assessing their role in treating outpatient odontogenic infections.
Topics: Ambulatory Care; Anti-Bacterial Agents; Azithromycin; Bacterial Infections; Clarithromycin; Delayed-Action Preparations; Erythromycin; Humans; Tooth Diseases | 2009 |
Macrolides, ketolides, and glycylcyclines: azithromycin, clarithromycin, telithromycin, tigecycline.
Topics: Anti-Bacterial Agents; Azithromycin; Bacterial Infections; Clarithromycin; Humans; Ketolides; Macrolides; Minocycline; Tetracyclines; Tigecycline | 2009 |
Recent advances in the medicinal chemistry of novel erythromycin-derivatized antibiotics.
Topics: Anti-Bacterial Agents; Azithromycin; Chemistry, Pharmaceutical; Clarithromycin; Drug Resistance, Microbial; Erythromycin; Humans; Ketolides; Macrolides | 2010 |
Effectiveness and safety of macrolides in cystic fibrosis patients: a meta-analysis and systematic review.
Topics: Anti-Bacterial Agents; Azithromycin; Clarithromycin; Cystic Fibrosis; Humans; Lung; Macrolides; Pneumonia, Bacterial; Randomized Controlled Trials as Topic; Respiratory Function Tests; Treatment Outcome | 2011 |
Susceptibility of bacterial isolates from community-acquired infections in sub-Saharan Africa and Asia to macrolide antibiotics.
Topics: Adult; Africa South of the Sahara; Anti-Bacterial Agents; Asia; Azithromycin; Child; Clarithromycin; Community-Acquired Infections; Confounding Factors, Epidemiologic; Drug Resistance, Bacterial; Erythromycin; Escherichia coli; Gram-Negative Bacteria; Gram-Positive Bacteria; Haemophilus influenzae; Humans; Klebsiella; Macrolides; Microbial Sensitivity Tests; Neisseria meningitidis; Salmonella enterica; Streptococcus agalactiae; Streptococcus pyogenes | 2011 |
Preventing COPD exacerbations with macrolides: a review and budget impact analysis.
Topics: Anti-Bacterial Agents; Azithromycin; Belgium; Clarithromycin; Drug Costs; Erythromycin; Health Care Costs; Humans; Macrolides; Pulmonary Disease, Chronic Obstructive; Treatment Outcome | 2013 |
Interventions for the prevention of mycobacterium avium complex in adults and children with HIV.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Azithromycin; Child; Clarithromycin; Clofazimine; Humans; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Randomized Controlled Trials as Topic; Rifabutin | 2013 |
Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD).
Topics: Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Aza Compounds; Azithromycin; Clarithromycin; Disease Progression; Erythromycin; Fluoroquinolones; Humans; Moxifloxacin; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinolines; Randomized Controlled Trials as Topic | 2013 |
Inhalation of macrolides: a novel approach to treatment of pulmonary infections.
Topics: Administration, Inhalation; Aerosols; Animals; Anti-Bacterial Agents; Azithromycin; Bronchiectasis; Clarithromycin; Cystic Fibrosis; Erythromycin; Humans; Ketolides; Lung; Macrolides; Pulmonary Disease, Chronic Obstructive; Rats | 2015 |
Antibiotics for bronchiolitis in children under two years of age.
Topics: Ampicillin; Anti-Bacterial Agents; Azithromycin; Bronchiolitis; Clarithromycin; Erythromycin; Humans; Infant; Length of Stay; Randomized Controlled Trials as Topic | 2014 |
Efficacy and safety of World Health Organization group 5 drugs for multidrug-resistant tuberculosis treatment.
Topics: Amoxicillin; Antitubercular Agents; Azithromycin; Cilastatin; Clarithromycin; Clavulanic Acid; HIV Infections; Humans; Imipenem; Isoxazoles; Macrolides; Meropenem; Mycobacterium tuberculosis; Oxazolidinones; Randomized Controlled Trials as Topic; Thienamycins; Thioridazine; Treatment Outcome; Tuberculosis, Multidrug-Resistant; World Health Organization | 2015 |
Past, present and future of macrolide therapy for chronic rhinosinusitis in Japan.
Topics: Anti-Bacterial Agents; Azithromycin; Bronchiolitis; Chronic Disease; Clarithromycin; Erythromycin; Haemophilus Infections; History, 20th Century; History, 21st Century; Humans; Japan; Macrolides; Nasal Polyps; Rhinitis; Sinusitis | 2016 |
Infections caused by Mycobacterium abscessus: epidemiology, diagnostic tools and treatment.
Topics: Anti-Bacterial Agents; Azithromycin; Clarithromycin; Cystic Fibrosis; Humans; Mycobacterium; Mycobacterium Infections; Prevalence; Respiratory Tract Infections; Treatment Outcome; Virulence | 2016 |
Treatment of Infections Caused by Rhodococcus equi.
Topics: Actinomycetales Infections; Animals; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Drug Resistance, Multiple, Bacterial; Erythromycin; Horse Diseases; Horses; Pneumonia, Bacterial; Rhodococcus equi; Rifampin | 2017 |
[LONG TERM TREATMENT WITH MACROLIDES IN CHRONIC LUNG DISEASES].
Topics: Anti-Bacterial Agents; Azithromycin; Clarithromycin; Cystic Fibrosis; Erythromycin; Humans; Lung Diseases; Macrolides | 2016 |
Antimicrobial Resistance in
Topics: Animal Diseases; Animals; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Drug Combinations; Drug Resistance, Bacterial; Erythromycin; Fluoroquinolones; Horses; Lincosamides; Macrolides; Microbial Sensitivity Tests; Rhodococcus equi; Rifampin; Streptogramin B | 2017 |
Macrolide antibiotics for bronchiectasis.
Topics: Adult; Anti-Bacterial Agents; Azithromycin; Bronchiectasis; Child, Preschool; Clarithromycin; Erythromycin; Humans; Macrolides; Randomized Controlled Trials as Topic; Roxithromycin | 2018 |
Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD).
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Antibiotic Prophylaxis; Aza Compounds; Azithromycin; Clarithromycin; Clavulanic Acid; Disease Progression; Drug Administration Schedule; Erythromycin; Fluoroquinolones; Humans; Moxifloxacin; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinolines; Randomized Controlled Trials as Topic; Roxithromycin; Trimethoprim, Sulfamethoxazole Drug Combination | 2018 |
Topics: Aged; Amikacin; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Databases, Factual; Female; Humans; Imipenem; Lung Diseases; Male; Microbial Sensitivity Tests; Middle Aged; Mycobacterium abscessus; Mycobacterium Infections, Nontuberculous | 2019 |
Stevens-Johnson syndrome and toxic epidermal necrolysis associated with the use of macrolide antibiotics: a review of published cases.
Topics: Anti-Bacterial Agents; Azithromycin; Clarithromycin; Erythromycin; Humans; Ketolides; Macrolides; Roxithromycin; Stevens-Johnson Syndrome | 2021 |
Delirium associated with the use of macrolide antibiotics: a review.
Topics: Anti-Bacterial Agents; Azithromycin; Child; Clarithromycin; Delirium; Erythromycin; Humans | 2022 |
Diverse effects of clarithromycin and proposal of its clinical application for treating COVID-19 as a repurposing drug.
Topics: Angiotensin-Converting Enzyme 2; Azithromycin; Clarithromycin; COVID-19 Drug Treatment; Drug Repositioning; Humans; Hydrogen-Ion Concentration; Immunologic Factors; SARS-CoV-2 | 2021 |
Comparative efficacy of azithromycin versus clarithromycin in combination with beta-lactams to treat community-acquired pneumonia in hospitalized patients: a systematic review.
Topics: Adult; Anti-Bacterial Agents; Azithromycin; beta-Lactams; Clarithromycin; Community-Acquired Infections; Humans; Pneumonia, Bacterial | 2021 |
Efficacy of erythromycin compared to clarithromycin and azithromycin in adults or adolescents with community-acquired pneumonia: A Systematic Review and meta-analysis of randomized controlled trials.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Community-Acquired Infections; Erythromycin; Humans; Pneumonia; Randomized Controlled Trials as Topic | 2022 |
58 trial(s) available for clarithromycin and zithromax
| Article | Year |
|---|---|
Pharmacokinetics of EDP-420 after ascending single oral doses in healthy adult volunteers.
Topics: Administration, Oral; Adolescent; Adult; Anti-Bacterial Agents; Bridged-Ring Compounds; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Macrolides; Male; Middle Aged; Treatment Outcome; Young Adult | 2009 |
Intrapulmonary pharmacokinetics of S-013420, a novel bicyclolide antibacterial, in healthy Japanese subjects.
Topics: Adult; Anti-Bacterial Agents; Area Under Curve; Asian People; Bridged-Ring Compounds; Bronchoalveolar Lavage; Chromatography, High Pressure Liquid; Humans; Macrolides; Macrophages, Alveolar; Male; Mass Spectrometry; Middle Aged; Pulmonary Alveoli; Young Adult | 2010 |
New antibiotics look good against M. avium.
Topics: Acquired Immunodeficiency Syndrome; Azithromycin; Clarithromycin; Clofazimine; Drug Therapy, Combination; Erythromycin; Humans; Mycobacterium avium-intracellulare Infection | 1992 |
Efficacy of a three day course of azithromycin in moderately severe community-acquired pneumonia.
Topics: Adult; Azithromycin; Clarithromycin; Community-Acquired Infections; Drug Administration Schedule; Female; Hospitalization; Humans; Male; Middle Aged; Pneumonia, Bacterial; Treatment Outcome | 1995 |
Comparison of azithromycin versus clarithromycin in the treatment of patients with upper respiratory tract infections.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Azithromycin; Bacterial Infections; Child; Clarithromycin; Drug Administration Schedule; Erythromycin; Escherichia coli Infections; Female; Humans; Male; Middle Aged; Otitis Media; Pharyngitis; Respiratory Tract Infections; Sinusitis; Staphylococcal Infections; Staphylococcus aureus; Streptococcal Infections; Streptococcus pyogenes; Tonsillitis | 1993 |
Comparison of azithromycin versus clarithromycin in the treatment of patients with lower respiratory tract infection.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Azithromycin; Bacterial Infections; Bronchitis; Clarithromycin; Drug Administration Schedule; Erythromycin; Female; Humans; Male; Middle Aged; Pneumonia; Respiratory Tract Infections | 1993 |
Severe neutropenia caused by recommended prophylactic doses of rifabutin.
Topics: Acute Disease; Adult; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Drug Interactions; Female; Humans; Male; Neutropenia; Rifabutin | 1996 |
Effect of single oral dose of azithromycin, clarithromycin, and roxithromycin on polymorphonuclear leukocyte function assessed ex vivo by flow cytometry.
Topics: Adult; Anti-Bacterial Agents; Azithromycin; Chromatography, High Pressure Liquid; Clarithromycin; Cross-Over Studies; Escherichia coli; Female; Flow Cytometry; Humans; Male; Neutrophils; Phagocytosis; Reactive Oxygen Species; Roxithromycin | 1996 |
Interaction between midazolam and clarithromycin: comparison with azithromycin.
Topics: Adult; Analysis of Variance; Anti-Anxiety Agents; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Cross-Over Studies; Drug Interactions; Female; Humans; Male; Midazolam; Middle Aged; Sleep | 1996 |
Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin.
Topics: Adult; Anti-Bacterial Agents; Azithromycin; Biotransformation; Bronchi; Bronchoalveolar Lavage Fluid; Chromatography, High Pressure Liquid; Clarithromycin; Epithelium; Female; Humans; In Vitro Techniques; Lung; Macrophages, Alveolar; Male; Prospective Studies | 1996 |
Efficacy of short-term treatment of pertussis with clarithromycin and azithromycin.
Topics: Adolescent; Anti-Bacterial Agents; Azithromycin; Bordetella pertussis; Child; Child, Preschool; Clarithromycin; Drug Administration Schedule; Female; Humans; Infant; Male; Microbial Sensitivity Tests; Treatment Outcome; Whooping Cough | 1996 |
Helicobacter pylori eradication using one-week low-dose lansoprazole plus amoxycillin and either clarithromycin or azithromycin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Prospective Studies; Proton Pump Inhibitors | 1996 |
Cure of Helicobacter pylori infection in the elderly: effects of eradication on gastritis and serological markers.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Antibodies, Bacterial; Azithromycin; Biomarkers; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Pepsinogens | 1996 |
Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers.
Topics: Administration, Oral; Adolescent; Adult; Anti-Bacterial Agents; Azithromycin; Bronchoalveolar Lavage Fluid; Clarithromycin; Drug Administration Schedule; Epithelium; Female; Humans; Lung; Macrophages, Alveolar; Male; Middle Aged | 1997 |
Pharmacokinetic and pharmacodynamic interaction study between midazolam and the macrolide antibiotics, erythromycin, clarithromycin, and the azalide azithromycin.
Topics: Anti-Anxiety Agents; Anti-Bacterial Agents; Area Under Curve; Azithromycin; Clarithromycin; Cross-Over Studies; Drug Interactions; Erythromycin; Female; Humans; Male; Midazolam | 1997 |
A four-day low dose triple therapy regimen for the treatment of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Azithromycin; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Prospective Studies; Tinidazole; Treatment Outcome | 1998 |
[Effects of the triple therapy in the eradication of Helicobacter pylori: comparison of 3 different antibiotics].
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Azithromycin; Clarithromycin; Data Interpretation, Statistical; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Penicillins; Time Factors | 1997 |
The pattern of micro-organisms and the efficacy of new macrolide in acute lower respiratory tract infections.
Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Azithromycin; Bronchitis; Clarithromycin; Female; Humans; Klebsiella pneumoniae; Male; Pneumonia; Respiratory Tract Infections; Specimen Handling; Sputum; Staphylococcus aureus; Streptococcus; Streptococcus pneumoniae | 1998 |
Comparison of azithromycin and clarithromycin in their interactions with rifabutin in healthy volunteers.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Antibiotics, Antitubercular; Azithromycin; Clarithromycin; Drug Interactions; Female; Humans; Male; Rifabutin | 1998 |
Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences.
Topics: Administration, Oral; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Azithromycin; Clarithromycin; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Double-Blind Method; Erythromycin; Humans; Hypnotics and Sedatives; In Vitro Techniques; Microsomes, Liver; Oxidoreductases, N-Demethylating; Time Factors; Triazolam; Troleandomycin | 1998 |
Randomized, open-label trial of azithromycin plus ethambutol vs. clarithromycin plus ethambutol as therapy for Mycobacterium avium complex bacteremia in patients with human immunodeficiency virus infection. Veterans Affairs HIV Research Consortium.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Antitubercular Agents; Azithromycin; Bacteremia; Clarithromycin; Drug Therapy, Combination; Ethambutol; HIV-1; Humans; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Time Factors; Treatment Outcome | 1998 |
Prophylaxis for opportunistic infections among HIV-infected patients receiving medical care.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Analysis of Variance; Anti-Infective Agents; Atovaquone; Azithromycin; Clarithromycin; Dapsone; Ethnicity; Female; HIV Infections; Humans; Longitudinal Studies; Male; Medical Records; Mycobacterium avium-intracellulare Infection; Naphthoquinones; New York City; Pentamidine; Pneumonia, Pneumocystis; Practice Guidelines as Topic; Regression Analysis; Rifabutin; Risk-Taking; Time Factors; Toxoplasmosis; Trimethoprim, Sulfamethoxazole Drug Combination; United States; United States Public Health Service | 1998 |
Comparison of bactericidal activity after multidose administration of clarithromycin, azithromycin, and ceruroxime axetil against Streptococcus pneumoniae.
Topics: Anti-Bacterial Agents; Azithromycin; Cefuroxime; Cephalosporins; Clarithromycin; Cross-Over Studies; Drug Administration Schedule; Female; Half-Life; Humans; Male; Metabolic Clearance Rate; Microbial Sensitivity Tests; Penicillin Resistance; Serum Bactericidal Test; Streptococcus pneumoniae | 1998 |
Randomized, multicentre study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of adults with mild to moderate community-acquired pneumonia. Azithromycin Study Group.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Community-Acquired Infections; Female; Humans; Male; Middle Aged; Pneumonia, Bacterial; Treatment Outcome | 1998 |
Once-daily therapy for H. pylori infection: a randomized comparison of four regimens.
Topics: Adult; Amoxicillin; Azithromycin; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Omeprazole; Pilot Projects | 1999 |
Lack of effect of zafirlukast on the pharmacokinetics of azithromycin, clarithromycin, and 14-hydroxyclarithromycin in healthy volunteers.
Topics: Adult; Anti-Asthmatic Agents; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Cross-Over Studies; Drug Interactions; Female; Humans; Indoles; Leukotriene Antagonists; Male; Phenylcarbamates; Sulfonamides; Tosyl Compounds | 1999 |
Mononuclear and polymorphonuclear leukocyte dispositions of clarithromycin and azithromycin in AIDS patients requiring Mycobacterium avium complex prophylaxis.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-Bacterial Agents; Area Under Curve; Azithromycin; Clarithromycin; Cross-Over Studies; Female; Half-Life; Humans; Leukocytes, Mononuclear; Male; Microbial Sensitivity Tests; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Neutrophils | 1999 |
Pantoprazole, amoxycillin and either azithromycin or clarithromycin for eradication of Helicobacter pylori in duodenal ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Azithromycin; Benzimidazoles; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Pantoprazole; Penicillins; Proton Pump Inhibitors; Sulfoxides | 2000 |
A randomized, double-blind trial comparing azithromycin and clarithromycin in the treatment of disseminated Mycobacterium avium infection in patients with human immunodeficiency virus.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Ethambutol; Female; Gastrointestinal Diseases; Humans; Male; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Survival Analysis; Treatment Outcome | 2000 |
Antivirals key to MAC prevention regimen.
Topics: Acquired Immunodeficiency Syndrome; Anti-Infective Agents; Azithromycin; Clarithromycin; Double-Blind Method; Drug Resistance, Microbial; Drug Therapy, Combination; Humans; Mycobacterium avium-intracellulare Infection; Randomized Controlled Trials as Topic; Rifabutin | 1996 |
A randomized comparison of four omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia.
Topics: Administration, Oral; Adult; Amoxicillin; Ampicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Azithromycin; Breath Tests; Clarithromycin; Drug Therapy, Combination; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Omeprazole; Penicillins; Treatment Outcome; Urea | 2001 |
Clarithromycin versus azithromycin in the treatment of Mediterranean spotted fever in children: a randomized controlled trial.
Topics: Adolescent; Anti-Bacterial Agents; Azithromycin; Boutonneuse Fever; Child; Child, Preschool; Clarithromycin; Drug Administration Schedule; Female; Humans; Infant; Male; Rickettsia conorii; Treatment Outcome | 2002 |
A study of the interaction potential of azithromycin and clarithromycin with atorvastatin in healthy volunteers.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Area Under Curve; Atorvastatin; Azithromycin; Clarithromycin; Confidence Intervals; Drug Interactions; Female; Healthy Volunteers; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles | 2002 |
Double-blind, placebo-controlled study comparing the effect of azithromycin with clarithromycin on oropharyngeal and bowel microflora in volunteers.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Azithromycin; Bacteria; Candida; Clarithromycin; Double-Blind Method; Feces; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Oropharynx | 2002 |
Infection fighters. MAC prevention takes a holiday.
Topics: AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Antiretroviral Therapy, Highly Active; Azithromycin; CD4 Lymphocyte Count; Clarithromycin; Female; Humans; Male; Mycobacterium avium-intracellulare Infection; Placebos; Viral Load | 2000 |
Comparison of azithromycin and clarithromycin in triple therapy regimens for the eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Azithromycin; Bismuth; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Omeprazole; Prospective Studies; Stomach Diseases | 2002 |
Comparative analysis of azithromycin and clarithromycin efficacy and tolerability in the treatment of chronic prostatitis caused by Chlamydia trachomatis.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Azithromycin; Chlamydia Infections; Chlamydia trachomatis; Chronic Disease; Clarithromycin; Dose-Response Relationship, Drug; Humans; Male; Maximum Tolerated Dose; Middle Aged; Prospective Studies; Prostatitis; Treatment Outcome | 2002 |
Esberitox N as supportive therapy when providing standard antibiotic treatment in subjects with a severe bacterial infection (acute exacerbation of chronic bronchitis). A multicentric, prospective, double-blind, placebo-controlled study.
Topics: Adjuvants, Immunologic; Adult; Anti-Bacterial Agents; Azithromycin; Bacterial Infections; Bronchitis, Chronic; Chronic Disease; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Humans; Lung Diseases, Obstructive; Pilot Projects; Plant Extracts; Roxithromycin; Time Factors | 2002 |
[Macrolides in the treatment of children with Mediterranean spotted fever].
Topics: Adolescent; Anti-Bacterial Agents; Azithromycin; Boutonneuse Fever; Child; Child, Preschool; Chloramphenicol; Clarithromycin; Female; Humans; Infant; Italy; Macrolides; Male; Randomized Controlled Trials as Topic; Sicily; Tetracyclines; Treatment Outcome | 2002 |
Is azithromycin the first-choice macrolide for treatment of community-acquired pneumonia?
Topics: Adult; Aged; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Community-Acquired Infections; Follow-Up Studies; Humans; Length of Stay; Middle Aged; Pneumonia, Bacterial; Prospective Studies; Treatment Outcome | 2003 |
Comparative study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of community-acquired pneumonia in adults.
Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Community-Acquired Infections; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Pneumonia; Prospective Studies | 2004 |
Effect of macrolides on in vivo ion transport across cystic fibrosis nasal epithelium.
Topics: Adolescent; Adult; Animals; Azithromycin; Child; Clarithromycin; Cross-Over Studies; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Double-Blind Method; Humans; Ion Transport; Macrolides; Male; Membrane Potentials; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred CFTR; Mice, Knockout; Nasal Mucosa | 2005 |
Once-daily azithromycin for 3 days compared with clarithromycin for 10 days for acute exacerbation of chronic bronchitis: a multicenter, double-blind, randomized study.
Topics: Acute Disease; Administration, Oral; Anti-Bacterial Agents; Azithromycin; Bronchitis, Chronic; Clarithromycin; Double-Blind Method; Drug Administration Schedule; Female; Haemophilus influenzae; Humans; Male; Middle Aged; Moraxella catarrhalis; Streptococcus pneumoniae; Treatment Outcome | 2005 |
Single-dose azithromycin microspheres vs clarithromycin extended release for the treatment of mild-to-moderate community-acquired pneumonia in adults.
Topics: Adult; Aged; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Community-Acquired Infections; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Male; Microspheres; Middle Aged; Pneumonia | 2005 |
Evaluation of bitterness suppression of macrolide dry syrups by jellies.
Topics: Adult; Anti-Bacterial Agents; Azithromycin; Cacao; Chromatography, High Pressure Liquid; Clarithromycin; Data Interpretation, Statistical; Flavoring Agents; Humans; Hydrogen-Ion Concentration; Macrolides; Quinine; Solubility; Solutions; Taste | 2006 |
Quantitative determination of azithromycin in human plasma by liquid chromatography-mass spectrometry and its application in a bioequivalence study.
Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Azithromycin; Chromatography, High Pressure Liquid; Clarithromycin; Humans; Male; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Therapeutic Equivalency | 2006 |
Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Azithromycin; Carrier State; Clarithromycin; Double-Blind Method; Drug Resistance, Bacterial; Female; Humans; Macrolides; Male; Middle Aged; Pharynx; Streptococcus | 2007 |
Clinical and bacteriological outcomes in hospitalised patients with community-acquired pneumonia treated with azithromycin plus ceftriaxone, or ceftriaxone plus clarithromycin or erythromycin: a prospective, randomised, multicentre study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anti-Bacterial Agents; Azithromycin; Ceftriaxone; Clarithromycin; Community-Acquired Infections; Drug Therapy, Combination; Erythromycin; Female; Hospitalization; Humans; Injections, Intravenous; Male; Middle Aged; Pneumonia; Prospective Studies; Random Allocation; Treatment Outcome | 2007 |
Influence of azithromycin and clarithromycin on macrolide susceptibility of viridans streptococci from the oral cavity of healthy volunteers.
Topics: Adult; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Drug Resistance, Bacterial; Female; Humans; Macrolides; Male; Microbial Sensitivity Tests; Middle Aged; Mouth; Viridans Streptococci | 2008 |
Macrolide antibiotics and survival in patients with acute lung injury.
Topics: Acute Lung Injury; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; APACHE; Azithromycin; Clarithromycin; Combined Modality Therapy; Drug Administration Schedule; Erythromycin; Female; Hospital Mortality; Humans; Length of Stay; Macrolides; Male; Middle Aged; Pentoxifylline; Respiration, Artificial; Survival Rate; Tidal Volume | 2012 |
Therapeutic efficacy of macrolides, minocycline, and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae pneumonia in pediatric patients.
Topics: Adolescent; Anti-Bacterial Agents; Azithromycin; Child; Child, Preschool; Clarithromycin; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Infant; Infant, Newborn; Male; Minocycline; Mutation; Mycoplasma pneumoniae; Naphthyridines; Pneumonia, Mycoplasma; RNA, Bacterial; RNA, Ribosomal, 23S; Treatment Outcome | 2013 |
Azithromycin based triple therapy versus standard clarithromycin based triple therapy in eradication of Helicobacter pylori infection in Iran: a randomized controlled clinical trial.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Azithromycin; Clarithromycin; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Iran; Male; Omeprazole; Treatment Outcome | 2013 |
Expression comparison of azithromycin and clarithromycin in triple-therapy regimens for eradication of Helicobacter pylori in hemodialysis patients.
Topics: Amoxicillin; Anti-Bacterial Agents; Antigens, Bacterial; Azithromycin; Breath Tests; Chi-Square Distribution; Clarithromycin; Double-Blind Method; Feces; Female; Helicobacter Infections; Helicobacter pylori; Humans; Iran; Male; Middle Aged; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Renal Dialysis; Time Factors; Treatment Outcome | 2014 |
Intermittent antibiotic therapy for nodular bronchiectatic Mycobacterium avium complex lung disease.
Topics: Aged; Anti-Bacterial Agents; Antitubercular Agents; Azithromycin; Clarithromycin; Comorbidity; Drug Administration Schedule; Drug Therapy, Combination; Ethambutol; Female; Humans; Logistic Models; Macrolides; Male; Middle Aged; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Outcome and Process Assessment, Health Care; Practice Guidelines as Topic; Republic of Korea; Retrospective Studies; Rifampin; Sputum | 2015 |
Replacement of clarithromycin with azithromycin in triple therapy regimens for the eradication of Helicobacter pylori: A randomized clinical trial.
Topics: Amoxicillin; Azithromycin; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Iran; Male; Omeprazole; Stomach Ulcer | 2014 |
Probiotics for standard triple Helicobacter pylori eradication: a randomized, double-blind, placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Bifidobacterium; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lacticaseibacillus rhamnosus; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Pantoprazole; Placebos; Probiotics; Prospective Studies; Proton Pump Inhibitors; Surveys and Questionnaires; Treatment Outcome | 2015 |
Therapeutic efficacy of macrolides in management of patients with mild COVID-19.
Topics: Adult; Azithromycin; Clarithromycin; COVID-19; COVID-19 Drug Treatment; Female; Fever; Humans; Male; Middle Aged; Patient Acuity; Treatment Outcome | 2021 |
Introducing a Novel Combination Therapy with Macrolides for the Treatment of Chronic Rhinosinusitis: A Randomized Controlled Trial.
Topics: Adult; Anti-Bacterial Agents; Azithromycin; Chronic Disease; Clarithromycin; Humans; Macrolides; Rhinitis; Single-Blind Method; Sinusitis; Treatment Outcome | 2022 |
469 other study(ies) available for clarithromycin and zithromax
| Article | Year |
|---|---|
Quantitative structure-activity relationships among macrolide antibacterial agents: in vitro and in vivo potency against Pasteurella multocida.
Topics: Animals; Anti-Bacterial Agents; Chromatography, High Pressure Liquid; Hydrogen-Ion Concentration; Macrolides; Mice; Microbial Sensitivity Tests; Molecular Structure; Pasteurella Infections; Pasteurella multocida; Structure-Activity Relationship | 1997 |
Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens.
Topics: Animals; Anti-Bacterial Agents; Colony Count, Microbial; Crystallography, X-Ray; Drug Evaluation, Preclinical; Drug Resistance, Microbial; Drug Resistance, Multiple; Enterococcus; Erythromycin; Haemophilus Infections; Haemophilus influenzae; Ketolides; Macrolides; Male; Mice; Models, Molecular; Molecular Conformation; Respiratory Tract Infections; Staphylococcal Infections; Staphylococcus; Streptococcus; Streptococcus pneumoniae | 1998 |
Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens.
Topics: Animals; Anti-Bacterial Agents; Drug Resistance, Microbial; Erythromycin; Gram-Negative Bacteria; Gram-Positive Bacteria; Haemophilus influenzae; Ketolides; Macrolides; Mice; Microbial Sensitivity Tests; Molecular Structure | 1999 |
Beta-keto-ester chemistry and ketolides. Synthesis and antibacterial activity of 2-halogeno, 2-methyl and 2,3 enol-ether ketolides.
Topics: Animals; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Macrolides; Mice; Structure-Activity Relationship | 2000 |
Novel erythromycin derivatives with aryl groups tethered to the C-6 position are potent protein synthesis inhibitors and active against multidrug-resistant respiratory pathogens.
Topics: Animals; Anti-Bacterial Agents; Carbamates; Cell-Free System; Drug Resistance, Multiple; Erythromycin; Haemophilus influenzae; Ketolides; Lung; Mice; Models, Molecular; Protein Biosynthesis; Protein Synthesis Inhibitors; Rats; Respiratory Tract Infections; Ribosomes; Staphylococcus aureus; Streptococcus pneumoniae; Streptococcus pyogenes; Structure-Activity Relationship; Transcription, Genetic | 2001 |
Synthesis and antibacterial activity of a novel series of acylides: 3-O-(3-pyridyl)acetylerythromycin A derivatives.
Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Area Under Curve; Drug Resistance, Multiple, Bacterial; Erythromycin; Haemophilus influenzae; Macrolides; Mice; Staphylococcal Infections; Staphylococcus aureus; Stereoisomerism; Streptococcal Infections; Streptococcus pneumoniae; Structure-Activity Relationship | 2003 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
Topics: Amidohydrolases; Drug Resistance, Bacterial; Microbial Sensitivity Tests; Peptides; Pneumococcal Infections; Species Specificity; Streptococcus pneumoniae; Time Factors | 2007 |
High-level telithromycin resistance in a clinical isolate of Streptococcus pneumoniae.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Culture Media; Drug Resistance, Bacterial; Genotype; Humans; Ketolides; Methyltransferases; Microbial Sensitivity Tests; Mutation; Phenotype; Pneumococcal Infections; Ribosomal Proteins; Streptococcus pneumoniae | 2007 |
EDP-420, a bicyclolide (bridged bicyclic macrolide), is active against Mycobacterium avium.
Topics: Animals; Anti-Bacterial Agents; Bridged-Ring Compounds; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Female; Humans; Macrolides; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests; Mycobacterium avium | 2007 |
Roxithromycin favorably modifies the initial phase of resistance against infection with macrolide-resistant Streptococcus pneumoniae in a murine pneumonia model.
Topics: Animals; Anti-Bacterial Agents; Bacterial Proteins; Bronchoalveolar Lavage Fluid; Chemokine CCL2; Disease Models, Animal; Drug Resistance, Bacterial; Lung; Macrolides; Male; Matrix Metalloproteinase 7; Mice; Mice, Inbred CBA; Pneumonia, Pneumococcal; Roxithromycin; Streptolysins | 2007 |
Genetic characteristics and clonal dissemination of beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains isolated from the upper respiratory tract of patients in Japan.
Topics: Adolescent; Adult; Ampicillin; Ampicillin Resistance; Anti-Bacterial Agents; beta-Lactamases; Child; Child, Preschool; Female; Gene Frequency; Genotype; Haemophilus influenzae; Humans; Infant; Infant, Newborn; Japan; Male; Microbial Sensitivity Tests; Middle Aged; Mutation; Polymerase Chain Reaction; Respiratory Tract Infections | 2007 |
Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
Topics: Anti-Bacterial Agents; Aza Compounds; Azithromycin; Clarithromycin; Clavulanic Acid; Clindamycin; Drug Resistance, Bacterial; Fluoroquinolones; Gemifloxacin; Imipenem; Ketolides; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Streptococcus pneumoniae | 2007 |
Increased macrolide resistance of Mycoplasma pneumoniae in pediatric patients with community-acquired pneumonia.
Topics: Adolescent; Anti-Bacterial Agents; Child; Child, Preschool; Community-Acquired Infections; Drug Resistance, Bacterial; Humans; Infant; Infant, Newborn; Macrolides; Microbial Sensitivity Tests; Mycoplasma pneumoniae; Pneumonia, Mycoplasma; RNA, Ribosomal, 23S | 2008 |
Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics.
Topics: Animals; Anti-Bacterial Agents; Cell Line; Cells, Cultured; Colon; Crohn Disease; Culture Media; Escherichia coli; Humans; Macrophages; Mice; Microbial Sensitivity Tests; Monocytes; Mucous Membrane | 2008 |
Induction of erm(C) expression by noninducing antibiotics.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Drug Resistance, Bacterial; Enzyme Induction; Escherichia coli; Gene Expression Regulation, Bacterial; Ketolides; Macrolides; Methyltransferases; Microbial Sensitivity Tests; Molecular Sequence Data; Protein Conformation; Protein Sorting Signals; Ribosomes; RNA, Messenger | 2008 |
Antimicrobial susceptibilities of geographically diverse clinical human isolates of Leptospira.
Topics: Ampicillin; Anti-Bacterial Agents; Azithromycin; Cefepime; Cefotaxime; Ceftriaxone; Cephalosporins; Ciprofloxacin; Egypt; Hawaii; Humans; Leptospira; Leptospirosis; Levofloxacin; Microbial Sensitivity Tests; Nicaragua; Ofloxacin; Tetracycline; Thailand | 2008 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
Topics: Animals; Anti-Bacterial Agents; Cricetinae; Fibroblasts; Gram-Negative Bacteria; Kidney Cortex; Lung; Microbial Sensitivity Tests; Microvilli; Polymyxin B; Rats; Structure-Activity Relationship | 2008 |
In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria.
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Humans; In Vitro Techniques; Microbial Sensitivity Tests; Minocycline; Mycobacterium; Mycobacterium Infections; Pigmentation; Species Specificity; Tigecycline | 2008 |
Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Proteins; Macrolides; Molecular Sequence Data; Multidrug Resistance-Associated Proteins; Mutagenesis, Site-Directed; Sequence Homology, Amino Acid | 2009 |
Susceptibility of Mycobacterium bovis BCG vaccine strains to antituberculous antibiotics.
Topics: Antitubercular Agents; BCG Vaccine; Microbial Sensitivity Tests; Mycobacterium bovis | 2009 |
Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Bacterial Proteins; Base Sequence; Chromosome Walking; DNA-Binding Proteins; Genetic Engineering; Genome, Bacterial; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Point Mutation; Sequence Analysis, DNA; Sequence Homology, Amino Acid; Staphylococcus aureus; Vancomycin; Vancomycin Resistance | 2009 |
Synthesis and antibacterial activity of 4'',11-di-O-arylalkylcarbamoyl azithromycin derivatives.
Topics: Anti-Bacterial Agents; Azithromycin; Bacterial Proteins; Chemistry, Pharmaceutical; Drug Design; Drug Resistance, Multiple, Bacterial; Macrolides; Membrane Proteins; Methyltransferases; Microbial Sensitivity Tests; Models, Chemical; Streptococcal Infections; Streptococcus pneumoniae | 2009 |
Characterization of macrolide efflux pump mef subclasses detected in clinical isolates of Streptococcus pyogenes isolated between 1999 and 2005.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Community-Acquired Infections; Drug Resistance, Bacterial; Global Health; Humans; Macrolides; Membrane Proteins; Microbial Sensitivity Tests; Molecular Sequence Data; Population Surveillance; Respiratory Tract Infections; Sequence Analysis, DNA; Streptococcal Infections; Streptococcus pyogenes | 2009 |
Concurrent titration and determination of antibiotic resistance in ureaplasma species with identification of novel point mutations in genes associated with resistance.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Bronchoalveolar Lavage Fluid; Ciprofloxacin; Clarithromycin; Culture Media; Drug Resistance, Bacterial; Erythromycin; Humans; Infant, Newborn; Infant, Premature, Diseases; Microbial Sensitivity Tests; Point Mutation; Polymerase Chain Reaction; Sequence Analysis, DNA; Species Specificity; Tetracycline; Ureaplasma; Ureaplasma Infections | 2009 |
Antimicrobial susceptibility of Mycoplasma pneumoniae isolates and molecular analysis of macrolide-resistant strains from Shanghai, China.
Topics: Adhesins, Bacterial; Anti-Bacterial Agents; Child; China; Drug Resistance, Bacterial; Genes, rRNA; Humans; Macrolides; Microbial Sensitivity Tests; Mutation; Mycoplasma pneumoniae; Pneumonia, Mycoplasma; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Respiratory Tract Infections; RNA, Ribosomal, 23S; Sequence Analysis, DNA | 2009 |
Comparative antipneumococcal activities of sulopenem and other drugs.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Lactams; Microbial Sensitivity Tests; Penicillin-Binding Proteins; Streptococcus pneumoniae | 2009 |
Synthesis and antibacterial activity of novel 15-membered macrolide derivatives: 4''-carbamate, 11,12-cyclic carbonate-4''-carbamate and 11,4''-di-O-arylcarbamoyl analogs of azithromycin.
Topics: Anti-Bacterial Agents; Azithromycin; Carbamates; Carbonates; Drug Resistance, Bacterial; Microbial Sensitivity Tests; Staphylococcal Infections; Staphylococcus; Streptococcal Infections; Streptococcus pneumoniae | 2009 |
Synthesis of novel macrolide derivatives with imidazo[4,5-b]pyridinyl sulfur contained alkyl side chains and their antibacterial activity.
Topics: Anti-Bacterial Agents; Chemistry, Pharmaceutical; Clarithromycin; Drug Design; Drug Resistance, Multiple, Bacterial; Erythromycin; Humans; Imidazoles; Ketolides; Macrolides; Microbial Sensitivity Tests; Models, Chemical; Respiratory Tract Infections; Staphylococcus aureus; Streptococcus pneumoniae; Sulfides; Sulfur | 2009 |
Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages.
Topics: Anti-Bacterial Agents; Cell Line; Humans; Ketolides; Legionella pneumophila; Listeria monocytogenes; Macrophages; Microbial Sensitivity Tests; Molecular Structure; Staphylococcus aureus | 2009 |
Role of porins in the susceptibility of Mycobacterium smegmatis and Mycobacterium chelonae to aldehyde-based disinfectants and drugs.
Topics: Antitubercular Agents; Disinfectants; Drug Resistance, Bacterial; Glutaral; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation; Mycobacterium chelonae; Mycobacterium smegmatis; o-Phthalaldehyde; Porins | 2009 |
Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR.
Topics: Microbial Sensitivity Tests; Mycoplasma genitalium; Polymerase Chain Reaction | 2009 |
In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms.
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Macrolides; Microbial Sensitivity Tests; Penicillin G; Streptococcus pneumoniae; Streptococcus pyogenes; Triazoles | 2010 |
Synthesis and antibacterial activity of novel 3-O-carbamoyl derivatives of clarithromycin and 11,12-cyclic carbonate azithromycin.
Topics: Anti-Bacterial Agents; Azithromycin; Clarithromycin; Drug Evaluation, Preclinical; Microbial Sensitivity Tests; Molecular Structure; Streptococcus pneumoniae | 2010 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Antimicrobial susceptibilities of multidrug-resistant Campylobacter jejuni and C. coli strains: in vitro activities of 20 antimicrobial agents.
Topics: Anti-Bacterial Agents; Campylobacter coli; Campylobacter Infections; Campylobacter jejuni; Carbapenems; Drug Resistance, Multiple, Bacterial; Erythromycin; Feces; Finland; Humans; Macrolides; Microbial Sensitivity Tests; Minocycline; Tigecycline | 2010 |
In vitro activity of CEM-101, a new fluoroketolide antibiotic, against Chlamydia trachomatis and Chlamydia (Chlamydophila) pneumoniae.
Topics: Adult; Anti-Bacterial Agents; Child; Child, Preschool; Chlamydia Infections; Chlamydia trachomatis; Chlamydophila Infections; Chlamydophila pneumoniae; Female; Humans; Infant; Macrolides; Microbial Sensitivity Tests; Pneumonia, Bacterial; Triazoles | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Nucleotide selectivity of antibiotic kinases.
Topics: Anti-Bacterial Agents; Bacteria; Binding, Competitive; Drug Resistance, Bacterial; Guanosine Triphosphate; Kanamycin Kinase; Models, Chemical; Nucleotides; Phosphotransferases (Alcohol Group Acceptor); Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Substrate Specificity | 2010 |
Enhancement of biofilm formation by subinhibitory concentrations of macrolides in icaADBC-positive and -negative clinical isolates of Staphylococcus epidermidis.
Topics: Anti-Bacterial Agents; Base Sequence; Biofilms; DNA Primers; Dose-Response Relationship, Drug; Erythromycin; Gene Expression; Genes, Bacterial; Humans; In Vitro Techniques; Macrolides; Microscopy, Electron, Scanning; Reverse Transcriptase Polymerase Chain Reaction; Staphylococcal Infections; Staphylococcus epidermidis | 2010 |
Synthesis and antibacterial activities of a novel alkylide: 3-O-(3-aryl-2-propargyl) and 3-O-(3-aryl-2-propenyl)clarithromycin derivatives.
Topics: Anti-Bacterial Agents; Clarithromycin; Microbial Sensitivity Tests; Staphylococcus aureus; Streptococcus pneumoniae; Structure-Activity Relationship | 2010 |
Antimicrobial resistance among respiratory pathogens in Spain: latest data and changes over 11 years (1996-1997 to 2006-2007).
Topics: Ampicillin; Anti-Bacterial Agents; Cefotaxime; Erythromycin; Haemophilus influenzae; Lincosamides; Macrolides; Microbial Sensitivity Tests; Penicillins; Respiratory Tract Infections; Spain; Streptococcus pneumoniae; Streptococcus pyogenes; Streptogramin B | 2010 |
Synthesis and antibacterial activity of novel 4''-O-arylalkylcarbamoyl and 4''-O-((arylalkylamino)-4-oxo-butyl)carbamoyl clarithromycin derivatives.
Topics: Anti-Bacterial Agents; Clarithromycin; Genes, Bacterial; Microbial Sensitivity Tests; Streptococcus pneumoniae | 2010 |
A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane.
Topics: Animals; Anti-Bacterial Agents; Cell Membrane Permeability; Cricetinae; Cricetulus; Drug Synergism; Fibroblasts; Gram-Negative Bacteria; Guinea Pigs; Lung; Male; Microbial Sensitivity Tests; Polymyxin B; Rats; Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Synthesis and antibacterial activity of 3-O-carbamoyl derivatives of 6,11-di-O-methylerythromycin A: a novel class of acylides.
Topics: Anti-Bacterial Agents; Bacteria; Clarithromycin; Drug Discovery; Microbial Sensitivity Tests | 2010 |
In vitro activity of tebipenem, a new oral carbapenem antibiotic, against beta-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae.
Topics: Ampicillin Resistance; Bacterial Proteins; beta-Lactamases; Carbapenems; Drug Resistance, Bacterial; Haemophilus influenzae; Microbial Sensitivity Tests; Polymerase Chain Reaction | 2010 |
Optimized Nile Red efflux assay of AcrAB-TolC multidrug efflux system shows competition between substrates.
Topics: Anti-Bacterial Agents; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Chlortetracycline; Dipeptides; Doxorubicin; Doxycycline; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Proteins; Minocycline; Onium Compounds; Organophosphorus Compounds; Tetracycline | 2010 |
Determination of CEM-101 activity tested against clinical isolates of Neisseria meningitidis from a worldwide collection.
Topics: Anti-Bacterial Agents; Azithromycin; Ceftriaxone; Ciprofloxacin; Humans; Ketolides; Macrolides; Microbial Sensitivity Tests; Minocycline; Neisseria meningitidis; Penicillins; Rifampin; Sulfamethoxazole; Triazoles; Trimethoprim | 2010 |
Synthesis and antibacterial activities of 6-O-methylerythromycin A 9-O-(3-aryl-2-propenyl) oxime ketolide, 2,3-enol ether, and alkylide analogues.
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Ethers; Ketolides; Staphylococcus aureus; Streptococcus pneumoniae | 2010 |
4''-O-(omega-Quinolylamino-alkylamino)propionyl derivatives of selected macrolides with the activity against the key erythromycin resistant respiratory pathogens.
Topics: Anti-Bacterial Agents; Bacterial Infections; Drug Resistance, Bacterial; Erythromycin; Humans; Macrolides; Microbial Sensitivity Tests; Propionates | 2010 |
Update on fusidic acid (CEM-102) tested against Neisseria gonorrhoeae and Chlamydia trachomatis.
Topics: Anti-Bacterial Agents; Chlamydia trachomatis; Fusidic Acid; Neisseria gonorrhoeae | 2010 |
6-Alkylquinolone-3-carboxylic acid tethered to macrolides synthesis and antimicrobial profile.
Topics: Anti-Bacterial Agents; Azithromycin; Clarithromycin; Humans; Macrolides; Microbial Sensitivity Tests; Quinolones; Structure-Activity Relationship | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
In vitro activities of several antimicrobial agents against recently isolated and genotyped Chlamydia trachomatis urogenital serovars D through K.
Topics: Anti-Infective Agents; Azithromycin; Chlamydia trachomatis; Clarithromycin; Doxycycline; Erythromycin; Genotype; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin | 2010 |
Synthesis and antibacterial evaluation of novel clarithromycin derivatives with C-4″ elongated arylalkyl groups against macrolide-resistant strains.
Topics: Anti-Bacterial Agents; Clarithromycin; Drug Design; Drug Resistance, Bacterial; Macrolides; Microbial Sensitivity Tests; Molecular Conformation; Staphylococcus aureus; Stereoisomerism; Streptococcus pneumoniae; Streptococcus pyogenes; Structure-Activity Relationship | 2011 |
Modeling cellular pharmacokinetics of 14- and 15-membered macrolides with physicochemical properties.
Topics: Cell Line, Tumor; Chemical Phenomena; Humans; Leukocytes; Lung; Lung Neoplasms; Macrolides; Models, Biological; Primary Cell Culture; Respiratory Mucosa; Structure-Activity Relationship | 2011 |
Chemistry and biology of macrolide antiparasitic agents.
Topics: Anti-Bacterial Agents; Antiparasitic Agents; Cells, Cultured; Humans; Macrolides; Magnetic Resonance Spectroscopy; Microbial Sensitivity Tests; Models, Molecular; Spectrometry, Mass, Electrospray Ionization; Structure-Activity Relationship; Toxoplasma | 2011 |
Synthesis and antibacterial activity of novel 4″-O-benzimidazolyl clarithromycin derivatives.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Benzimidazoles; Clarithromycin; Drug Resistance, Bacterial; Erythromycin; Gene Expression; Hydrazines; Membrane Proteins; Methyltransferases; Staphylococcus aureus; Streptococcus pneumoniae; Structure-Activity Relationship | 2011 |
Synthesis of macrolones with central piperazine ring in the linker and its influence on antibacterial activity.
Topics: Anti-Bacterial Agents; Macrolides; Piperazine; Piperazines; Quinolones; Structure-Activity Relationship | 2011 |
Synthesis and antibacterial activity of a novel series of acylides active against community acquired respiratory pathogens.
Topics: Anti-Bacterial Agents; Chemistry, Pharmaceutical; Clarithromycin; Drug Design; Drug Resistance, Bacterial; Haemophilus influenzae; Humans; Ketolides; Microbial Sensitivity Tests; Models, Chemical; Nitrogen; Respiratory Tract Infections; Streptococcus pneumoniae | 2012 |
Structure-activity relationships of novel alkylides: 3-O-arylalkyl clarithromycin derivatives with improved antibacterial activities.
Topics: Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Multiple, Bacterial; Humans; Macrolides; Microbial Sensitivity Tests; Staphylococcal Infections; Staphylococcus; Staphylococcus aureus; Streptococcal Infections; Streptococcus; Streptococcus pneumoniae; Streptococcus pyogenes; Structure-Activity Relationship | 2012 |
Novel desosamine-modified 14- and 15-membered macrolides without antibacterial activity.
Topics: Amino Sugars; Anti-Bacterial Agents; Cyclization | 2012 |
Synthesis and antibacterial activity of 6-O-(heteroaryl-isoxazolyl)propynyl 2-fluoro ketolides.
Topics: Anti-Bacterial Agents; Crystallography, X-Ray; Drug Resistance, Bacterial; Erythromycin; Haemophilus Infections; Haemophilus influenzae; Halogenation; Humans; Ketolides; Microbial Sensitivity Tests; Models, Molecular; Respiratory Tract Infections; Staphylococcal Infections; Staphylococcus | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Synthesis, antibacterial activity and docking of 14-membered 9-O-(3-arylalkyl) oxime 11,12-cyclic carbonate ketolides.
Topics: Anti-Bacterial Agents; Bacteria; Carbonates; Cyclization; Ketolides; Microbial Sensitivity Tests; Models, Molecular; Molecular Docking Simulation | 2013 |
Synthesis and antibacterial evaluation of novel 11,4″-disubstituted azithromycin analogs with greatly improved activity against erythromycin-resistant bacteria.
Topics: Anti-Bacterial Agents; Azithromycin; Drug Resistance, Bacterial; Erythromycin; Microbial Sensitivity Tests; Molecular Structure; Staphylococcus aureus; Streptococcus pneumoniae | 2013 |
Synthesis and antibacterial activity of 9-oxime ether non-ketolides, and novel binding mode of alkylides with bacterial rRNA.
Topics: Anti-Bacterial Agents; Clarithromycin; Erythromycin; Ether; Ketolides; Models, Molecular; Oximes; RNA, Bacterial; RNA, Ribosomal | 2013 |
Design, synthesis, and biological evaluations of novel 7-[7-amino-7-methyl-5-azaspiro[2.4]heptan-5-yl]-8-methoxyquinolines with potent antibacterial activity against respiratory pathogens.
Topics: Animals; Anti-Bacterial Agents; Drug Design; Fluoroquinolones; Haemophilus influenzae; Male; Mice; Microbial Sensitivity Tests; Quinolones; Rats; Respiratory Tract Infections; Spiro Compounds; Staphylococcus aureus; Streptococcus pneumoniae | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Synthesis of novel 15-membered 8a-azahomoerythromycin A acylides: Consequences of structural modification at the C-3 and C-6 position on antibacterial activity.
Topics: Animals; Anti-Bacterial Agents; Biological Availability; Drug Resistance, Bacterial; Erythromycin; Humans; Macrolides; Structure-Activity Relationship | 2017 |
Synthesis and antibacterial activity of novel 3-O-descladinosylazithromycin derivatives.
Topics: Anti-Bacterial Agents; Azithromycin; Bacteria; Bacterial Proteins; Chemistry Techniques, Synthetic; Drug Resistance, Bacterial; Microbial Sensitivity Tests; Models, Molecular; Structure-Activity Relationship | 2017 |
Around the macrolide - Impact of 3D structure of macrocycles on lipophilicity and cellular accumulation.
Topics: Anti-Bacterial Agents; Azithromycin; Clarithromycin; Humans; Models, Biological; Models, Chemical; Molecular Conformation; Molecular Dynamics Simulation | 2017 |
Synthesis and antibacterial activity of novel 4″-O-(1-aralkyl-1,2,3-triazol-4-methyl-carbamoyl) azithromycin analogs.
Topics: Anti-Bacterial Agents; Azithromycin; Dose-Response Relationship, Drug; Escherichia coli; Microbial Sensitivity Tests; Molecular Structure; Staphylococcus aureus; Streptococcus pneumoniae; Streptococcus pyogenes; Structure-Activity Relationship | 2017 |
Synthesis and antibacterial evaluation of novel 11-O-carbamoyl clarithromycin ketolides.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Clarithromycin; Drug Resistance, Bacterial; Erythromycin; Gram-Negative Bacteria; Gram-Positive Bacteria; Ketolides; Membrane Proteins; Methyltransferases; Microbial Sensitivity Tests; Streptococcus pneumoniae; Streptococcus pyogenes; Structure-Activity Relationship | 2017 |
Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
Topics: Anti-Bacterial Agents; Drug Design; Genistein; Mycobacterium avium; Quinolones | 2017 |
Synthesis and antibacterial evaluation of novel 11-O-aralkylcarbamoyl-3-O-descladinosylclarithromycin derivatives.
Topics: Anti-Bacterial Agents; Bacillus subtilis; Clarithromycin; Dose-Response Relationship, Drug; Microbial Sensitivity Tests; Molecular Structure; Staphylococcus aureus; Streptococcus pneumoniae; Streptococcus pyogenes; Structure-Activity Relationship | 2018 |
Synthesis and antibacterial activity of novel 3-O-arylalkylcarbamoyl-3-O-descladinosyl-9-O-(2-chlorobenzyl)oxime clarithromycin derivatives.
Topics: Anti-Bacterial Agents; Bacillus subtilis; Clarithromycin; Drug Design; Escherichia coli; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Molecular Docking Simulation; Molecular Structure; Oximes; Pseudomonas aeruginosa; Ribosomes; Streptococcus pneumoniae; Streptococcus pyogenes | 2018 |
Lipophilic Permeability Efficiency Reconciles the Opposing Roles of Lipophilicity in Membrane Permeability and Aqueous Solubility.
Topics: 1-Octanol; Cell Membrane Permeability; Cyclosporins; Hydrogen Bonding; Hydrophobic and Hydrophilic Interactions; Peptides; Peptides, Cyclic; Pharmaceutical Preparations; Small Molecule Libraries; Solubility; Structure-Activity Relationship; Water | 2018 |
Design, synthesis and structure-activity relationships of novel macrolones: Hybrids of 2-fluoro 9-oxime ketolides and carbamoyl quinolones with highly improved activity against resistant pathogens.
Topics: Anti-Bacterial Agents; Dose-Response Relationship, Drug; Drug Design; Drug Resistance, Bacterial; Ketolides; Microbial Sensitivity Tests; Molecular Structure; Oximes; Quinolones; Streptococcus pneumoniae; Streptococcus pyogenes; Structure-Activity Relationship | 2019 |
Synthesis and structure-bactericidal activity relationships of non-ketolides: 9-Oxime clarithromycin 11,12-cyclic carbonate featured with three-to eight-atom-length spacers at 3-OH.
Topics: Anti-Bacterial Agents; Bacteria; Clarithromycin; Dose-Response Relationship, Drug; Microbial Sensitivity Tests; Molecular Docking Simulation; Molecular Structure; Structure-Activity Relationship | 2019 |
Design, synthesis and antibacterial evaluation of novel 15-membered 11a-azahomoclarithromycin derivatives with the 1, 2, 3-triazole side chain.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacillus subtilis; Clarithromycin; Dose-Response Relationship, Drug; Drug Design; Microbial Sensitivity Tests; Molecular Structure; Staphylococcus aureus; Streptococcus pneumoniae; Structure-Activity Relationship; Triazoles | 2019 |
Differentiating the Pharmacodynamics and Toxicology of Macrolide and Ketolide Antibiotics.
Topics: Animals; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Drug Resistance, Bacterial; Drug-Related Side Effects and Adverse Reactions; Humans; Ketolides; Macrolides | 2020 |
A novel series of 11-O-carbamoyl-3-O-descladinosyl clarithromycin derivatives bearing 1,2,3-triazole group: Design, synthesis and antibacterial evaluation.
Topics: Anti-Bacterial Agents; Clarithromycin; Humans; Structure-Activity Relationship; Triazoles | 2020 |
Design, synthesis and structure-activity relationships of novel 15-membered macrolides: Quinolone/quinoline-containing sidechains tethered to the C-6 position of azithromycin acylides.
Topics: Anti-Bacterial Agents; Azithromycin; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Drug Design; Escherichia coli; Macrolides; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Molecular Structure; Quinolines; Quinolones; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2020 |
Design, synthesis and antibacterial evaluation of novel C-11, C-9 or C-2'-substituted 3-O-descladinosyl-3-ketoclarithromycin derivatives.
Topics: Anti-Bacterial Agents; Clarithromycin; Dose-Response Relationship, Drug; Microbial Sensitivity Tests; Molecular Structure; Staphylococcus; Structure-Activity Relationship | 2021 |
Design, synthesis and antibacterial evaluation of novel 3-O-substituted 15-membered azalides possessing 1,2,3-triazole side chains.
Topics: Anti-Bacterial Agents; Azithromycin; Bacteria; Microbial Sensitivity Tests; Molecular Docking Simulation; Molecular Structure; Ribosomes; Structure-Activity Relationship; Triazoles | 2021 |
New macrolide antibiotics: azithromycin and clarithromycin.
Topics: Animals; Azithromycin; Bacterial Infections; Clarithromycin; Erythromycin; Humans | 1992 |
Two macrolide antimicrobials approved for marketing.
Topics: Azithromycin; Bacterial Infections; Clarithromycin; Erythromycin; Humans; United States; United States Food and Drug Administration | 1992 |
Clarithromycin and azithromycin.
Topics: Azithromycin; Bacterial Infections; Clarithromycin; Clinical Trials as Topic; Erythromycin; Humans; Microbial Sensitivity Tests | 1992 |
Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and M. chelonae-like organisms.
Topics: Azithromycin; Clarithromycin; Erythromycin; Microbial Sensitivity Tests; Mycobacterium; Roxithromycin | 1992 |
In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae.
Topics: Anti-Bacterial Agents; Azithromycin; Cells, Cultured; Chlamydophila pneumoniae; Clarithromycin; Erythromycin; Microbial Sensitivity Tests; Ofloxacin | 1992 |
Influence of azithromycin and other macrolides on the intracellular killing of Staphylococcus aureus by human polymorphonuclear leucocytes of healthy donors and a patient with Chédiak-Higashi syndrome.
Topics: Anti-Bacterial Agents; Azithromycin; Chediak-Higashi Syndrome; Child; Clarithromycin; Colony Count, Microbial; Erythromycin; Female; Humans; Neutrophils; Phagocytosis; Roxithromycin; Staphylococcus aureus | 1992 |
The in-vitro activity of new streptogramins, RP 59500, RP 57669 and RP 54476, alone and in combination.
Topics: Azithromycin; Bacteria; Cefotaxime; Ciprofloxacin; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Erythromycin; Gentamicins; Gram-Negative Bacteria; Humans; In Vitro Techniques; Microbial Sensitivity Tests; Miocamycin; Roxithromycin; Virginiamycin | 1992 |
Activity of azithromycin against Mycobacterium avium infection in beige mice.
Topics: Animals; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Culture Media; Drug Therapy, Combination; Erythromycin; Female; Male; Mice; Mice, Inbred C57BL; Mycobacterium avium; Tuberculosis | 1992 |
Activities of various macrolide antibiotics against Mycobacterium leprae infection in mice.
Topics: Animals; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Erythromycin; Leprosy; Mice; Mice, Inbred BALB C; Mycobacterium leprae; Roxithromycin | 1991 |
The in vitro activity of some 14-, 15- and 16- membered macrolides against Staphylococcus spp., Legionella spp., Mycoplasma spp. and Ureaplasma urealyticum.
Topics: Anti-Bacterial Agents; Azithromycin; Clarithromycin; Drug Resistance, Microbial; Erythromycin; Legionella; Leucomycins; Microbial Sensitivity Tests; Mycoplasma; Roxithromycin; Staphylococcus; Ureaplasma | 1991 |
Activities of sparfloxacin, azithromycin, temafloxacin, and rifapentine compared with that of clarithromycin against multiplication of Mycobacterium avium complex within human macrophages.
Topics: 4-Quinolones; Acquired Immunodeficiency Syndrome; Anti-Bacterial Agents; Azithromycin; Cell Division; Clarithromycin; Erythromycin; Fluoroquinolones; Humans; In Vitro Techniques; Leprostatic Agents; Macrophages; Microbial Sensitivity Tests; Mycobacterium avium Complex; Quinolones; Rifampin | 1991 |
Comparative in vitro activity of azithromycin, clarithromycin, erythromycin and lomefloxacin against Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum.
Topics: 4-Quinolones; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Clarithromycin; Erythromycin; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Mycoplasma; Mycoplasma pneumoniae; Quinolones; Reproducibility of Results; Ureaplasma | 1990 |
Activity in vitro against Toxoplasma gondii of azithromycin and clarithromycin alone and with pyrimethamine.
Topics: Animals; Azithromycin; Clarithromycin; Drug Interactions; Erythromycin; Pyrimethamine; Regression Analysis; Toxoplasma | 1990 |
The development of macrolides and related compounds.
Topics: Anti-Bacterial Agents; Azithromycin; Clarithromycin; Drug Design; Erythromycin | 1989 |
Comparative antimicrobial activity of the new macrolides against Borrelia burgdorferi.
Topics: 4-Quinolones; Animals; Anti-Infective Agents; Azithromycin; Borrelia; Clarithromycin; Erythromycin; Fluoroquinolones; Gerbillinae; Leucomycins; Lyme Disease; Microbial Sensitivity Tests; Quinolones; Species Specificity | 1989 |
Activity of new macrolides against Bordetella pertussis and Bordetella parapertussis.
Topics: Anti-Bacterial Agents; Azithromycin; Bordetella; Bordetella pertussis; Clarithromycin; Drug Resistance, Microbial; Erythromycin; Leucomycins; Macrolides; Microbial Sensitivity Tests | 1989 |
In vitro effects of four macrolides (roxithromycin, spiramycin, azithromycin [CP-62,993], and A-56268) on Toxoplasma gondii.
Topics: Animals; Azithromycin; Clarithromycin; Erythromycin; Female; Leucomycins; Macrophages; Mice; Toxoplasma; Tritium; Uracil | 1988 |
In vitro activities of azithromycin (CP 62,993), clarithromycin (A-56268; TE-031), erythromycin, roxithromycin, and clindamycin.
Topics: Azithromycin; Bacteria; Clarithromycin; Clindamycin; Culture Media; Drug Resistance, Microbial; Erythromycin; Haemophilus influenzae; Hydrogen-Ion Concentration; Leucomycins | 1988 |
In vivo evaluation of three acid-stable azalide compounds, L-701,677, L-708,299 and L-708,365 compared to erythromycin, azithromycin and clarithromycin.
Topics: Animals; Anti-Bacterial Agents; Azithromycin; Bacterial Infections; Clarithromycin; Drug Evaluation, Preclinical; Drug Stability; Erythromycin; Female; Half-Life; Klebsiella Infections; Macrolides; Mice; Mice, Inbred DBA; Molecular Structure; Staphylococcal Infections; Streptococcal Infections | 1995 |
Susceptibility of Streptococcus pyogenes to azithromycin, clarithromycin, erythromycin and roxithromycin in vitro.
Topics: Anti-Bacterial Agents; Azithromycin; Clarithromycin; Erythromycin; Humans; Microbial Sensitivity Tests; Netherlands; Roxithromycin; Streptococcus pyogenes | 1995 |
Susceptibilities of 201 anaerobes to erythromycin, azithromycin, clarithromycin, and roxithromycin by oxyrase agar dilution and E test methodologies.
Topics: Agar; Azithromycin; Bacteria, Anaerobic; Bacterial Infections; Clarithromycin; Drug Resistance, Microbial; Erythromycin; Evaluation Studies as Topic; Humans; Microbial Sensitivity Tests; Oxygenases; Roxithromycin | 1995 |
Relative potencies of azithromycin, clarithromycin and five other orally administered antibiotics.
Topics: Anti-Bacterial Agents; Azithromycin; Clarithromycin; Drug Resistance, Microbial; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Respiratory Tract Infections | 1995 |
Effect of an acidic environment on the susceptibility of Helicobacter pylori to trospectomycin and other antimicrobial agents.
Topics: Ampicillin; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Clindamycin; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Metronidazole; Microbial Sensitivity Tests; Spectinomycin | 1995 |
Activities of clarithromycin, azithromycin, and ofloxacin in combination with liposomal or unencapsulated granulocyte-macrophage colony-stimulating factor against intramacrophage Mycobacterium avium-Mycobacterium intracellulare.
Topics: Azithromycin; Cells, Cultured; Clarithromycin; Dose-Response Relationship, Drug; Drug Carriers; Drug Interactions; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Kinetics; Liposomes; Macrophages; Microbial Sensitivity Tests; Mycobacterium avium Complex; Ofloxacin; Recombinant Proteins; Time Factors | 1995 |
Infections due to Rhodococcus equi in three HIV-infected patients: microbiological findings and antibiotic susceptibility.
Topics: Actinomycetales Infections; Adult; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Azithromycin; Bacteremia; Bronchoalveolar Lavage Fluid; Clarithromycin; Drug Resistance, Microbial; Drug Synergism; Drug Therapy, Combination; Erythromycin; Female; Gentamicins; HIV Infections; Humans; Imipenem; Male; Pleurisy; Pneumonia, Bacterial; Rhodococcus equi; Rifampin; Sputum; Teicoplanin; Vancomycin | 1994 |
Postantibiotic effects and postantibiotic sub-MIC effects of roxithromycin, clarithromycin, and azithromycin on respiratory tract pathogens.
Topics: Azithromycin; Clarithromycin; Haemophilus influenzae; Microbial Sensitivity Tests; Roxithromycin; Streptococcus | 1995 |
Impact of clarithromycin and azithromycin on patterns of treatment and survival among AIDS patients with disseminated Mycobacterium avium complex.
Topics: Adult; AIDS-Related Opportunistic Infections; Azithromycin; Clarithromycin; Cohort Studies; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Multivariate Analysis; Mycobacterium avium-intracellulare Infection; Retrospective Studies; Survival Rate | 1995 |
Pharmacokinetics of macrolides. Comparison of plasma, tissue and free concentrations with special reference to roxithromycin.
Topics: Adult; Anti-Bacterial Agents; Azithromycin; Blood Proteins; Bronchoalveolar Lavage Fluid; Clarithromycin; Cross-Over Studies; Female; Half-Life; Humans; Lung; Male; Palatine Tonsil; Random Allocation; Roxithromycin; Sputum; Tissue Distribution | 1995 |
Validation of NCCLS macrolide (azithromycin, clarithromycin, and erythromycin) interpretive criteria for Haemophilus influenzae tested with the Haemophilus test medium. National Committee for Clinical Laboratory Standards.
Topics: Anti-Bacterial Agents; Azithromycin; Clarithromycin; Culture Media; Erythromycin; Guidelines as Topic; Haemophilus influenzae; Humans; Microbial Sensitivity Tests | 1994 |
Relative potency of 10 drugs with anti-Pneumocystis carinii activity in an animal model.
Topics: Animals; Anti-Infective Agents; Atovaquone; Azithromycin; Clarithromycin; Clindamycin; Clinical Trials as Topic; Dapsone; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Therapy, Combination; Humans; Naphthoquinones; Pentamidine; Pneumocystis Infections; Proguanil; Pyrimethamine; Rats; Sulfadoxine; Sulfamethoxazole; Trimethoprim; Trimethoprim, Sulfamethoxazole Drug Combination | 1994 |
Comparative activities of azithromycin and clarithromycin against Mycobacterium avium infection in beige mice.
Topics: Animals; Azithromycin; Clarithromycin; Culture Media; Disease Models, Animal; Female; Lung; Male; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Microbial Sensitivity Tests; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Spleen | 1994 |
Activities of azithromycin and clarithromycin against nontuberculous mycobacteria in beige mice.
Topics: Animals; Azithromycin; Clarithromycin; Culture Media; Female; Lung; Male; Mice; Mice, Inbred Strains; Microbial Sensitivity Tests; Mycobacterium; Mycobacterium Infections; Spleen | 1994 |
Intermittent azithromycin for treatment of Mycobacterium avium infection in beige mice.
Topics: Animals; Azithromycin; Clarithromycin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Mice; Mice, Inbred C57BL; Mycobacterium avium; Rifampin; Tuberculosis | 1994 |
In vitro and in vivo activities of macrolides against Mycoplasma pneumoniae.
Topics: Animals; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Cricetinae; Erythromycin; Lung; Male; Mesocricetus; Microbial Sensitivity Tests; Mycoplasma pneumoniae; Pneumonia, Mycoplasma; Roxithromycin | 1994 |
Mycobacterium avium strains resistant to clarithromycin and azithromycin.
Topics: Azithromycin; Clarithromycin; Drug Resistance, Microbial; Humans; Microbial Sensitivity Tests; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection | 1993 |
Mycobacterium avium strains resistant to clarithromycin and azithromycin.
Topics: AIDS-Related Opportunistic Infections; Azithromycin; Clarithromycin; Drug Resistance, Microbial; Humans; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection | 1994 |
[Initial empiric treatment of pneumonia and the new antibiotics].
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Bacterial Infections; Cefixime; Cefotaxime; Cefuroxime; Clarithromycin; Fluoroquinolones; Humans; Pneumonia | 1994 |
[Comparative in vitro activity of new oral macrolides against Streptococcus pyogenes strains].
Topics: Anti-Bacterial Agents; Azithromycin; Clarithromycin; Drug Resistance, Microbial; Erythromycin; In Vitro Techniques; Microbial Sensitivity Tests; Penicillins; Roxithromycin; Streptococcal Infections; Streptococcus pyogenes; Time Factors | 1993 |
Effect of CO2 on susceptibilities of anaerobes to erythromycin, azithromycin, clarithromycin, and roxithromycin.
Topics: Azithromycin; Bacteria, Anaerobic; Carbon Dioxide; Clarithromycin; Drug Resistance, Microbial; Erythromycin; Gram-Negative Anaerobic Bacteria; Gram-Positive Bacteria; Microbial Sensitivity Tests; Oxygenases; Roxithromycin | 1994 |
Comparative in vitro activities of clarithromycin, azithromycin, and erythromycin against Borrelia burgdorferi.
Topics: Animals; Azithromycin; Borrelia burgdorferi Group; Clarithromycin; Erythromycin; Humans; Kinetics; Mice; Microbial Sensitivity Tests; Ticks; Time Factors | 1993 |
In vitro evaluation of activities of azithromycin, clarithromycin and sparfloxacin against Chlamydia trachomatis.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Chlamydia trachomatis; Clarithromycin; Dose-Response Relationship, Drug; Fluoroquinolones; Humans; In Vitro Techniques; Quinolones | 1993 |
Erythromycin, clarithromycin, and azithromycin: use of frequency distribution curves, scattergrams, and regression analyses to compare in vitro activities and describe cross-resistance.
Topics: Azithromycin; Clarithromycin; Drug Resistance, Microbial; Enterococcus; Erythromycin; Fusobacterium; Haemophilus influenzae; Microbial Sensitivity Tests; Moraxella catarrhalis; Pasteurella multocida; Regression Analysis; Staphylococcus; Statistics as Topic; Streptococcus | 1993 |
New drugs from 1991-1992.
Topics: 1-Naphthylamine; Anti-Bacterial Agents; Anti-Infective Agents; Anticholesteremic Agents; Antineoplastic Agents; Antiviral Agents; Azithromycin; Butanones; Cardiovascular Agents; Clarithromycin; Drug Approval; Drug Combinations; Drug Interactions; Enoxacin; Finasteride; Flumazenil; Fluoroquinolones; Humans; Ketorolac Tromethamine; Lactams; Nabumetone; Pyridines; Quinolones; Sertraline; Tolmetin; Tromethamine; United States; United States Food and Drug Administration; Zolpidem | 1993 |
Two new macrolide antibiotics: clarithromycin and azithromycin.
Topics: Azithromycin; Bacterial Infections; Clarithromycin; Drug Costs; Erythromycin; Humans | 1993 |
Outer membrane permeability barrier to azithromycin, clarithromycin, and roxithromycin in gram-negative enteric bacteria.
Topics: Azithromycin; Cell Membrane; Clarithromycin; Erythromycin; Escherichia coli; Gram-Negative Bacteria; Lipopolysaccharides; Microbial Sensitivity Tests; Polymyxins; Roxithromycin; Salmonella typhimurium | 1993 |
Effect of pH variation on the susceptibility of Helicobacter pylori to three macrolide antimicrobial agents and temafloxacin.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Clarithromycin; Drug Resistance, Microbial; Erythromycin; Fluoroquinolones; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Microbial Sensitivity Tests; Quinolones | 1993 |
In-vitro activity of ciprofloxacin, temafloxacin, azithromycin, clarithromycin and metronidazole against Giardia lamblia.
Topics: Animals; Anti-Infective Agents; Azithromycin; Ciprofloxacin; Clarithromycin; Erythromycin; Fluoroquinolones; Giardia lamblia; Metronidazole; Microbial Sensitivity Tests; Quinolones | 1993 |
Glycoside antibiotics alone and combined with tetracyclines for prophylaxis of experimental cryptosporidiosis in neonatal BALB/c mice.
Topics: Animals; Animals, Newborn; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Cryptosporidiosis; Cryptosporidium parvum; Disease Models, Animal; Doxycycline; Drug Synergism; Drug Therapy, Combination; Erythromycin; Mice; Mice, Inbred BALB C; Minocycline; Paromomycin; Tetracyclines | 1993 |
Inhibition of Pseudomonas aeruginosa virulence factors by subinhibitory concentrations of azithromycin and other macrolide antibiotics.
Topics: Anti-Bacterial Agents; Azithromycin; Cell Movement; Clarithromycin; Erythromycin; Hemolysin Proteins; Humans; Lipase; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Pyocyanine; Virulence | 1993 |
A comparison of the efficacy of azithromycin and clarithromycin in oral therapy of experimental airborne Legionnaires' disease.
Topics: Administration, Inhalation; Administration, Oral; Aerosols; Animals; Azithromycin; Clarithromycin; Disease Models, Animal; Erythromycin; Female; Guinea Pigs; Legionella pneumophila; Legionnaires' Disease; Lung | 1993 |
The comparative activity of azithromycin, macrolides and amoxycillin against streptococci in experimental infections.
Topics: Amoxicillin; Animals; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Disease Models, Animal; Endocarditis, Bacterial; Erythromycin; Female; Gerbillinae; Male; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Otitis Media; Pneumococcal Infections; Pneumonia; Rats; Roxithromycin; Streptococcal Infections; Streptococcus pyogenes | 1993 |
[The particular case of azalides: antibiotic diapedesis. Experimental data from a murine model of pneumococcal pneumonia].
Topics: Animals; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Disease Models, Animal; Erythromycin; Injections, Subcutaneous; Mice; Pneumonia, Pneumococcal; Roxithromycin; Spiramycin | 1995 |
Genetic basis of macrolide resistance in Mycobacterium avium isolated from patients with disseminated disease.
Topics: AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Azithromycin; Base Sequence; Clarithromycin; DNA, Bacterial; Drug Resistance, Microbial; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Nucleic Acid Conformation; Operon; Polymerase Chain Reaction; RNA, Bacterial; RNA, Messenger; RNA, Ribosomal, 23S | 1995 |
Azithromycin in the prophylaxis of opportunistic infections in AIDS.
Topics: AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Antibiotics, Antitubercular; Azithromycin; Clarithromycin; Clinical Trials as Topic; Humans; Mycobacterium avium-intracellulare Infection; Rifabutin | 1996 |
In vitro activities of azithromycin, clarithromycin, erythromycin, and tetracycline against 13 strains of Chlamydia pneumoniae.
Topics: Anti-Bacterial Agents; Azithromycin; Chlamydophila pneumoniae; Clarithromycin; Erythromycin; Microbial Sensitivity Tests; Tetracycline | 1996 |
Evaluation of in vitro spectra of activity of azithromycin, clarithromycin, and erythromycin tested against strains of Neisseria gonorrhoeae by reference agar dilution, disk diffusion, and Etest methods.
Topics: Agar; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Erythromycin; Evaluation Studies as Topic; Gonorrhea; Humans; In Vitro Techniques; Microbial Sensitivity Tests; Neisseria gonorrhoeae | 1996 |
Single-dose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin, and cefuroxime in volunteer subjects.
Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Bronchoalveolar Lavage Fluid; Bronchoscopy; Cefuroxime; Cephalosporins; Ciprofloxacin; Clarithromycin; Drug Administration Schedule; Epithelium; Female; Humans; Male; Pulmonary Alveoli | 1996 |
Rapid detection of mutations associated with macrolide resistance in Mycobacterium avium complex.
Topics: Anti-Bacterial Agents; Azithromycin; Clarithromycin; DNA Mutational Analysis; Drug Resistance, Microbial; Microbial Sensitivity Tests; Mutation; Mycobacterium avium Complex; Polymerase Chain Reaction | 1996 |
Comparative activities of clarithromycin, erythromycin, and azithromycin against penicillin-susceptible and penicillin-resistant pneumococci.
Topics: Anti-Bacterial Agents; Azithromycin; Clarithromycin; Drug Resistance, Microbial; Erythromycin; Microbial Sensitivity Tests; Penicillin Resistance; Penicillins; Streptococcus pneumoniae; United States | 1996 |
In vitro susceptibilities of 180 clinical isolates of Haemophilus influenzae to ampicillin, amoxycillin/clavulanate, cefaclor, cefuroxime, cefotaxime, clarithromycin, and azithromycin.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Azithromycin; Cefaclor; Cefotaxime; Cefuroxime; Child; Child, Preschool; Clarithromycin; Clavulanic Acids; Cross Infection; Haemophilus Infections; Haemophilus influenzae; Humans; In Vitro Techniques; Microbial Sensitivity Tests; Middle Aged | 1996 |
Effect of macrolide antibiotics on macrophage functions.
Topics: Animals; Anti-Bacterial Agents; Azithromycin; Cell Line; Chemotaxis; Clarithromycin; Cytotoxicity, Immunologic; Dose-Response Relationship, Drug; Erythromycin; Macrophages; Mice; Phagocytosis; Roxithromycin | 1996 |
Incidence of antibiotic-resistant Streptococcus pneumoniae and beta-lactamase-positive Haemophilus influenzae in clinical isolates from patients with otitis media.
Topics: Anti-Bacterial Agents; Azithromycin; beta-Lactamases; Child; Clarithromycin; Haemophilus Infections; Haemophilus influenzae; Humans; Incidence; Microbial Sensitivity Tests; Otitis Media; Penicillin Resistance; Pneumococcal Infections; Streptococcus pneumoniae | 1996 |
Cytotoxicity of macrolide antibiotics in a cultured human liver cell line.
Topics: Anti-Bacterial Agents; Azithromycin; Cell Line; Clarithromycin; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Epithelial Cells; Epithelium; Erythromycin; Humans; Liver; Proteins; Roxithromycin; Tetrazolium Salts; Thiazoles | 1996 |
Direct evidence for antipseudomonal activity of macrolides: exposure-dependent bactericidal activity and inhibition of protein synthesis by erythromycin, clarithromycin, and azithromycin.
Topics: Anti-Bacterial Agents; Azithromycin; Bacterial Proteins; Clarithromycin; Erythromycin; Kinetics; Microbial Sensitivity Tests; Protein Synthesis Inhibitors; Pseudomonas aeruginosa | 1996 |
Comparison of Etest to broth microdilution method for testing Streptococcus pneumoniae susceptibility to levofloxacin and three macrolides.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Clarithromycin; Erythromycin; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Penicillins; Streptococcus pneumoniae | 1996 |
Three new studies expand understanding of MAC therapy.
Topics: Azithromycin; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; Humans; Mycobacterium avium-intracellulare Infection; Rifabutin; Uveitis | 1996 |
In vitro activity of macrolides against intracellular Legionella pneumophila.
Topics: Anti-Bacterial Agents; Azithromycin; Bacteriological Techniques; Clarithromycin; Erythromycin; Humans; Legionella pneumophila; Legionnaires' Disease; Microbial Sensitivity Tests | 1996 |
In vitro activities of azithromycin, clarithromycin, and other antibiotics against Chlamydia pneumoniae.
Topics: 4-Quinolones; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Chlamydophila pneumoniae; Clarithromycin; Microbial Sensitivity Tests; Tetracyclines | 1996 |
The in-vitro anti-rickettsial activity of macrolides.
Topics: Animals; Anti-Bacterial Agents; Azithromycin; Chlorocebus aethiops; Clarithromycin; Colony Count, Microbial; Coxiella burnetii; Microbial Sensitivity Tests; Rickettsia; Rickettsia typhi; Vero Cells | 1996 |
Varying dosages of rifabutin affect white blood cell and platelet counts in human immunodeficiency virus--negative patients who are receiving multidrug regimens for pulmonary Mycobacterium avium complex disease.
Topics: Azithromycin; Clarithromycin; Dose-Response Relationship, Drug; Drug Therapy, Combination; HIV; Humans; Leukocyte Count; Lung Diseases; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Platelet Count; Rifabutin | 1996 |
Membrane-stabilizing, anti-inflammatory interactions of macrolides with human neutrophils.
Topics: Adult; Anti-Asthmatic Agents; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Azithromycin; Calcimycin; Cell Membrane; Clarithromycin; Erythromycin; Humans; Ionophores; Luminescent Measurements; Lysophosphatidylcholines; N-Formylmethionine Leucyl-Phenylalanine; Neutrophils; Platelet Activating Factor; Respiratory Burst; Roxithromycin; Superoxides; Tetradecanoylphorbol Acetate; Zymosan | 1996 |
Depression of the N-demethylation of erythromycin, azithromycin, clarithromycin and clindamycin in murine Toxoplasma infection.
Topics: Animals; Aryl Hydrocarbon Hydroxylases; Azithromycin; Clarithromycin; Clindamycin; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Erythromycin; Intestinal Mucosa; Jejunum; Kinetics; Mice; Microsomes; Microsomes, Liver; Oxidoreductases, N-Demethylating; Reference Values; Time Factors; Toxoplasmosis, Animal | 1996 |
Effect of minor pH changes on the in-vitro activity of azithromycin and clarithromycin.
Topics: Anti-Bacterial Agents; Azithromycin; Clarithromycin; Culture Media; Enterococcus faecalis; Hydrogen-Ion Concentration; Staphylococcus aureus | 1997 |
Inhibition of intracellular growth of Staphylococcus aureus by exposure of infected human monocytes to clarithromycin and azithromycin.
Topics: Azithromycin; Cell-Free System; Clarithromycin; Drug Evaluation, Preclinical; Drug Therapy, Combination; Humans; Microbial Sensitivity Tests; Monocytes; Neutrophils; Phagocytosis; Staphylococcal Infections; Staphylococcus aureus | 1997 |
Requirements for intracellular accumulation and release of clarithromycin and azithromycin by human phagocytes.
Topics: Anti-Bacterial Agents; Azithromycin; Calcium; Clarithromycin; Drug Evaluation, Preclinical; Erythromycin; Humans; Hydrogen-Ion Concentration; Macrophages, Alveolar; Monocytes; Neutrophils; Phagocytes; Temperature | 1997 |
New pharmacokinetic in vitro model for studies of antibiotic activity against intracellular microorganisms.
Topics: Amoxicillin; Anti-Bacterial Agents; Azithromycin; Cell Line; Clarithromycin; Drug Evaluation, Preclinical; Half-Life; Helicobacter; Humans; Microbial Sensitivity Tests | 1996 |
The activity of the methylpiperazinyl fluoroquinolone CG 5501: a comparison with other fluoroquinolones.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Bacteroides fragilis; Chlamydia; Ciprofloxacin; Clarithromycin; Doxycycline; Enterobacter; Erythromycin; Fluoroquinolones; Gatifloxacin; Gram-Positive Bacteria; Haemophilus influenzae; Microbial Sensitivity Tests; Naphthyridines; Piperazines; Pseudomonas aeruginosa; Quinolones; Streptococcus pneumoniae | 1997 |
Variability in susceptibilities of Haemophilus influenzae to clarithromycin and azithromycin due to medium pH.
Topics: Anti-Bacterial Agents; Azithromycin; Clarithromycin; Haemophilus influenzae; Hydrogen-Ion Concentration; Microbial Sensitivity Tests | 1997 |
In vitro activities of oral antimicrobial agents against penicillin-resistant Streptococcus pneumoniae: implications for outpatient treatment.
Topics: Administration, Oral; Adult; Ambulatory Care; Anti-Bacterial Agents; Azithromycin; Cefaclor; Cefprozil; Cefuroxime; Cephalosporins; Child; Clarithromycin; Clindamycin; Culture Media; Humans; Penicillin Resistance; Pneumococcal Infections; Streptococcus pneumoniae; Tetracycline; Trimethoprim, Sulfamethoxazole Drug Combination | 1997 |
Comparison of Etest and agar dilution for testing the activity of three macrolides against Bordetella parapertussis.
Topics: Agar; Anti-Bacterial Agents; Azithromycin; Bordetella; Child; Clarithromycin; Erythromycin; Evaluation Studies as Topic; Humans; Microbial Sensitivity Tests | 1997 |
Macrolide resistance among Streptococcus pneumoniae and Streptococcus pyogenes isolates from out-patients in the USA.
Topics: Anti-Bacterial Agents; Azithromycin; Clarithromycin; Drug Resistance, Microbial; Erythromycin; Microbial Sensitivity Tests; Penicillin G; Penicillin Resistance; Respiratory Tract Infections; Streptococcus pneumoniae; Streptococcus pyogenes; United States | 1997 |
Efficacy of azithromycin or clarithromycin for prophylaxis of viridans group streptococcus experimental endocarditis.
Topics: Amoxicillin; Animals; Anti-Bacterial Agents; Antibiotic Prophylaxis; Azithromycin; Clarithromycin; Clindamycin; Endocarditis, Bacterial; Erythromycin; Rabbits; Streptococcus | 1997 |
Rapid drug susceptibility of Mycobacterium avium complex using a fluorescence quenching method.
Topics: Acquired Immunodeficiency Syndrome; Agar; Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Ciprofloxacin; Clarithromycin; Fluoroimmunoassay; Humans; Microbial Sensitivity Tests; Mycobacterium avium; Nucleic Acid Hybridization; Rifabutin | 1997 |
Susceptibility of twenty penicillin-susceptible and -resistant pneumococci to levofloxacin, ciprofloxacin, ofloxacin, erythromycin, azithromycin, and clarithromycin by MIC and time-kill.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Bacteriological Techniques; Ciprofloxacin; Clarithromycin; Drug Resistance, Microbial; Erythromycin; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Sensitivity and Specificity; Species Specificity; Streptococcus pneumoniae | 1997 |
Susceptibility of penicillin-susceptible and -resistant pneumococci to dirithromycin compared with susceptibilities to erythromycin, azithromycin, clarithromycin, roxithromycin, and clindamycin.
Topics: Aminoglycosides; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Clindamycin; Erythromycin; Macrolides; Microbial Sensitivity Tests; Penicillin Resistance; Penicillins; Roxithromycin; Streptococcus pneumoniae | 1997 |
Comparative antianaerobic activities of the ketolides HMR 3647 (RU 66647) and HMR 3004 (RU 64004).
Topics: Anti-Bacterial Agents; Azithromycin; Bacteria, Anaerobic; Carbon Dioxide; Clarithromycin; Erythromycin; Hydrogen-Ion Concentration; Ketolides; Macrolides; Microbial Sensitivity Tests; Roxithromycin | 1997 |
Enhancement of Burkholderia cepacia antimicrobial susceptibility by cationic compounds.
Topics: 1-Naphthylamine; Anti-Infective Agents; Azithromycin; Bacterial Outer Membrane Proteins; Burkholderia cepacia; Cations; Ceftazidime; Cell Membrane Permeability; Ciprofloxacin; Clarithromycin; Fleroxacin; Fluorescent Dyes; Fluoroquinolones; Gentamicins; Magnesium; Microbial Sensitivity Tests; Microscopy, Electron; Novobiocin; Oxolinic Acid; Polysaccharides, Bacterial; Tobramycin | 1997 |
Comparison of charcoal- and starch-based media for testing susceptibilities of Legionella species to macrolides, azalides, and fluoroquinolones.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Charcoal; Ciprofloxacin; Clarithromycin; Culture Media; Erythromycin; Humans; Legionella; Legionella pneumophila; Legionellosis; Microbial Sensitivity Tests; Ofloxacin; Reproducibility of Results; Starch | 1997 |
In vitro activity of the new ketolide HMR 3004 compared to an azalide and macrolides against Streptococcus pneumoniae and Haemophilus influenzae.
Topics: Ampicillin Resistance; Anti-Bacterial Agents; Azithromycin; beta-Lactamases; Clarithromycin; Clindamycin; Drug Resistance, Microbial; Erythromycin; Haemophilus influenzae; Ketolides; Macrolides; Microbial Sensitivity Tests; Roxithromycin; Streptococcus pneumoniae | 1997 |
[Comparative antimicrobial activity of RP 59,500 (quinupristin-dalfopristin), the first semisynthetic injectable streptgramin, against gram-positive cocci and other recent clinical pathogens].
Topics: Anti-Bacterial Agents; Azithromycin; Clarithromycin; Enterococcus; Erythromycin; Gram-Positive Cocci; Humans; Methicillin Resistance; Roxithromycin; Staphylococcus aureus; Streptococcus agalactiae; Streptococcus pneumoniae; Streptococcus pyogenes; Virginiamycin | 1997 |
A new semi-solid agar dilution method for determining amoxycillin, clarithromycin and azithromycin MICs for Helicobacter pylori isolates.
Topics: Amoxicillin; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Helicobacter pylori; Microbial Sensitivity Tests; Penicillins | 1997 |
Azithromycin and clarithromycin inhibition of 50S ribosomal subunit formation in Staphylococcus aureus cells.
Topics: Anti-Bacterial Agents; Azithromycin; Clarithromycin; Dose-Response Relationship, Drug; Kinetics; Protein Biosynthesis; Ribosomal Proteins; Ribosomes; Staphylococcus aureus | 1998 |
Roxithromycin, clarithromycin, and azithromycin attenuate the injurious effects of bioactive phospholipids on human respiratory epithelium in vitro.
Topics: Anti-Bacterial Agents; Azithromycin; Cells, Cultured; Clarithromycin; Drug Interactions; Epithelial Cells; Humans; Phospholipids; Respiratory System; Roxithromycin | 1997 |
Emergence of Mycobacterium avium populations resistant to macrolides during experimental chemotherapy.
Topics: Animals; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Disease Models, Animal; Drug Resistance, Microbial; Female; Mice; Mice, Inbred C57BL; Mycobacterium avium; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Spleen | 1998 |
Possible effectiveness of clarithromycin and rifabutin for cryptosporidiosis chemoprophylaxis in HIV disease. HIV Outpatient Study (HOPS) Investigators.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Antibiotics, Antitubercular; Azithromycin; Clarithromycin; Cryptosporidiosis; Female; HIV Infections; Humans; Likelihood Functions; Male; Prospective Studies; Rifabutin; Statistics, Nonparametric | 1998 |
Evidence for Chlamydia pneumoniae infection in steroid-dependent asthma.
Topics: Administration, Inhalation; Adolescent; Aged; Anti-Bacterial Agents; Antibodies, Bacterial; Asthma; Azithromycin; Chlamydia Infections; Chlamydophila pneumoniae; Clarithromycin; Female; Glucocorticoids; Humans; Immunoglobulins; Male; Middle Aged; Nebulizers and Vaporizers | 1998 |
Bronchopulmonary pharmacokinetics of clarithromycin and azithromycin.
Topics: Anti-Bacterial Agents; Azithromycin; Clarithromycin; Humans; Macrophages, Alveolar | 1998 |
Activity of azithromycin, clarithromycin, roxithromycin, dirithromycin, quinupristin/dalfopristin and erythromycin against Legionella species by intracellular susceptibility testing in HL-60 cells.
Topics: Anti-Bacterial Agents; Azithromycin; Cell Line; Clarithromycin; Erythromycin; HL-60 Cells; Humans; Legionella; Legionella pneumophila; Macrolides; Microbial Sensitivity Tests; Monocytes; Roxithromycin; Virginiamycin | 1998 |
In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to two ketolides (HMR 3004 and HMR 3647), four macrolides (azithromycin, clarithromycin, erythromycin A, and roxithromycin), and two ansamycins (rifampin and rifapentine).
Topics: Anti-Bacterial Agents; Azithromycin; Bordetella; Bordetella pertussis; Clarithromycin; Erythromycin; Ketolides; Macrolides; Microbial Sensitivity Tests; Rifabutin; Rifampin; Roxithromycin | 1998 |
Anti-anaerobic activity of erythromycin, azithromycin and clarithromycin: effect of pH adjustment of media to compensate for pH shift caused by incubation in CO2.
Topics: Anti-Bacterial Agents; Azithromycin; Bacteria, Anaerobic; Bacterial Infections; Carbon Dioxide; Clarithromycin; Colony Count, Microbial; Culture Media; Drug Resistance, Microbial; Drug Resistance, Multiple; Erythromycin; Gram-Negative Bacteria; Humans; Hydrogen-Ion Concentration; Microbial Sensitivity Tests; Oxygenases | 1998 |
Comparative anti-inflammatory effects of roxithromycin, azithromycin and clarithromycin.
Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Azithromycin; Carrageenan; Clarithromycin; Edema; Hindlimb; Male; Rats; Rats, Wistar; Roxithromycin; Sulfonamides | 1998 |
Activities of HMR 3004 (RU 64004) and HMR 3647 (RU 66647) compared to those of erythromycin, azithromycin, clarithromycin, roxithromycin, and eight other antimicrobial agents against unusual aerobic and anaerobic human and animal bite pathogens isolated f
Topics: Animals; Anti-Bacterial Agents; Azithromycin; Bacteria, Aerobic; Bacteria, Anaerobic; Bites, Human; Clarithromycin; Erythromycin; Humans; Ketolides; Macrolides; Microbial Sensitivity Tests; Roxithromycin; Skin Diseases, Bacterial; Soft Tissue Infections; Wounds and Injuries | 1998 |
Postantibiotic effect and postantibiotic sub-MIC effect of levofloxacin compared to those of ofloxacin, ciprofloxacin, erythromycin, azithromycin, and clarithromycin against 20 pneumococci.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Ciprofloxacin; Clarithromycin; Erythromycin; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Streptococcus pneumoniae | 1998 |
[Effects of macrolide antibiotics to inhibit infiltration and proliferation of malignant tumor cells--in vitro evaluation].
Topics: Anti-Bacterial Agents; Azithromycin; Cell Division; Cell Line; Clarithromycin; Erythromycin; Fibrosarcoma; Humans; Immunologic Factors; Neoplasm Invasiveness; Roxithromycin; Teratocarcinoma; Tumor Cells, Cultured | 1997 |
[Actions of macrolide antibiotics on alginate production by Pseudomonas aeruginosa].
Topics: Alginates; Animals; Anti-Bacterial Agents; Antigen-Antibody Complex; Azithromycin; Clarithromycin; Erythromycin; Humans; Leucomycins; Macrolides; Mice; Pseudomonas aeruginosa; Roxithromycin | 1997 |
[Tumor neovascularization inhibiting and tumor proliferation and metastasis suppressing actions of 14-, 15-, and 16-member ring macrolides].
Topics: Animals; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Immunologic Factors; Josamycin; Male; Mice; Mice, Inbred C57BL; Neoplasm Metastasis; Neoplasms, Experimental; Neovascularization, Pathologic; Roxithromycin | 1998 |
[Inhibitory effects of macrolide antibiotics on infiltration and proliferation of lung cancer cell lines, A-549 and SBC-3].
Topics: Anti-Bacterial Agents; Azithromycin; Cell Line; Clarithromycin; Humans; Immunologic Factors; Lung Neoplasms; Tumor Cells, Cultured | 1998 |
Clarithromycin and azithromycin.
Topics: Anti-Bacterial Agents; Azithromycin; Clarithromycin; Humans; Otitis Media; Pneumonia, Bacterial; Soft Tissue Infections; Streptococcal Infections; Streptococcus pyogenes; Whooping Cough | 1998 |
Preventing Mycobacterium avium complex in patients who are using protease inhibitors: a cost-effectiveness analysis.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Antibiotic Prophylaxis; Antibiotics, Antitubercular; Azithromycin; Clarithromycin; Cost-Benefit Analysis; Drug Therapy, Combination; Health Care Costs; HIV Infections; HIV Protease Inhibitors; Humans; Male; Markov Chains; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Quality of Life; Rifabutin; United States | 1998 |
Dynamics of clarithromycin and azithromycin efficacies against experimental Haemophilus influenzae pulmonary infection.
Topics: Animals; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Haemophilus Infections; Haemophilus influenzae; Lung Diseases; Rats; Rats, Sprague-Dawley | 1998 |
Comparison of four antibiotics in a murine model of necrotizing cutaneous infections caused by toxigenic Streptococcus pyogenes and Staphylococcus aureus.
Topics: Analysis of Variance; Animals; Anti-Bacterial Agents; Azithromycin; Cefuroxime; Clarithromycin; Disease Models, Animal; Erythromycin; Fasciitis, Necrotizing; Mice; Mice, Hairless; Skin Diseases; Staphylococcal Infections; Staphylococcus aureus; Streptococcus pyogenes | 1998 |
Susceptibility of European respiratory tract isolates to trovafloxacin, ciprofloxacin, clarithromycin, azithromycin and ampicillin.
Topics: Ampicillin; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Ciprofloxacin; Clarithromycin; Drug Resistance, Microbial; Europe; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Cocci; Haemophilus influenzae; Humans; Klebsiella pneumoniae; Microbial Sensitivity Tests; Moraxella catarrhalis; Naphthyridines; Pseudomonas aeruginosa; Respiratory System; Staphylococcus aureus; Streptococcus pneumoniae | 1998 |
Macrolide antibiotic inhibition of translation and 50S ribosomal subunit assembly in methicillin-resistant Staphylococcus aureus cells.
Topics: Anti-Bacterial Agents; Azithromycin; Clarithromycin; Erythromycin; Methicillin Resistance; Microbial Sensitivity Tests; Protein Biosynthesis; Ribosomes; Staphylococcus aureus | 1998 |
Bacteriological efficacies of three macrolides compared with those of amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae.
Topics: Amoxicillin-Potassium Clavulanate Combination; Animals; Anti-Bacterial Agents; Area Under Curve; Azithromycin; Clarithromycin; Drug Therapy, Combination; Erythromycin; Haemophilus influenzae; Humans; Male; Microbial Sensitivity Tests; Rats; Rats, Sprague-Dawley; Respiratory Tract Infections; Streptococcus pneumoniae; Time Factors | 1998 |
Macrolide susceptibility and beta-lactamase production among haemophilus influenzae isolates in the United States, 1996-1997.
Topics: Anti-Bacterial Agents; Azithromycin; beta-Lactamases; Clarithromycin; Haemophilus influenzae; Humans; Microbial Sensitivity Tests; United States | 1998 |
Bactericidal activity of lansoprazole and three macrolides against Helicobacter pylori strains tested by the time-kill kinetic method.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Azithromycin; Biopsy; Clarithromycin; Drug Synergism; Helicobacter pylori; Humans; Kinetics; Lansoprazole; Microbial Sensitivity Tests; Omeprazole; Roxithromycin; Time Factors | 1998 |
Oral rifampin plus azithromycin or clarithromycin to treat osteomyelitis in rabbits.
Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Azithromycin; Biological Availability; Clarithromycin; Colony Count, Microbial; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Nafcillin; Osteomyelitis; Rabbits; Rifampin; Staphylococcal Infections; Tibia; Treatment Outcome | 1999 |
Pharmacological considerations in the emergence of resistance.
Topics: Anti-Bacterial Agents; Azithromycin; Clarithromycin; Drug Resistance, Microbial; Humans; Leukocytes | 1999 |
Effect of clarithromycin and azithromycin on production of cytokines by human monocytes.
Topics: Adult; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Cytokines; Dose-Response Relationship, Drug; Female; Humans; In Vitro Techniques; Male; Middle Aged; Monocytes | 1999 |
Antimicrobial activities and postantibiotic effects of clarithromycin, 14-hydroxy-clarithromycin, and azithromycin in epithelial cell lining fluid against clinical isolates of haemophilus influenzae and Streptococcus pneumoniae.
Topics: Anti-Bacterial Agents; Azithromycin; Clarithromycin; Dose-Response Relationship, Drug; Endothelium, Vascular; Haemophilus influenzae; Humans; Streptococcus pneumoniae | 1999 |
In vitro activities of clarithromycin and azithromycin against clinical isolates of Mycobacterium avium-M. intracellulare.
Topics: Anti-Bacterial Agents; Azithromycin; Clarithromycin; Humans; Microbial Sensitivity Tests; Mycobacterium avium Complex | 1999 |
Use of a low nutrient culture medium for the identification of bacteria causing severe ocular infection.
Topics: Aged; Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Ciprofloxacin; Clarithromycin; Culture Media; Endophthalmitis; Eye Infections, Bacterial; Female; Humans; Keratitis; Male; Middle Aged; Propionibacterium acnes; Pseudomonas aeruginosa; Staphylococcus aureus; Vancomycin | 1999 |
Use of a urea breath test to evaluate short-term treatments for cats naturally infected with Helicobacter heilmannii.
Topics: Animals; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Azithromycin; Biopsy; Bismuth; Breath Tests; Carbon Dioxide; Carbon Radioisotopes; Cat Diseases; Cats; Clarithromycin; Female; Gas Chromatography-Mass Spectrometry; Helicobacter; Helicobacter Infections; Male; Metronidazole; Polymerase Chain Reaction; Prospective Studies; Random Allocation; Ranitidine; Stomach Diseases; Tinidazole; Urea | 1999 |
Effect of carbon dioxide on testing of susceptibilities of respiratory tract pathogens to macrolide and azalide antimicrobial agents.
Topics: Anti-Bacterial Agents; Azithromycin; Carbon Dioxide; Clarithromycin; Colony Count, Microbial; Erythromycin; Haemophilus Infections; Haemophilus influenzae; Humans; Hydrogen-Ion Concentration; Lung Diseases, Obstructive; Microbial Sensitivity Tests; Moraxella catarrhalis; Neisseriaceae Infections; Pneumococcal Infections; Sputum; Streptococcus pneumoniae | 1999 |
Activity of telithromycin (HMR 3647) against anaerobic bacteria compared to those of eight other agents by time-kill methodology.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Azithromycin; Bacteria, Anaerobic; beta-Lactamases; Clarithromycin; Clindamycin; Drug Therapy, Combination; Erythromycin; Gram-Negative Anaerobic Bacteria; Gram-Positive Bacteria; Ketolides; Macrolides; Metronidazole; Microbial Sensitivity Tests; Roxithromycin; Virginiamycin | 1999 |
Systematic validation of disease models for pharmacoeconomic evaluations. Swiss HIV Cohort Study.
Topics: AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Computer Simulation; Disease Progression; Economics, Pharmaceutical; HIV Infections; Humans; Markov Chains; Mycobacterium avium-intracellulare Infection; Probability; Randomized Controlled Trials as Topic; Reproducibility of Results; Risk Factors; Switzerland | 1999 |
[Tissue penetration properties of macrolide antibiotics--comparative tissue distribution of erythromycin-stearate, clarithromycin, roxithromycin and azithromycin in rats].
Topics: Animals; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Erythromycin; Male; Organ Specificity; Rats; Rats, Wistar; Roxithromycin | 1999 |
Effect of subinhibitory concentrations of antimicrobial agents (quinolones and macrolide) on the production of verotoxin by enterohemorrhagic Escherichia coli O157:H7.
Topics: Animals; Anti-Infective Agents; Azithromycin; Bacterial Toxins; Chlorocebus aethiops; Clarithromycin; Dose-Response Relationship, Drug; Enterotoxins; Erythromycin; Escherichia coli O157; Fluoroquinolones; Humans; Macrolides; Norfloxacin; Piperazines; Quinolones; Shiga Toxin 1; Time Factors; Vero Cells | 1999 |
Activities of telithromycin (HMR 3647, RU 66647) compared to those of erythromycin, azithromycin, clarithromycin, roxithromycin, and other antimicrobial agents against unusual anaerobes.
Topics: Anti-Bacterial Agents; Azithromycin; Bacteria, Anaerobic; Bacterial Infections; Clarithromycin; Humans; Ketolides; Macrolides; Microbial Sensitivity Tests; Roxithromycin | 1999 |
Anti-inflammatory activity of macrolide antibiotics.
Topics: 6-Ketoprostaglandin F1 alpha; Adrenalectomy; Anesthesia; Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Azithromycin; Carrageenan; Cell Line; Clarithromycin; Cyclooxygenase 2; Cytokines; Dinoprostone; Dose-Response Relationship, Drug; Erythromycin; Inflammation Mediators; Isoenzymes; Leukotriene B4; Macrophages; Mice; Nitrates; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitrites; Pleurisy; Prostaglandin-Endoperoxide Synthases; Rats; Roxithromycin; Time Factors; Tumor Necrosis Factor-alpha | 2000 |
A time-kill evaluation of clarithromycin and azithromycin against two extracellular pathogens and the development of resistance.
Topics: Anti-Bacterial Agents; Azithromycin; Clarithromycin; Colony-Forming Units Assay; Haemophilus influenzae; Microbial Sensitivity Tests; Staphylococcus aureus; Time Factors | 1999 |
[Effect of macrolide antibiotics on adhesion by cancer cells].
Topics: Anti-Bacterial Agents; Azithromycin; Biocompatible Materials; Cell Adhesion; Clarithromycin; Collagen; Drug Combinations; Flow Cytometry; Humans; Laminin; Neoplasms; Proteoglycans; Tumor Cells, Cultured | 2000 |
Cost-effectiveness of sparfloxacin compared with other oral antimicrobials in outpatient treatment of community-acquired pneumonia.
Topics: Administration, Oral; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Anti-Infective Agents; Antitubercular Agents; Azithromycin; Cefaclor; Clarithromycin; Community-Acquired Infections; Cost-Benefit Analysis; Erythromycin; Fluoroquinolones; Humans; Models, Economic; Outpatients; Pneumonia; Treatment Outcome | 2000 |
Mycobacterium avium grown in Acanthamoeba castellanii is protected from the effects of antimicrobials.
Topics: Acanthamoeba; Animals; Anti-Bacterial Agents; Azithromycin; Clarithromycin; HT29 Cells; Humans; Mice; Microbial Sensitivity Tests; Mycobacterium avium; Rifabutin; U937 Cells | 2000 |
The cost-effectiveness of prophylaxis for Mycobacterium avium complex in AIDS.
Topics: AIDS-Related Opportunistic Infections; Azithromycin; Clarithromycin; Cost-Benefit Analysis; Drug Therapy, Combination; Humans; Mycobacterium avium-intracellulare Infection; Quality-Adjusted Life Years; Rifabutin | 1999 |
Treatment of Chlamydia pneumoniae.
Topics: Adolescent; Amoxicillin-Potassium Clavulanate Combination; Antibodies, Bacterial; Azithromycin; Child; Child, Preschool; Chlamydophila Infections; Chlamydophila pneumoniae; Clarithromycin; Erythromycin; Humans; Pneumonia, Bacterial | 2000 |
Comparative pharmacodynamic analysis of Q-T interval prolongation induced by the macrolides clarithromycin, roxithromycin, and azithromycin in rats.
Topics: Algorithms; Animals; Anti-Bacterial Agents; Arrhythmias, Cardiac; Azithromycin; Body Temperature; Clarithromycin; Electrocardiography; Heart Rate; Infusions, Intravenous; Male; Models, Biological; Rats; Rats, Sprague-Dawley; Roxithromycin | 2000 |
Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin.
Topics: Aged; Anti-Bacterial Agents; Azithromycin; Bacteremia; Child, Preschool; Clarithromycin; Drug Resistance, Microbial; Female; Humans; Male; Middle Aged; Pneumococcal Infections; Streptococcus pneumoniae; Treatment Failure | 2000 |
Influence of variations in test methods on susceptibility of Haemophilus influenzae to ampicillin, azithromycin, clarithromycin, and telithromycin.
Topics: Ampicillin; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Culture Media; Haemophilus Infections; Haemophilus influenzae; Humans; Ketolides; Macrolides; Microbial Sensitivity Tests; Quality Control | 2001 |
Comparative in vitro activity of moxifloxacin by E-test against Streptococcus pyogenes.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Azithromycin; Clarithromycin; Drug Resistance, Microbial; Fluoroquinolones; Humans; Lactams; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Streptococcus pyogenes | 2001 |
In vitro activity and pharmacodynamics of azithromycin and clarithromycin against Streptococcus pneumoniae based on serum and intrapulmonary pharmacokinetics.
Topics: Anti-Bacterial Agents; Area Under Curve; Azithromycin; Clarithromycin; Lung; Microbial Sensitivity Tests; Streptococcus pneumoniae | 2001 |
In vitro susceptibility of recent clinical isolates of Chlamydia trachomatis to macrolides and tetracyclines.
Topics: Anti-Bacterial Agents; Azithromycin; Cell Line; Cells, Cultured; Chlamydia trachomatis; Clarithromycin; Doxycycline; Drug Resistance, Microbial; Erythromycin; Female; Humans; Male; Microbial Sensitivity Tests; Roxithromycin; Tetracycline | 2001 |
Comparative serum bactericidal activity of clarithromycin and azithromycin against macrolide-sensitive and resistant strains of Streptococcus pneumoniae.
Topics: Administration, Oral; Adult; Azithromycin; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Streptococcus pneumoniae | 2001 |
Macrolide therapy of group A streptococcal pharyngitis: 10 days of macrolide therapy (clarithromycin) is more effective in streptococcal eradication than 5 days (azithromycin).
Topics: Administration, Oral; Adolescent; Adult; Anti-Bacterial Agents; Azithromycin; Child; Clarithromycin; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Pharyngitis; Streptococcal Infections; Streptococcus pyogenes; Treatment Outcome | 2001 |
Advances in the diagnosis and treatment of Mycobacterium avium complex (MAC) disease.
Topics: AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Azithromycin; Bacteremia; Bone Marrow; Clarithromycin; Drug Therapy, Combination; Humans; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Rifabutin | 1994 |
Advances in prevention and treatment of MAC.
Topics: AIDS-Related Opportunistic Infections; Azithromycin; CD4 Lymphocyte Count; Clarithromycin; Clinical Trials as Topic; Clofazimine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ethambutol; Humans; Mycobacterium avium-intracellulare Infection; Rifabutin; Rifampin | 1995 |
Macrolides, azalides, and streptogrammins.
Topics: AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Bacteremia; Bacterial Infections; Clarithromycin; Clofazimine; Cryptosporidiosis; Drug Therapy, Combination; Duodenal Ulcer; Ethambutol; Humans; Microbial Sensitivity Tests; Mycobacterium avium-intracellulare Infection; Pneumonia; Smoking; Virginiamycin | 1996 |
Progress report: prophylaxis and therapy for MAC.
Topics: Acquired Immunodeficiency Syndrome; Antitubercular Agents; Azithromycin; Clarithromycin; Clofazimine; Drug Therapy, Combination; Ethambutol; Humans; Mycobacterium avium-intracellulare Infection; Rifabutin | 1996 |
MAC prophylaxis revisited.
Topics: Acquired Immunodeficiency Syndrome; Azithromycin; CD4 Lymphocyte Count; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Humans; Mycobacterium avium-intracellulare Infection; Rifabutin | 1996 |
Recent development in the treatment and prevention of disseminated Mycobacterium avium complex (MAC).
Topics: AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antibiotics, Antitubercular; Antifungal Agents; Azithromycin; Clarithromycin; Clinical Trials as Topic; Dexamethasone; Drug Interactions; Drug Resistance, Microbial; Drug Therapy, Combination; Ethambutol; Fluconazole; Humans; Mycobacterium avium-intracellulare Infection; Rifabutin; Risk Factors; Uveitis | 1996 |
The effect of azithromycin and clarithromycin on ex vivo interleukin-8 (IL-8) release from whole blood and IL-8 production by human alveolar macrophages.
Topics: Analysis of Variance; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Humans; Interleukin-8; Leukocytes, Mononuclear; Macrophages, Alveolar | 2001 |
Comparative in vitro activity of ABT-773, a novel antibacterial ketolide.
Topics: Anti-Bacterial Agents; Azithromycin; Clarithromycin; Drug Resistance, Multiple; Enterococcus; Erythromycin; Helicobacter pylori; Humans; Ketolides; Microbial Sensitivity Tests; Staphylococcus; Streptococcus; Time Factors | 2001 |
[Effect of macrolide antibiotics on apoptosis induction].
Topics: Anti-Bacterial Agents; Apoptosis; Azithromycin; Cells, Cultured; Clarithromycin; Fas Ligand Protein; fas Receptor; Humans; Josamycin; Lymphocytes; Membrane Glycoproteins | 2001 |
In vitro activity of midecamycin diacetate, a 16-membered macrolide, against Streptococcus pyogenes isolated in France, 1995-1999.
Topics: Anti-Bacterial Agents; Azithromycin; Clarithromycin; Clindamycin; Colony Count, Microbial; Drug Resistance, Microbial; Erythromycin; France; Humans; Josamycin; Leucomycins; Microbial Sensitivity Tests; Phenotype; Polymerase Chain Reaction; Roxithromycin; Streptococcus pyogenes | 2001 |
Efficacy of azithromycin, clarithromycin and beta-lactam agents against experimentally induced bronchopneumonia caused by Haemophilus influenzae in mice.
Topics: Animals; Anti-Bacterial Agents; Azithromycin; beta-Lactams; Bronchopneumonia; Clarithromycin; Disease Models, Animal; Haemophilus Infections; Haemophilus influenzae; Male; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Treatment Outcome | 2001 |
Reversible ototoxic effect of azithromycin and clarithromycin on transiently evoked otoacoustic emissions in guinea pigs.
Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Erythromycin; Guinea Pigs; Injections, Intravenous; Otoacoustic Emissions, Spontaneous | 2001 |
Activities of a new fluoroketolide, HMR 3787, and its (des)-fluor derivative RU 64399 compared to those of telithromycin, erythromycin A, azithromycin, clarithromycin, and clindamycin against macrolide-susceptible or -resistant Streptococcus pneumoniae an
Topics: Anti-Bacterial Agents; Azithromycin; Clarithromycin; Clindamycin; Drug Resistance; Erythromycin; Ketolides; Macrolides; Microbial Sensitivity Tests; Streptococcus pneumoniae; Streptococcus pyogenes | 2001 |
[Prevalence of primary Helicobacter pylori resistance to eight antimicrobial agents in a hospital in Madrid].
Topics: Adult; Aged; Amoxicillin; Azithromycin; Cefotaxime; Ciprofloxacin; Clarithromycin; Clindamycin; Cross Infection; Drug Resistance; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Prevalence; Pyloric Antrum; Spain; Tetracycline | 2001 |
Effect of prolonged treatment with azithromycin, clarithromycin, or levofloxacin on Chlamydia pneumoniae in a continuous-infection Model.
Topics: Anti-Bacterial Agents; Azithromycin; Chlamydophila pneumoniae; Clarithromycin; Cytokines; Humans; Levofloxacin; Microbial Sensitivity Tests; Models, Biological; Ofloxacin; Tumor Cells, Cultured | 2002 |
Potential of macrolide antibiotics to inhibit protein synthesis of Pseudomonas aeruginosa: suppression of virulence factors and stress response.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Bacterial Proteins; Ceftazidime; Cephalosporins; Clarithromycin; Clindamycin; Erythromycin; In Vitro Techniques; Josamycin; Microbial Sensitivity Tests; Minocycline; Ofloxacin; Oleandomycin; Protein Synthesis Inhibitors; Pseudomonas aeruginosa; Time Factors; Tobramycin | 2000 |
Erythromycin susceptibility of viridans streptococci from the normal throat flora of patients treated with azithromycin or clarithromycin.
Topics: Anti-Bacterial Agents; Azithromycin; Clarithromycin; Drug Resistance, Bacterial; Erythromycin; Humans; Microbial Sensitivity Tests; Pharynx; Polymerase Chain Reaction; Streptococcal Infections; Streptococcus | 2002 |
Effects of erythromycin, clarithromycin, roxithromycin and azithromycin on murine gut colonization by Candida albicans.
Topics: Animals; Anti-Bacterial Agents; Antifungal Agents; Azithromycin; Candida albicans; Candidiasis; Clarithromycin; Digestive System; Drug Therapy, Combination; Erythromycin; Mice; Mice, Inbred ICR; Roxithromycin; Tissue Distribution | 2002 |
[Changes of antibody titers during antimicrobial therapy including levofloxacin for Chlamydia infections in the obstetrics and gynecology field].
Topics: Antibodies, Bacterial; Azithromycin; Chlamydia Infections; Chlamydia trachomatis; Clarithromycin; Drug Therapy, Combination; Female; Humans; Immunoglobulin G; Levofloxacin; Maternal-Fetal Exchange; Ofloxacin; Pregnancy; Pregnancy Complications, Infectious | 2002 |
Repeat positive cultures in Mycobacterium intracellulare lung disease after macrolide therapy represent new infections in patients with nodular bronchiectasis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Azithromycin; Bronchiectasis; Clarithromycin; DNA, Bacterial; Electrophoresis, Gel, Pulsed-Field; Female; Humans; Lung Diseases; Male; Middle Aged; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Polymerase Chain Reaction; Prospective Studies; Sputum | 2002 |
Inhibitory effects of 14-membered ring macrolide antibiotics on bleomycin-induced acute lung injury.
Topics: Animals; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Apoptosis; Azithromycin; Bleomycin; Bronchoalveolar Lavage Fluid; Chemokine CXCL1; Chemokines, CXC; Chemotactic Factors; Clarithromycin; Disease Models, Animal; Dose-Response Relationship, Drug; Growth Substances; In Situ Nick-End Labeling; Intercellular Signaling Peptides and Proteins; Josamycin; Lung; Male; Mice; Mice, Inbred ICR; Pulmonary Edema; Respiratory Distress Syndrome; Roxithromycin; Time Factors; Treatment Outcome | 2002 |
In vitro selection of resistance in Haemophilus influenzae by amoxicillin-clavulanate, cefpodoxime, cefprozil, azithromycin, and clarithromycin.
Topics: Amino Acid Sequence; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Azithromycin; Cefpodoxime; Cefprozil; Ceftizoxime; Cephalosporins; Clarithromycin; Drug Resistance; Drug Therapy, Combination; Genes, Bacterial; Haemophilus influenzae; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation; Reverse Transcriptase Polymerase Chain Reaction; Transformation, Bacterial | 2002 |
Quantitative comparison of the cytocidal effect of seven macrolide antibiotics on human periodontal ligament fibroblasts.
Topics: Alkaline Phosphatase; Anti-Bacterial Agents; Apoptosis; Azithromycin; Cell Survival; Cells, Cultured; Clarithromycin; Collagen Type I; Dose-Response Relationship, Drug; Erythromycin; Fibroblasts; Gene Expression; Humans; Josamycin; Lethal Dose 50; Leucomycins; Miocamycin; Periodontal Ligament; RNA, Messenger; Roxithromycin; Statistics as Topic; Time Factors | 2002 |
Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes.
Topics: Animals; Anti-Bacterial Agents; Arrhythmias, Cardiac; Azithromycin; Blood Pressure; Clarithromycin; Electrocardiography; Erythromycin; Heart; Heart Rate; In Vitro Techniques; Long QT Syndrome; Male; Rabbits; Time Factors; Torsades de Pointes | 2002 |
[Macrolide consumption according to geographic areas in the province of Valladolid].
Topics: Anti-Bacterial Agents; Azithromycin; Clarithromycin; Drug Utilization Review; Erythromycin; Humans; Leucomycins; Retrospective Studies; Roxithromycin; Spain; Spiramycin | 2002 |
Influence of macrolide susceptibility on efficacies of clarithromycin and azithromycin against Streptococcus pneumoniae in a murine lung infection model.
Topics: Animals; Anti-Bacterial Agents; Area Under Curve; Azithromycin; Clarithromycin; Disease Models, Animal; Drug Resistance, Multiple, Bacterial; Half-Life; Humans; Lung Diseases; Mice; Microbial Sensitivity Tests; Serotyping; Streptococcal Infections; Streptococcus pneumoniae | 2003 |
Multisite reproducibility of results obtained by two broth dilution methods for susceptibility testing of Mycobacterium avium complex.
Topics: Anti-Bacterial Agents; Azithromycin; Clarithromycin; Culture Media; Humans; Microbial Sensitivity Tests; Mycobacterium avium; Reproducibility of Results | 2003 |
A comparison between disk diffusion and microdilution for susceptibility testing of Mycobacterium fortuitum complex.
Topics: Amikacin; Anti-Bacterial Agents; Azithromycin; Ciprofloxacin; Clarithromycin; Colony Count, Microbial; Erythromycin; Microbial Sensitivity Tests; Mycobacterium fortuitum; Ofloxacin; Tetracycline | 2002 |
Effects of an efflux mechanism and ribosomal mutations on macrolide susceptibility of Haemophilus influenzae clinical isolates.
Topics: Anti-Bacterial Agents; Azithromycin; Clarithromycin; Drug Resistance, Bacterial; Genes, Bacterial; Haemophilus Infections; Haemophilus influenzae; Humans; Microbial Sensitivity Tests; Mutation; Phenotype; Reverse Transcriptase Polymerase Chain Reaction; Ribosomes | 2003 |
[Comparative in vitro activities of several antimicrobial agents against Helicobacter pylori].
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Ciprofloxacin; Clarithromycin; Drug Resistance, Bacterial; Erythromycin; Fluoroquinolones; Gastric Mucosa; Helicobacter pylori; Humans; Levofloxacin; Microbial Sensitivity Tests; Norfloxacin; Ofloxacin; Penicillins; Stomach Ulcer | 2002 |
[Effects of 14-, 15-, and 16-membered ring macrolides on IL-8 gene expression in BET-1A cells].
Topics: Anti-Bacterial Agents; Azithromycin; Bronchi; Cells, Cultured; Clarithromycin; Depression, Chemical; Epithelial Cells; Erythromycin; Gene Expression; Humans; Inflammation Mediators; Interleukin-8; Miocamycin; Structure-Activity Relationship; Tumor Necrosis Factor-alpha | 2001 |
Comparative in vitro investigations of the interaction between some macrolides and Cu(II), Zn(II) and Fe(II).
Topics: Anti-Bacterial Agents; Azithromycin; Chromatography, High Pressure Liquid; Clarithromycin; Copper; Iron; Magnetic Resonance Spectroscopy; Roxithromycin; Spectrophotometry, Ultraviolet; Zinc | 2003 |
Antibiotic therapy for ambulatory patients with community-acquired pneumonia in an emergency department setting.
Topics: Adolescent; Adult; Aged; Alberta; Ambulatory Care; Analysis of Variance; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Community-Acquired Infections; Emergency Service, Hospital; Female; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Pneumonia, Bacterial; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Treatment Outcome | 2003 |
In vitro susceptibilities of Rhodococcus equi and other common equine pathogens to azithromycin, clarithromycin, and 20 other antimicrobials.
Topics: Animals; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Horses; Microbial Sensitivity Tests; Rhodococcus equi | 2003 |
[Cat scratch disease].
Topics: Animals; Azithromycin; Bartonella henselae; Cat-Scratch Disease; Cats; Ciprofloxacin; Clarithromycin; Humans; Insect Vectors; Serologic Tests; Siphonaptera; Zoonoses | 2003 |
Chlamydia pneumoniae resists antibiotics in lymphocytes.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Cells, Cultured; Chlamydia Infections; Chlamydophila pneumoniae; Clarithromycin; Female; Fluoroquinolones; Humans; Lymphocytes; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Minocycline; Naphthyridines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Bacterial | 2003 |
Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes.
Topics: Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Azithromycin; Clarithromycin; Cytochrome P-450 CYP3A; Drug Interactions; Erythromycin; Humans; Hydroxylation; Macrolides; Microsomes, Liver; Midazolam; Models, Biological; Oxidoreductases, N-Demethylating; Time Factors | 2003 |
Alterations in penicillin binding protein gene of Streptococcus pneumoniae and their correlation with susceptibility patterns.
Topics: Aminoacyltransferases; Anti-Bacterial Agents; Azithromycin; Bacterial Proteins; Carrier Proteins; Clarithromycin; Drug Resistance, Bacterial; Genes, Bacterial; Hexosyltransferases; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Muramoylpentapeptide Carboxypeptidase; Mutation; Ofloxacin; Penicillin G; Penicillin Resistance; Penicillin-Binding Proteins; Peptidyl Transferases; Pneumococcal Infections; Streptococcus pneumoniae; Thienamycins | 2003 |
[Antimicrobial activities of macrolides against recent clinical isolates, and analysis of resistant mechanisms].
Topics: Anti-Bacterial Agents; Azithromycin; Bacteria; Clarithromycin; Drug Resistance, Bacterial; Erythromycin; Haemophilus influenzae; Microbial Sensitivity Tests; Miocamycin; Moraxella catarrhalis; Staphylococcus; Streptococcus agalactiae; Streptococcus pneumoniae; Streptococcus pyogenes | 2003 |
[Susceptibility of major pathogens of acute pharyngitis and tonsillitis to levofloxacin and other oral antimicrobial drugs].
Topics: Acute Disease; Ampicillin; Anti-Infective Agents; Azithromycin; Cefdinir; Cefpodoxime; Ceftizoxime; Cephalosporins; Clarithromycin; Enterobacteriaceae; Haemophilus influenzae; Humans; Levofloxacin; Ofloxacin; Penicillin G; Pharyngitis; Streptococcus pneumoniae; Streptococcus pyogenes; Tonsillitis | 2003 |
[Influence of clarithromycin and azithromycin on cell cycle of neoplasms].
Topics: Anti-Bacterial Agents; Azithromycin; Cell Cycle; Clarithromycin; Depression, Chemical; Dose-Response Relationship, Drug; Humans; Neoplasms; Tumor Cells, Cultured | 2003 |
Effects of eight antibacterial agents on cell survival and expression of epithelial-cell- or cell-adhesion-related genes in human gingival epithelial cells.
Topics: Anti-Bacterial Agents; Azithromycin; Cell Adhesion; Cell Differentiation; Cell Division; Cell Line; Cell Survival; Clarithromycin; Enoxacin; Epithelial Cells; Erythromycin; Fibroblast Growth Factors; Gingiva; Humans; Integrins; Keratins; Laminin; Lethal Dose 50; Minocycline; Ofloxacin; Proteins; Roxithromycin; Tetracycline | 2004 |
[Macrolide antibiotic resistance rates and phenotypes of group A beta hemolytic streptococci isolated between the years 1999-2000 and 2001-2002].
Topics: Anti-Bacterial Agents; Azithromycin; Clarithromycin; Drug Resistance, Bacterial; Erythromycin; Humans; Microbial Sensitivity Tests; Pharynx; Phenotype; Streptococcus pyogenes | 2003 |
Selection of resistance of telithromycin against Haemophilus influenzae, Moraxella catarrhalis and streptococci in comparison with macrolides.
Topics: Anti-Bacterial Agents; Azithromycin; Clarithromycin; Drug Resistance, Bacterial; Gene Frequency; Haemophilus influenzae; Humans; Ketolides; Macrolides; Microbial Sensitivity Tests; Moraxella catarrhalis; Mutation; Respiratory Tract Infections; Streptococcus; Streptococcus pneumoniae | 2004 |
Clarithromycin and azithromycin induce apoptosis of activated lymphocytes via down-regulation of Bcl-xL.
Topics: Adult; Anti-Bacterial Agents; Antigen-Presenting Cells; Apoptosis; Azithromycin; bcl-2-Associated X Protein; bcl-X Protein; CD28 Antigens; CD3 Complex; Cells, Cultured; Clarithromycin; Down-Regulation; Fas Ligand Protein; fas Receptor; Humans; In Vitro Techniques; Lymphocyte Activation; Lymphocytes; Membrane Glycoproteins; Proto-Oncogene Proteins c-bcl-2; Stimulation, Chemical | 2004 |
Macrolide antibiotics induce apoptosis of human peripheral lymphocytes in vitro.
Topics: Annexin A5; Anti-Bacterial Agents; Apoptosis; Azithromycin; Cells, Cultured; Clarithromycin; Fas Ligand Protein; fas Receptor; Flow Cytometry; Humans; Josamycin; Lymphocytes; Macrolides; Membrane Glycoproteins; Receptors, Tumor Necrosis Factor; Time Factors | 2004 |
Antimicrobial susceptibility and macrolide resistance genes in Streptococcus pyogenes collected in Austria and Hungary.
Topics: Anti-Bacterial Agents; Austria; Azithromycin; Bacterial Proteins; beta-Lactams; Clarithromycin; Drug Resistance, Bacterial; Erythromycin; Female; Humans; Hungary; Josamycin; Macrolides; Membrane Proteins; Microbial Sensitivity Tests; Pharyngitis; Pharynx; Skin; Streptococcal Infections; Streptococcus pyogenes; Tetracycline Resistance; Tonsillitis; Vagina | 2004 |
Genetic and culture-based approaches for detecting macrolide resistance in Chlamydia pneumoniae.
Topics: Anti-Bacterial Agents; Azithromycin; Chlamydia Infections; Chlamydophila pneumoniae; Clarithromycin; DNA Primers; Drug Resistance, Bacterial; Humans; Macrolides; Microbial Sensitivity Tests; Phenotype; Reverse Transcriptase Polymerase Chain Reaction; RNA, Bacterial; RNA, Ribosomal, 23S | 2004 |
Effectiveness of amoxicillin, azithromycin, cefprozil and clarithromycin in the treatment of acute otitis media in children: a population-based study.
Topics: Acute Disease; Administration, Oral; Amoxicillin; Anti-Bacterial Agents; Azithromycin; Cefprozil; Cephalosporins; Child; Child, Preschool; Clarithromycin; Cohort Studies; Female; Follow-Up Studies; Humans; Male; Otitis Media; Quebec; Risk Factors; Time Factors; Treatment Outcome | 2005 |
Model for simulation of HIV/AIDS and cost-effectiveness of preventing non-tuberculous mycobacterial (MAC)-disease.
Topics: Acquired Immunodeficiency Syndrome; Anti-Bacterial Agents; Azithromycin; CD4 Lymphocyte Count; Clarithromycin; Cost-Benefit Analysis; Drug Therapy, Combination; Health Care Costs; Humans; Models, Economic; Mycobacterium avium-intracellulare Infection; Protease Inhibitors; Quality-Adjusted Life Years; Rifabutin | 2004 |
Corneal pharmacokinetics of topically applied azithromycin and clarithromycin.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Azithromycin; Biological Availability; Chromatography, High Pressure Liquid; Clarithromycin; Cornea; Models, Animal; Ophthalmic Solutions; Rabbits; Tissue Distribution | 2004 |
Antipneumococcal activities of two novel macrolides, GW 773546 and GW 708408, compared with those of erythromycin, azithromycin, clarithromycin, clindamycin, and telithromycin.
Topics: Anti-Bacterial Agents; Azithromycin; Clarithromycin; Clindamycin; Drug Resistance, Bacterial; Erythromycin; Genes, Bacterial; Ketolides; Macrolides; Microbial Sensitivity Tests; Mutation; Streptococcus pneumoniae; Time Factors | 2004 |
Activities of two novel macrolides, GW 773546 and GW 708408, compared with those of telithromycin, erythromycin, azithromycin, and clarithromycin against Haemophilus influenzae.
Topics: Anti-Bacterial Agents; Azithromycin; Clarithromycin; Drug Resistance, Bacterial; Erythromycin; Haemophilus influenzae; Ketolides; Macrolides; Microbial Sensitivity Tests; Ribosomal Proteins; RNA, Ribosomal, 23S; Time Factors | 2004 |
A subinhibitory concentration of clarithromycin inhibits Mycobacterium avium biofilm formation.
Topics: Acquired Immunodeficiency Syndrome; Anti-Bacterial Agents; Aza Compounds; Azithromycin; Biofilms; Clarithromycin; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Microscopy, Electron, Scanning; Moxifloxacin; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Quinolines | 2004 |
Antibiotic-induced apoptosis in human activated peripheral lymphocytes.
Topics: Annexin A5; Anti-Bacterial Agents; Apoptosis; Azithromycin; Clarithromycin; Humans; Lymphocyte Activation; Lymphocytes; Macrolides; Propidium; Respiratory Tract Infections | 2005 |
Lower mortality among patients with community-acquired pneumonia treated with a macrolide plus a beta-lactam agent versus a beta-lactam agent alone.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Azithromycin; Cefotaxime; Ceftriaxone; Clarithromycin; Community-Acquired Infections; Drug Therapy, Combination; Erythromycin; Humans; Pneumonia, Bacterial | 2005 |
An economic and outcomes assessment of first-line monotherapy in the treatment of community-acquired pneumonia within managed care.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Community-Acquired Infections; Databases as Topic; Erythromycin; Female; Health Care Costs; Humans; Levofloxacin; Male; Managed Care Programs; Middle Aged; Models, Econometric; Ofloxacin; Pneumonia, Bacterial; Retrospective Studies; Risk Assessment; Treatment Outcome | 2005 |
Cellular uptake and efflux of azithromycin, erythromycin, clarithromycin, telithromycin, and cethromycin.
Topics: Animals; Anti-Bacterial Agents; Azithromycin; Cell Line; Clarithromycin; Dogs; Epithelial Cells; Erythromycin; Humans; Ketolides; Macrolides; Mice; Neutrophils; Phagocytes | 2005 |
In vitro selection of resistance to clarithromycin in Streptococcus pneumoniae clinical isolates.
Topics: Amoxicillin; Aza Compounds; Azithromycin; Clarithromycin; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Sampling Studies; Sensitivity and Specificity; Streptococcus pneumoniae | 2005 |
[Pulmonary infection due to Mycobacterium malmoense].
Topics: Azithromycin; Clarithromycin; Drug Therapy, Combination; Ethambutol; Humans; Lung Diseases; Male; Middle Aged; Mycobacterium Infections, Nontuberculous; Rifampin | 2005 |
Occurrence and sorption behavior of sulfonamides, macrolides, and trimethoprim in activated sludge treatment.
Topics: Adsorption; Anti-Infective Agents; Azithromycin; Clarithromycin; Environmental Monitoring; Humans; Macrolides; Sewage; Sulfamethoxazole; Sulfonamides; Trimethoprim; Waste Disposal, Fluid; Water Pollutants, Chemical | 2005 |
Macrolide antibiotics modulate ERK phosphorylation and IL-8 and GM-CSF production by human bronchial epithelial cells.
Topics: Anti-Bacterial Agents; Azithromycin; Bronchi; Cells, Cultured; Clarithromycin; Dexamethasone; Dose-Response Relationship, Drug; Enzyme Inhibitors; Epithelial Cells; Extracellular Signal-Regulated MAP Kinases; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Imidazoles; Interleukin-8; Lipopolysaccharides; Mitogen-Activated Protein Kinases; Phosphorylation; Pyridines; Reference Values; Threonine; Time Factors; Tyrosine | 2006 |
[The mechanism of apoptosis induction in lymphocytes by macrolide antibiotics and the related intra-cellular molecular structure].
Topics: Anti-Bacterial Agents; Apoptosis; Azithromycin; bcl-2-Associated X Protein; bcl-X Protein; Clarithromycin; Fas Ligand Protein; fas Receptor; Humans; Josamycin; Lymphocytes; Membrane Glycoproteins; Proto-Oncogene Proteins c-bcl-2 | 2004 |
Prediction of time-dependent CYP3A4 drug-drug interactions: impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition.
Topics: Algorithms; Area Under Curve; Azithromycin; Biological Transport; Clarithromycin; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Diltiazem; Drug Interactions; Enzyme Inhibitors; Erythromycin; Humans; Intestinal Mucosa; Intestines; Metabolic Clearance Rate; Models, Biological; Time Factors | 2006 |
Kinetic bactericidal activity of telithromycin, azithromycin and clarithromycin against respiratory pathogens.
Topics: Anti-Bacterial Agents; Azithromycin; Clarithromycin; Haemophilus influenzae; Ketolides; Microbial Sensitivity Tests; Moraxella catarrhalis; Protein Synthesis Inhibitors; Streptococcus; Streptococcus pneumoniae; Time Factors | 2005 |
Recommended antimicrobial agents for the treatment and postexposure prophylaxis of pertussis: 2005 CDC Guidelines.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Azithromycin; Child; Child, Preschool; Clarithromycin; Erythromycin; Humans; Infant; Whooping Cough | 2005 |
Effect of efflux on telithromycin and macrolide susceptibility in Haemophilus influenzae.
Topics: Anti-Bacterial Agents; Azithromycin; Clarithromycin; Drug Resistance, Microbial; Haemophilus Infections; Haemophilus influenzae; Ketolides; Macrolides; Microbial Sensitivity Tests; Time Factors | 2006 |
[Prevalence and treatment of pharyngeal Chlamydia trachomatis infections].
Topics: Adult; Anti-Bacterial Agents; Azithromycin; Chlamydia Infections; Chlamydia trachomatis; Clarithromycin; Female; Humans; Japan; Levofloxacin; Ofloxacin; Pharyngitis; Prevalence; Sex Work; Sexual Behavior; Uterine Diseases | 2006 |
Efficacy of macrolides and telithromycin against leptospirosis in a hamster model.
Topics: Animals; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Cricetinae; Disease Models, Animal; Dose-Response Relationship, Drug; Doxycycline; Female; Ketolides; Leptospira interrogans; Leptospirosis; Macrolides; Mesocricetus; Serotyping; Species Specificity; Survival Analysis | 2006 |
Occurrence of levofloxacin, clarithromycin and azithromycin in wastewater treatment plant in Japan.
Topics: Anti-Bacterial Agents; Azithromycin; Chromatography, Liquid; Clarithromycin; Conservation of Natural Resources; Japan; Levofloxacin; Mass Spectrometry; Ofloxacin; Sewage; Time Factors; Waste Disposal, Fluid; Water Pollutants, Chemical; Water Purification | 2006 |
Enhancement of antimicrobial activities of cefteram or clavulanic acid/amoxicillin against cefixime-resistant Neisseria gonorrhoeae in the presence of clarithromycin or azithromycin.
Topics: Amoxicillin; Anti-Bacterial Agents; Azithromycin; beta-Lactams; Cefixime; Cefmenoxime; Clarithromycin; Clavulanic Acid; Drug Resistance, Bacterial; Drug Synergism; Erythromycin; Humans; Male; Neisseria gonorrhoeae | 2006 |
Intrinsic and selected resistance to antibiotics binding the ribosome: analyses of Brucella 23S rrn, L4, L22, EF-Tu1, EF-Tu2, efflux and phylogenetic implications.
Topics: Anti-Bacterial Agents; Azithromycin; Binding, Competitive; Brucella; Clarithromycin; DNA, Bacterial; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Erythromycin; Microbial Sensitivity Tests; Molecular Sequence Data; Peptide Elongation Factor Tu; Phylogeny; Polymorphism, Genetic; Protein Isoforms; Ribosomal Proteins; Ribosomes; RNA, Ribosomal, 23S; Sequence Analysis, DNA | 2006 |
In vitro induction of resistance by tissue concentrations of azithromycin, clarithromycin, cefixime and amoxicillin/clavulanate in clinical isolates of Streptococcus pyogenes.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Azithromycin; Cefixime; Cells, Cultured; Clarithromycin; Drug Resistance, Bacterial; Humans; Macrolides; Microbial Sensitivity Tests; Mutation; Streptococcus pyogenes | 2006 |
Primary resistance and antibiotic minimum inhibitory concentrations for Helicobacter pylori strains, in Split, Croatia.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Azithromycin; Cells, Cultured; Clarithromycin; Croatia; Drug Resistance, Bacterial; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Microbial Sensitivity Tests | 2006 |
Effect of macrolide antibiotics on uptake of digoxin into rat liver.
Topics: Animals; Anti-Bacterial Agents; Azithromycin; Biological Transport; Blood Flow Velocity; Cardiotonic Agents; Clarithromycin; Digoxin; Dose-Response Relationship, Drug; Drug Interactions; Erythromycin; Hepatocytes; Josamycin; Liver; Macrolides; Male; Permeability; Rats; Rats, Sprague-Dawley; Roxithromycin; Tissue Distribution | 2007 |
Attention prescribers: be careful with antibiotics.
Topics: Anti-Bacterial Agents; Azithromycin; Clarithromycin; Drug Resistance, Bacterial; Humans; Pharyngeal Diseases; Randomized Controlled Trials as Topic; Streptococcal Infections | 2007 |
Differing effects of clarithromycin and azithromycin on cytokine production by murine dendritic cells.
Topics: Animals; Anti-Bacterial Agents; Antigens, CD; Azithromycin; Bone Marrow Cells; Cells, Cultured; Clarithromycin; Coculture Techniques; Cytokines; Dendritic Cells; Female; Lipopolysaccharides; Mice; Mice, Inbred BALB C; T-Lymphocytes | 2007 |
Pulmonary disposition of erythromycin, azithromycin, and clarithromycin in foals.
Topics: Administration, Oral; Animals; Animals, Newborn; Anti-Bacterial Agents; Azithromycin; Bronchoalveolar Lavage; Clarithromycin; Erythromycin; Female; Horses; Lung; Male | 2007 |
Determination of six anti-infectives in wastewater using tandem solid-phase extraction and liquid chromatography-tandem mass spectrometry.
Topics: Anti-Infective Agents; Azithromycin; Chromatography, Liquid; Ciprofloxacin; Clarithromycin; Ofloxacin; Sewage; Solid Phase Extraction; Sulfamethoxazole; Tandem Mass Spectrometry; Trimethoprim; Water Pollutants, Chemical | 2007 |
[Comparison of antimicrobial and bactericidal activities and postantibiotic effects of macrolides antibiotics against clinical isolates, and examination of shape alteration by scanning electron microscope].
Topics: Azithromycin; Bacterial Proteins; Clarithromycin; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Erythromycin; Humans; Macrolides; Membrane Proteins; Methicillin Resistance; Methyltransferases; Microscopy, Electron, Scanning; Miocamycin; Polymerase Chain Reaction; Staphylococcus aureus; Streptococcus agalactiae; Streptococcus pneumoniae; Streptococcus pyogenes | 2007 |
Streptococcus pneumoniae bacteraemia: pharmacodynamic correlations with outcome and macrolide resistance--a controlled study.
Topics: Anti-Bacterial Agents; Area Under Curve; Azithromycin; Bacteremia; Clarithromycin; Drug Resistance, Bacterial; Erythromycin; Humans; Macrolides; Microbial Sensitivity Tests; Pneumococcal Infections; Retrospective Studies; Streptococcus pneumoniae; Treatment Failure | 2007 |
The serum amyloid A response to sterile silver nitrate in mice and its inhibition by dexamethasone and macrolide antibiotics.
Topics: Acute-Phase Reaction; Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Azithromycin; Cell Count; Clarithromycin; Dexamethasone; Female; Inflammation; Interleukin-1beta; Interleukin-6; Leukocyte Count; Macrolides; Mice; Mice, Inbred BALB C; Muscle, Skeletal; Neutrophils; Platelet Count; Roxithromycin; Serum Amyloid A Protein; Silver Nitrate; Subcutaneous Fat | 2007 |
Subinhibitory concentrations of telithromycin, clarithromycin and azithromycin reduce methicillin-resistant Staphylococcus aureus coagulase in vitro and in vivo.
Topics: Animals; Azithromycin; Clarithromycin; Coagulase; Enzyme Inhibitors; Humans; Ketolides; Male; Methicillin Resistance; Mice; Staphylococcus aureus | 2008 |
In vitro activity of telithromycin against Haemophilus influenzae at epithelial lining fluid concentrations.
Topics: Anti-Bacterial Agents; Azithromycin; beta-Lactamases; Carbon Dioxide; Clarithromycin; Haemophilus Infections; Haemophilus influenzae; Humans; Ketolides; Microbial Sensitivity Tests; Respiratory Tract Infections; Time Factors | 2008 |
[Macrolide antibiotics. Fast development of resistant streptococci].
Topics: Anti-Bacterial Agents; Azithromycin; Clarithromycin; Drug Resistance, Bacterial; Humans; Macrolides; Streptococcal Infections; Streptococcus | 2008 |
Involvement of intestinal uptake transporters in the absorption of azithromycin and clarithromycin in the rat.
Topics: Administration, Oral; Animals; Antirheumatic Agents; Area Under Curve; Azithromycin; Biological Transport, Active; Cell Line; Clarithromycin; Dogs; Histamine H1 Antagonists, Non-Sedating; Infusions, Intravenous; Intestinal Absorption; Male; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Rats; Rats, Sprague-Dawley; Rifamycins; Taurocholic Acid; Terfenadine; Transfection | 2008 |
Efficacy of azythromicin-based triple therapy for Helicobacter pylori infection: a retrospective study.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Proton Pump Inhibitors; Retrospective Studies; Treatment Outcome | 2008 |
Different effects of telithromycin on MUC5AC production induced by human neutrophil peptide-1 or lipopolysaccharide in NCI-H292 cells compared with azithromycin and clarithromycin.
Topics: alpha-Defensins; Anti-Bacterial Agents; Azithromycin; Cell Line; Clarithromycin; Enzyme-Linked Immunosorbent Assay; Humans; Ketolides; Lipopolysaccharides; Mitogen-Activated Protein Kinase 3; Mucin 5AC; Phosphorylation; Reverse Transcriptase Polymerase Chain Reaction | 2009 |
[Levofloxacin and macrolides in chronic bronchitis exacerbation: comparative analysis of the treatment efficacy and nonrelapsing periods].
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Azithromycin; Bronchitis, Chronic; Clarithromycin; Female; Humans; Levofloxacin; Macrolides; Male; Middle Aged; Ofloxacin; Treatment Outcome; Young Adult | 2007 |
Pharmacodynamic target attainment potential of azithromycin, clarithromycin, and telithromycin in serum and epithelial lining fluid of community-acquired pneumonia patients with penicillin-susceptible, intermediate, and resistant Streptococcus pneumoniae.
Topics: Anti-Bacterial Agents; Area Under Curve; Azithromycin; Clarithromycin; Community-Acquired Infections; Drug Resistance, Bacterial; Humans; Ketolides; Microbial Sensitivity Tests; Monte Carlo Method; Pneumonia, Pneumococcal; Probability; Streptococcus pneumoniae | 2009 |
On the efficacy of macrolide-based therapy for Helicobacter pylori infection.
Topics: Anti-Bacterial Agents; Azithromycin; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Roxithromycin; Treatment Outcome | 2009 |
In vitro transcorneal diffusion of the antimicrobial macrolides azithromycin and clarithromycin and the impact on microbial keratitis.
Topics: Adult; Aged; Animals; Anti-Bacterial Agents; Azithromycin; Chromatography, High Pressure Liquid; Clarithromycin; Cornea; Corneal Ulcer; Diffusion; Eye Infections, Bacterial; Humans; Middle Aged; Permeability; Rabbits; Tandem Mass Spectrometry; Young Adult | 2009 |
[Disappearance of Streptococcus pyogenes macrolide resistance in an area of northeastern Italy: a possible link with rational long-acting macrolide consumption].
Topics: Anti-Bacterial Agents; Azithromycin; Clarithromycin; Delayed-Action Preparations; Drug Resistance, Multiple, Bacterial; Drug Utilization; Erythromycin; Humans; Italy; Macrolides; Streptococcal Infections; Streptococcus pyogenes | 2009 |
Macrolide-induced digoxin toxicity: a population-based study.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Azithromycin; Cardiotonic Agents; Case-Control Studies; Clarithromycin; Comorbidity; Digoxin; Drug Interactions; Erythromycin; Female; Humans; Macrolides; Male; Polypharmacy | 2009 |
Azithromycin and clarithromycin inhibit lipopolysaccharide-induced murine pulmonary neutrophilia mainly through effects on macrophage-derived granulocyte-macrophage colony-stimulating factor and interleukin-1beta.
Topics: Animals; Azithromycin; Cell Line; Clarithromycin; Granulocyte-Macrophage Colony-Stimulating Factor; Inflammation Mediators; Interleukin-1beta; Lipopolysaccharides; Lung; Male; Mice; Mice, Inbred BALB C; Neutrophil Infiltration; Neutrophils | 2009 |
Azithromycin, clarithromycin and telithromycin inhibit MUC5AC induction by Chlamydophila pneumoniae in airway epithelial cells.
Topics: Animals; Anti-Bacterial Agents; Azithromycin; Blotting, Western; Cells, Cultured; Chlamydophila Infections; Chlamydophila pneumoniae; Clarithromycin; Enzyme-Linked Immunosorbent Assay; Epithelial Cells; Extracellular Signal-Regulated MAP Kinases; Gene Expression; Ketolides; Mice; Mucin 5AC; NF-kappa B; NF-kappa B p50 Subunit; Respiratory Mucosa; Reverse Transcriptase Polymerase Chain Reaction; Transcription Factor RelA | 2009 |
Interaction of macrolide antibiotics with intestinally expressed human and rat organic anion-transporting polypeptides.
Topics: Animals; Anti-Bacterial Agents; Azithromycin; Biological Transport; Chlorocebus aethiops; Clarithromycin; COS Cells; Dogs; Dose-Response Relationship, Drug; Erythromycin; Estrone; Humans; Intestinal Mucosa; Intestines; Kinetics; Macrolides; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Rats; Taurocholic Acid; Transfection | 2009 |
Macrolide antibiotics aggravate experimental autoimmune encephalomyelitis and inhibit inducible nitric oxide synthase.
Topics: Amino Acid Sequence; Animals; Anti-Bacterial Agents; Azithromycin; Blotting, Western; Cells, Cultured; Chlamydophila Infections; Chlamydophila pneumoniae; Clarithromycin; Encephalomyelitis, Autoimmune, Experimental; Female; Gene Expression Regulation, Enzymologic; Leukocytes, Mononuclear; Macrolides; Nitric Oxide; Nitric Oxide Synthase Type II; Oligopeptides; Rats; Rats, Inbred Lew; Reverse Transcriptase Polymerase Chain Reaction; Time Factors | 2009 |
Canadian province-level risk factor analysis of macrolide consumption patterns (2000-2006).
Topics: Anti-Bacterial Agents; Azithromycin; Canada; Clarithromycin; Drug Utilization; Erythromycin; Health Knowledge, Attitudes, Practice; Humans; Influenza, Human; Macrolides; Risk Factors; Seasons; Socioeconomic Factors | 2010 |
CEM-101 activity against Gram-positive organisms.
Topics: Anti-Bacterial Agents; Azithromycin; Ceftriaxone; Clarithromycin; Drug Resistance, Bacterial; Drug Synergism; Erythromycin; Gentamicins; Gram-Positive Bacteria; Ketolides; Macrolides; Microbial Sensitivity Tests; Ofloxacin; Staphylococcus aureus; Staphylococcus epidermidis; Streptococcus pneumoniae; Streptococcus pyogenes; Triazoles; Trimethoprim, Sulfamethoxazole Drug Combination; Vancomycin | 2010 |
[Antimicrobial susceptibility patterns of Legionella isolates in the environment and in patients].
Topics: Anti-Bacterial Agents; Azithromycin; Ciprofloxacin; Clarithromycin; Clindamycin; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Humans; Legionella; Legionellosis; Microbial Sensitivity Tests; Naphthyridines | 2010 |
Macrolides versus quinolones in Legionella pneumonia: results from the Community-Acquired Pneumonia Organization international study.
Topics: Administration, Oral; Anti-Bacterial Agents; Azithromycin; Chi-Square Distribution; Clarithromycin; Community-Acquired Infections; Female; Humans; Kaplan-Meier Estimate; Legionella pneumophila; Legionnaires' Disease; Length of Stay; Levofloxacin; Male; Ofloxacin; Retrospective Studies; Time Factors; Treatment Outcome | 2010 |
Antimicrobial susceptibility testing of historical and recent clinical isolates of Bordetella pertussis in the United Kingdom using the Etest method.
Topics: Adolescent; Anti-Bacterial Agents; Azithromycin; Bordetella pertussis; Child; Child, Preschool; Clarithromycin; Drug Resistance, Bacterial; Erythromycin; Female; Humans; Infant; Infant, Newborn; Male; Microbial Sensitivity Tests; United Kingdom; Young Adult | 2010 |
Azithromycin inhibits nontypeable Haemophilus influenzae-induced MUC5AC expression and secretion via inhibition of activator protein-1 in human airway epithelial cells.
Topics: Anti-Bacterial Agents; Azithromycin; Cell Line, Tumor; Clarithromycin; Epithelial Cells; Haemophilus Infections; Haemophilus influenzae; Humans; Mucin 5AC; RNA, Messenger; Transcription Factor AP-1 | 2010 |
Characterization of macrolide resistance in Mycoplasma pneumoniae isolated from children in Shanghai, China.
Topics: Anti-Bacterial Agents; Azithromycin; Bacterial Typing Techniques; Child; Child, Preschool; China; Clarithromycin; DNA Fingerprinting; Drug Resistance, Bacterial; Erythromycin; Fluoroquinolones; Genotype; Humans; Macrolides; Microbial Sensitivity Tests; Mycoplasma pneumoniae; Pneumonia, Mycoplasma; Point Mutation; Polymorphism, Restriction Fragment Length; RNA, Bacterial; RNA, Ribosomal, 23S; Tetracyclines | 2010 |
Disposition of oral telithromycin in foals and in vitro activity of the drug against macrolide-susceptible and macrolide-resistant Rhodococcus equi isolates.
Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Azithromycin; Bronchoalveolar Lavage; Bronchoalveolar Lavage Fluid; Clarithromycin; Drug Resistance, Bacterial; Epithelium; Erythromycin; Female; Horses; Ketolides; Linear Models; Lung; Macrolides; Male; Microbial Sensitivity Tests; Rhodococcus equi | 2010 |
Successful clarithromycin desensitization in a multiple macrolide-allergic patient.
Topics: Aged; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Desensitization, Immunologic; Dose-Response Relationship, Immunologic; Drug Hypersensitivity; Female; Humans; Mycobacterium avium; Treatment Outcome; Tuberculosis | 2010 |
Assessment of clarithromycin susceptibility in strains belonging to the Mycobacterium abscessus group by erm(41) and rrl sequencing.
Topics: Anti-Bacterial Agents; Azithromycin; Clarithromycin; DNA, Bacterial; Genes, rRNA; Humans; Methyltransferases; Microbial Sensitivity Tests; Molecular Sequence Data; Mycobacterium; Mycobacterium Infections; RNA, Ribosomal, 23S; Sequence Analysis, DNA | 2011 |
In vitro intracellular activity and in vivo efficacy of modithromycin, a novel bicyclolide, against Legionella pneumophila.
Topics: Animals; Anti-Bacterial Agents; Azithromycin; Bridged-Ring Compounds; Cell Line; Cells, Cultured; Clarithromycin; Disease Models, Animal; Humans; Ketolides; Legionella pneumophila; Legionnaires' Disease; Levofloxacin; Macrolides; Mice; Microbial Sensitivity Tests; Ofloxacin | 2011 |
The risk of hypotension following co-prescription of macrolide antibiotics and calcium-channel blockers.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Azithromycin; Calcium Channel Blockers; Case-Control Studies; Clarithromycin; Cross-Over Studies; Cytochrome P-450 Enzyme Inhibitors; Drug Synergism; Drug Therapy, Combination; Erythromycin; Female; Humans; Hypotension; Macrolides; Male; Matched-Pair Analysis; Ontario; Patient Admission | 2011 |
Macrolide antibiotics broadly and distinctively inhibit cytokine and chemokine production by COPD sputum cells in vitro.
Topics: Anti-Bacterial Agents; Azithromycin; Cell Survival; Cells, Cultured; Chemokines; Clarithromycin; Cytokines; Erythromycin; Humans; Macrolides; Pulmonary Disease, Chronic Obstructive; Roxithromycin; Sputum | 2011 |
Topical azithromycin and clarithromycin inhibit acute and chronic skin inflammation in sensitized mice, with apparent selectivity for Th2-mediated processes in delayed-type hypersensitivity.
Topics: Administration, Topical; Animals; Anti-Inflammatory Agents; Azithromycin; Cell Degranulation; Clarithromycin; Dermatitis, Contact; Dexamethasone; Ear; Hypersensitivity, Delayed; Immunoglobulin E; Interferon-gamma; Interleukin-1beta; Interleukin-4; Mast Cells; Mice; Oxazolone; Skin; Tetradecanoylphorbol Acetate; Th2 Cells; Tumor Necrosis Factor-alpha | 2012 |
[Regional difference of antibiotic resistance of helicobacter pylori strains in Korea].
Topics: Amoxicillin; Anti-Bacterial Agents; Aza Compounds; Azithromycin; Ciprofloxacin; Clarithromycin; Drug Resistance, Bacterial; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Ofloxacin; Quinolines; Republic of Korea; Tetracycline | 2011 |
Susceptibility of Ureaplasma urealyticum to tetracycline, doxycycline, erythromycin, roxithromycin, clarithromycin, azithromycin, levofloxacin and moxifloxacin.
Topics: Anti-Bacterial Agents; Aza Compounds; Azithromycin; Clarithromycin; Dose-Response Relationship, Drug; Doxycycline; Erythromycin; Female; Fluoroquinolones; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Reproducibility of Results; Roxithromycin; Tetracycline; Time Factors; Ureaplasma Infections; Ureaplasma urealyticum | 2011 |
Distribution characteristics of clarithromycin and azithromycin, macrolide antimicrobial agents used for treatment of respiratory infections, in lung epithelial lining fluid and alveolar macrophages.
Topics: Animals; Anti-Bacterial Agents; Area Under Curve; Azithromycin; Body Fluids; Cell Line; Clarithromycin; Lung; Macrophages, Alveolar; Rats; Respiratory Mucosa; Tissue Distribution | 2011 |
Neomacrolides in the treatment of patients with severe asthma and/or bronchiectasis: a retrospective observational study.
Topics: Adult; Age Factors; Anti-Bacterial Agents; Asthma; Azithromycin; Bronchiectasis; Clarithromycin; Cohort Studies; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Forced Expiratory Volume; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Respiratory Function Tests; Retrospective Studies; Severity of Illness Index; Sex Factors; Treatment Outcome | 2011 |
[Detection and the antibiotic susceptibility analysis of mycoplasma and chlamydia in urogenital tract infections of 327 cases patients with tubal infertility].
Topics: Adult; Anti-Bacterial Agents; Azithromycin; Chlamydia; Chlamydia Infections; Clarithromycin; Doxycycline; Erythromycin; Female; Humans; Infertility, Female; Josamycin; Microbial Sensitivity Tests; Minocycline; Mycoplasma; Mycoplasma Infections; Roxithromycin; Spectinomycin; Tetracycline; Ureaplasma urealyticum; Urogenital System; Young Adult | 2011 |
The effect of azithromycin on the maturation and function of murine bone marrow-derived dendritic cells.
Topics: Animals; Azithromycin; B7-2 Antigen; Bone Marrow Cells; CD40 Antigens; Cholecalciferol; Clarithromycin; Cytokines; Dendritic Cells; Female; Interleukin-12; Lipopolysaccharides; Lymphocyte Culture Test, Mixed; Mice; Mice, Inbred C57BL; NF-kappa B; Toll-Like Receptor 4 | 2011 |
Valosin containing protein (VCP) interacts with macrolide antibiotics without mediating their anti-inflammatory activities.
Topics: Adenosine Triphosphatases; Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Azithromycin; Cell Cycle Proteins; Cell Line; Clarithromycin; Drug Design; Gene Silencing; Humans; Mice; Protein Binding; Proteomics; Reproducibility of Results; Valosin Containing Protein | 2012 |
[The effects of macrolides (EM900, clarithromycin and azithromycin) on IL-17-induced IL-8 production by airway epithelial cells].
Topics: Anti-Inflammatory Agents; Azithromycin; Cells, Cultured; Clarithromycin; Erythromycin; Humans; Interleukin-17; Interleukin-8; Recombinant Proteins; Respiratory Mucosa | 2009 |
Molecular dynamics in supercooled liquid and glassy states of antibiotics: azithromycin, clarithromycin and roxithromycin studied by dielectric spectroscopy. Advantages given by the amorphous state.
Topics: Anti-Bacterial Agents; Azithromycin; Clarithromycin; Dielectric Spectroscopy; Drug Stability; Molecular Dynamics Simulation; Roxithromycin; Temperature; X-Ray Diffraction | 2012 |
Macrolides for acute lung injury.
Topics: Acute Lung Injury; Anti-Inflammatory Agents, Non-Steroidal; Azithromycin; Clarithromycin; Erythromycin; Female; Humans; Macrolides; Male; Pentoxifylline | 2012 |
Azithromycin inhibits mucus hypersecretion from airway epithelial cells.
Topics: Ampicillin; Animals; Anti-Bacterial Agents; Antibodies, Monoclonal; Azithromycin; Bronchi; Cell Line, Tumor; Clarithromycin; Epithelial Cells; Gene Expression Regulation; Goblet Cells; Humans; Josamycin; Lipopolysaccharides; Mucin 5AC; Mucus; Rats; Trachea | 2012 |
Macrolide-resistant Bordetella pertussis infection in newborn girl, France.
Topics: Azithromycin; Bordetella pertussis; Clarithromycin; DNA Mutational Analysis; Drug Resistance, Bacterial; Exchange Transfusion, Whole Blood; Female; Humans; Infant, Newborn; RNA, Ribosomal, 23S; Treatment Outcome; Whooping Cough | 2012 |
Cantharidin-induced inflammation in mouse ear model for translational research of novel anti-inflammatories.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Azithromycin; Cantharidin; Clarithromycin; Disease Models, Animal; Dose-Response Relationship, Drug; Ear, External; Edema; Irritants; Male; Mice; Mice, Inbred Strains; Otitis Externa; Translational Research, Biomedical | 2012 |
Long-term combination treatment of azithromycin with other macrolides: a new era.
Topics: Azithromycin; Clarithromycin; Female; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections | 2012 |
A case of refractory chronic respiratory tract infection due to Pseudomonas aeruginosa successfully controlled by combination of clarithromycin and azithromycin.
Topics: Anti-Bacterial Agents; Azithromycin; Clarithromycin; Drug Therapy, Combination; Female; Humans; Immunologic Factors; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Treatment Outcome | 2012 |
N'-substituted-2'-O,3'-N-carbonimidoyl bridged macrolides: novel anti-inflammatory macrolides without antimicrobial activity.
Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Azithromycin; Bronchiolitis; Bronchoalveolar Lavage Fluid; Cell Line; Clarithromycin; Cystic Fibrosis; Drug Interactions; Drug Resistance, Bacterial; Erythromycin; Haemophilus Infections; Haemophilus influenzae; Humans; Interleukin-6; Lipopolysaccharides; Lung; Macrolides; Male; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Moraxella catarrhalis; Neutrophils; Rats; Rats, Sprague-Dawley; Streptococcus | 2012 |
Transport characteristics of clarithromycin, azithromycin and telithromycin, antibiotics applied for treatment of respiratory infections, in Calu-3 cell monolayers as model lung epithelial cells.
Topics: Adenosine Triphosphatases; Algorithms; Animals; Anti-Bacterial Agents; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Azithromycin; Biological Transport, Active; Cell Line; Clarithromycin; Epithelial Cells; Ketolides; Lung; Mice; Multidrug Resistance-Associated Proteins; Protein Binding; Respiratory Tract Infections | 2012 |
Macrolide treatment for Mycobacterium abscessus and Mycobacterium massiliense infection and inducible resistance.
Topics: Animals; Anti-Bacterial Agents; Azithromycin; Bone Marrow Cells; Clarithromycin; Disease Models, Animal; Drug Resistance, Multiple, Bacterial; Female; Humans; In Vitro Techniques; Macrolides; Mice; Mice, Inbred C57BL; Mycobacterium; Mycobacterium Infections, Nontuberculous; Republic of Korea | 2012 |
Treatment of Mycobacterium abscessus: all macrolides are equal, but perhaps some are more equal than others.
Topics: Animals; Azithromycin; Clarithromycin; Female; Humans; Mycobacterium; Mycobacterium Infections, Nontuberculous | 2012 |
Minimal inhibitory and mutant prevention concentrations of azithromycin, clarithromycin and erythromycin for clinical isolates of Streptococcus pneumoniae.
Topics: Anti-Bacterial Agents; Attention; Azithromycin; Canada; Clarithromycin; Erythromycin; Humans; Microbial Sensitivity Tests; Mutation; Pneumococcal Infections; Streptococcus pneumoniae | 2013 |
Macrolides inhibit cytokine production by alveolar macrophages in bronchiolitis obliterans organizing pneumonia.
Topics: Aged; Azithromycin; Cells, Cultured; Chemokines, CC; Clarithromycin; Cryptogenic Organizing Pneumonia; Cytokines; Dexamethasone; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Female; Humans; Interleukin-1beta; Interleukin-6; Interleukin-8; Lipopolysaccharides; Macrophages, Alveolar; Male; Middle Aged; Receptors, Tumor Necrosis Factor, Type II; Tumor Necrosis Factor-alpha | 2013 |
Safety of macrolides during pregnancy.
Topics: Adult; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Erythromycin; Female; Heart Defects, Congenital; Humans; Logistic Models; Macrolides; Pregnancy; Prenatal Exposure Delayed Effects; Pyloric Stenosis; Risk | 2013 |
Macrolides inhibit Fusobacterium nucleatum-induced MUC5AC production in human airway epithelial cells.
Topics: Azithromycin; Cell Line; Clarithromycin; Clindamycin; Enzyme-Linked Immunosorbent Assay; Epithelial Cells; Fusobacterium nucleatum; Humans; Macrolides; Metronidazole; Mucin 5AC; Reverse Transcriptase Polymerase Chain Reaction | 2013 |
Sunitinib in combination with clarithromycin or azithromycin - is there a risk of interaction or not?
Topics: Administration, Oral; Animals; Area Under Curve; Azithromycin; Chromatography, High Pressure Liquid; Clarithromycin; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Enzyme Inhibitors; Half-Life; Indoles; Isoenzymes; Male; Metabolic Clearance Rate; Protein Kinase Inhibitors; Pyrroles; Rabbits; Risk Assessment; Spectrophotometry, Ultraviolet; Sunitinib | 2012 |
Differential effects of clarithromycin and azithromycin on delayed rectifier K(+)-channel currents in murine thymocytes.
Topics: Animals; Anti-Bacterial Agents; Azithromycin; Cell Membrane; Clarithromycin; Cytokines; Dose-Response Relationship, Drug; Immunologic Factors; Kv1.3 Potassium Channel; Male; Mice; Patch-Clamp Techniques; Thymocytes | 2013 |
Macrolide antibiotics block autophagy flux and sensitize to bortezomib via endoplasmic reticulum stress-mediated CHOP induction in myeloma cells.
Topics: Animals; Apoptosis; Autophagy; Azithromycin; Boronic Acids; Bortezomib; Cell Line, Tumor; Clarithromycin; Endoplasmic Reticulum Stress; Erythromycin; Fibroblasts; Gene Expression Regulation, Neoplastic; Humans; Macrolides; Mice; Multiple Myeloma; Pyrazines; Transcription Factor CHOP | 2013 |
Statin toxicity from macrolide antibiotic coprescription: a population-based cohort study.
Topics: Acute Kidney Injury; Aged; Anti-Bacterial Agents; Azithromycin; Cause of Death; Clarithromycin; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Erythromycin; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Retrospective Studies; Rhabdomyolysis | 2013 |
Use of long-term antibiotic treatment in COPD patients in the UK: a retrospective cohort study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Cohort Studies; Disease Progression; Doxycycline; Erythromycin; Female; Humans; Longitudinal Studies; Male; Middle Aged; Oxytetracycline; Penicillins; Practice Guidelines as Topic; Practice Patterns, Physicians'; Pulmonary Disease, Chronic Obstructive; Retrospective Studies; Sex Factors; United Kingdom | 2013 |
Mutant prevention concentration and mutant selection window for 10 antimicrobial agents against Rhodococcus equi.
Topics: Actinomycetales Infections; Animals; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Erythromycin; Gentamicins; Horse Diseases; Horses; Macrolides; Microbial Sensitivity Tests; Mutation; Rhodococcus equi; Rifampin; Vancomycin | 2013 |
Nodular bronchiectatic Mycobacterium avium complex pulmonary disease. Natural course on serial computed tomographic scans.
Topics: Aged; Anti-Bacterial Agents; Azithromycin; Bronchiectasis; Clarithromycin; Disease Progression; Drug Therapy, Combination; Ethambutol; Female; Humans; Lung; Male; Middle Aged; Multiple Pulmonary Nodules; Multivariate Analysis; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Pneumonia, Bacterial; Proportional Hazards Models; Retrospective Studies; Rifampin; Tomography, X-Ray Computed | 2013 |
Subcellular distribution of azithromycin and clarithromycin in rat alveolar macrophages (NR8383) in vitro.
Topics: Animals; Anti-Bacterial Agents; Azithromycin; Biological Transport; Cell Line; Clarithromycin; Macrophages, Alveolar; Rats | 2013 |
Calcium-channel blocker-clarithromycin drug interactions and acute kidney injury.
Topics: Acute Disease; Acute Kidney Injury; Aged; Aged, 80 and over; Anti-Bacterial Agents; Azithromycin; Calcium Channel Blockers; Clarithromycin; Cohort Studies; Cytochrome P-450 CYP3A; Drug Interactions; Female; Hospitalization; Humans; Male; Practice Patterns, Physicians'; Retrospective Studies; Risk | 2013 |
Recent progress towards understanding genetic variation in the Mycobacterium abscessus complex.
Topics: Anti-Bacterial Agents; Azithromycin; Bacterial Proteins; Clarithromycin; DNA, Bacterial; Drug Resistance, Bacterial; Female; Genetic Variation; Host-Pathogen Interactions; Humans; Lung; Male; Mycobacterium; Mycobacterium Infections, Nontuberculous; Phylogeny; Respiratory Tract Infections; Sequence Analysis, DNA; Soft Tissue Infections; Virulence | 2013 |
Macrolide/Azalide therapy for nodular/bronchiectatic mycobacterium avium complex lung disease.
Topics: Aged; Anti-Bacterial Agents; Azithromycin; Bronchiectasis; Clarithromycin; DNA, Bacterial; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Electrophoresis, Gel, Pulsed-Field; Female; Follow-Up Studies; Genotype; Humans; Lung Diseases; Macrolides; Male; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Practice Guidelines as Topic; Recurrence; Retrospective Studies; Sputum; Treatment Outcome | 2014 |
Erm(41)-dependent inducible resistance to azithromycin and clarithromycin in clinical isolates of Mycobacterium abscessus.
Topics: Anti-Bacterial Agents; Azithromycin; Bacterial Proteins; Clarithromycin; Culture Media; Drug Resistance, Bacterial; Genes, Bacterial; Humans; Macrolides; Microbial Sensitivity Tests; Mycobacterium | 2014 |
Survey of the occurrence of pharmaceuticals in Spanish finished drinking waters.
Topics: Azithromycin; Chromatography, Liquid; Clarithromycin; Drinking Water; Environmental Monitoring; Erythromycin; Ibuprofen; Pharmaceutical Preparations; Spain; Sulfamethoxazole; Tandem Mass Spectrometry; Water Pollutants, Chemical | 2014 |
Drug-drug interactions and acute kidney injury: caveat prescriptor.
Topics: Acute Kidney Injury; Anti-Bacterial Agents; Azithromycin; Calcium Channel Blockers; Clarithromycin; Female; Humans; Male | 2014 |
Is primary mycobacterium avium complex prophylaxis necessary in patients with CD4 <50 cells/μL who are virologically suppressed on cART?
Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Anti-HIV Agents; Antibiotic Prophylaxis; Antiretroviral Therapy, Highly Active; Azithromycin; CD4 Lymphocyte Count; Clarithromycin; Female; Follow-Up Studies; HIV Infections; Humans; Incidence; Male; Middle Aged; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Retrospective Studies; Rifabutin; RNA, Viral; United States; Viral Load | 2014 |
Azithromycin inhibits MUC5AC induction via multidrug-resistant Acinetobacter baumannii in human airway epithelial cells.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Azithromycin; Blotting, Western; Bronchi; Cells, Cultured; Clarithromycin; Drug Resistance, Multiple, Bacterial; Enzyme-Linked Immunosorbent Assay; Epithelial Cells; Gene Expression Regulation; Humans; Mucin 5AC; Pneumonia, Ventilator-Associated; Reverse Transcriptase Polymerase Chain Reaction | 2014 |
In vitro synergism observed with azithromycin, clarithromycin, minocycline, or tigecycline in association with antifungal agents against Pythium insidiosum.
Topics: Animals; Antifungal Agents; Azithromycin; Clarithromycin; Drug Combinations; Drug Synergism; Humans; In Vitro Techniques; Microbial Sensitivity Tests; Minocycline; Pythiosis; Pythium; Tigecycline | 2014 |
Disseminated Mycobacterium celatum disease with prolonged pulmonary involvement.
Topics: Aged; Anti-Bacterial Agents; Azithromycin; Ciprofloxacin; Clarithromycin; Drug Therapy, Combination; Ethambutol; Female; Humans; Isoniazid; Lung; Lung Diseases; Mycobacterium; Mycobacterium Infections; Pyrazinamide; Radiography | 2014 |
Embrace simplicity when treating lady windermere.
Topics: Azithromycin; Bronchiectasis; Clarithromycin; Female; Humans; Lung Diseases; Macrolides; Male; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection | 2014 |
Diagnosis of helicobacter pylori infection.
Topics: Amoxicillin; Azithromycin; Clarithromycin; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male | 2014 |
Gilles de la Tourette Syndrome caused by Mycoplasma pneumoniae successfully treated with macrolides.
Topics: Azithromycin; Child, Preschool; Clarithromycin; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Pneumonia, Mycoplasma; Tourette Syndrome; Treatment Outcome | 2014 |
New insights into the in vitro susceptibility of Pythium insidiosum.
Topics: Acetamides; Anti-Bacterial Agents; Antifungal Agents; Azithromycin; Clarithromycin; Doxycycline; Linezolid; Microbial Sensitivity Tests; Minocycline; Mupirocin; Oxazolidinones; Pythium; Tigecycline | 2014 |
Group determination of 14-membered macrolide antibiotics and azithromycin using antibodies against common epitopes.
Topics: Animals; Anti-Bacterial Agents; Antibodies; Azithromycin; Body Fluids; Cattle; Clarithromycin; Cross Reactions; Enzyme-Linked Immunosorbent Assay; Epitopes; Erythromycin; Food Contamination; Humans; Limit of Detection; Macrolides; Rabbits; Roxithromycin; Water Pollutants, Chemical | 2015 |
[The analysis of species identification and susceptibility testing of Mycobacterium abscessus].
Topics: Amikacin; Anti-Bacterial Agents; Antibiotics, Antitubercular; Azithromycin; Cefoxitin; Clarithromycin; Humans; Nontuberculous Mycobacteria; RNA, Ribosomal, 16S | 2014 |
Risks of cardiac arrhythmia and mortality among patients using new-generation macrolides, fluoroquinolones, and β-lactam/β-lactamase inhibitors: a Taiwanese nationwide study.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Arrhythmias, Cardiac; Azithromycin; beta-Lactamase Inhibitors; Cardiovascular Diseases; Ciprofloxacin; Clarithromycin; Comorbidity; Female; Fluoroquinolones; Humans; Levofloxacin; Logistic Models; Male; Moxifloxacin; Risk; Taiwan | 2015 |
Calcium channel blocker-clarithromycin drug interaction did not increase the risk of nonvertebral fracture: a population-based study.
Topics: Aged; Azithromycin; Calcium Channel Blockers; Clarithromycin; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Female; Humans; Male; Odds Ratio; Retrospective Studies; Risk | 2015 |
Azithromycin suppresses CD4(+) T-cell activation by direct modulation of mTOR activity.
Topics: Anti-Bacterial Agents; Apoptosis; Azithromycin; CD4-Positive T-Lymphocytes; Cell Proliferation; Clarithromycin; Cytokines; Humans; Immunosuppressive Agents; Lymphocyte Activation; Phosphatidylinositol 3-Kinases; Protein Processing, Post-Translational; Ribosomal Protein S6; Signal Transduction; TOR Serine-Threonine Kinases | 2014 |
Association of the in vitro susceptibility of clinical isolates of chlamydia trachomatis with serovar and duration of antibiotic exposure.
Topics: Animals; Anti-Bacterial Agents; Azithromycin; Chlamydia Infections; Chlamydia trachomatis; Clarithromycin; Doxycycline; Drug Resistance, Bacterial; Fibroblasts; Humans; In Vitro Techniques; Mice; Microbial Sensitivity Tests; Serogroup | 2015 |
Novel macrolide-resistance genes, mef(C) and mph(G), carried by plasmids from Vibrio and Photobacterium isolated from sediment and seawater of a coastal aquaculture site.
Topics: Animals; Anti-Bacterial Agents; Aquatic Organisms; Azithromycin; Clarithromycin; Drug Resistance, Bacterial; Erythromycin; Escherichia coli; Genes, Bacterial; Geologic Sediments; Macrolides; Membrane Transport Proteins; Microbial Sensitivity Tests; Molecular Sequence Data; Phosphotransferases; Photobacterium; Plasmids; Seawater; Vibrio | 2015 |
Are the antimicrobial properties of macrolides required for their therapeutic efficacy in chronic neutrophilic airway diseases?
Topics: Amoxicillin; Animals; Anti-Bacterial Agents; Asthma; Azithromycin; Bronchiolitis Obliterans; Chlamydophila Infections; Clarithromycin; Female; Haemophilus Infections; Humans; Lung Transplantation; Male | 2015 |
Prevalence and molecular analysis of macrolide-resistant Moraxella catarrhalis clinical isolates in Japan, following emergence of the highly macrolide-resistant strain NSH1 in 2011.
Topics: Anti-Bacterial Agents; Azithromycin; Clarithromycin; Clindamycin; Drug Resistance, Multiple, Bacterial; Erythromycin; Japan; Microbial Sensitivity Tests; Moraxella catarrhalis; Moraxellaceae Infections; Mutation; RNA, Ribosomal, 23S | 2015 |
The enhancement of cardiac toxicity by concomitant administration of Berberine and macrolides.
Topics: Animals; Anti-Bacterial Agents; Azithromycin; Berberine; Clarithromycin; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Synergism; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Heart Diseases; HEK293 Cells; Humans; Male; Membrane Potentials; Microsomes, Liver; Myocytes, Cardiac; Potassium Channel Blockers; Rats; Rats, Wistar; Risk Assessment; Transfection | 2015 |
Azithromycin is more allergenic than clarithromycin in children with suspected hypersensitivity reaction to macrolides.
Topics: Adolescent; Age Factors; Anti-Bacterial Agents; Azithromycin; Biomarkers; Child; Child, Preschool; Clarithromycin; Drug Hypersensitivity; Female; Humans; Immunoglobulin E; Infant; Intradermal Tests; Italy; Male; Predictive Value of Tests; Retrospective Studies; Risk Factors | 2015 |
Disseminated Mycobacterium kansasii disease in complete DiGeorge syndrome.
Topics: Antibiotic Prophylaxis; Azithromycin; Biopsy; Clarithromycin; DiGeorge Syndrome; Humans; Infant; Male; Mycobacterium Infections, Nontuberculous; Mycobacterium kansasii; Organ Transplantation; T-Lymphocytes; Thymus Gland; Tomography, X-Ray Computed | 2015 |
Toxicity of macrolide antibiotics on isolated heart mitochondria: a justification for their cardiotoxic adverse effect.
Topics: Animals; Anti-Bacterial Agents; Azithromycin; Cardiotoxins; Clarithromycin; Cytochromes c; Erythromycin; In Vitro Techniques; Macrolides; Male; Membrane Potential, Mitochondrial; Mitochondria, Heart; Mitochondria, Liver; Mitochondrial Swelling; Myocytes, Cardiac; Rats, Wistar; Reactive Oxygen Species; Succinate Dehydrogenase | 2016 |
Postcesarean section wound infection caused by Mycobacterium massiliense.
Topics: Adult; Anti-Bacterial Agents; Azithromycin; Bacterial Proteins; Cesarean Section; Chaperonin 60; Cilastatin; Cilastatin, Imipenem Drug Combination; Clarithromycin; Drug Combinations; Electrophoresis, Gel, Pulsed-Field; Female; Fluoroquinolones; Humans; Imipenem; Methyltransferases; Microbial Sensitivity Tests; Molecular Typing; Moxifloxacin; Mycobacterium Infections; Nontuberculous Mycobacteria; Pregnancy; Surgical Wound Infection; Teicoplanin | 2016 |
In Vitro and In Vivo Antimicrobial Activities of Minocycline in Combination with Azithromycin, Clarithromycin, or Tigecycline against Pythium insidiosum.
Topics: Animals; Antifungal Agents; Azithromycin; Clarithromycin; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Microbial Sensitivity Tests; Minocycline; Multivariate Analysis; Pythiosis; Pythium; Rabbits; Skin; Tigecycline | 2016 |
Use of macrolides during pregnancy and the risk of birth defects: a population-based study.
Topics: Adult; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Cohort Studies; Erythromycin; Female; Heart Defects, Congenital; Humans; Infant, Newborn; Macrolides; Penicillins; Pregnancy; Pregnancy Trimester, First; Prenatal Exposure Delayed Effects; Quebec; Registries; Risk Factors | 2015 |
Macrolides sensitize EGFR-TKI-induced non-apoptotic cell death via blocking autophagy flux in pancreatic cancer cell lines.
Topics: Apoptosis; Autophagy; Azithromycin; Cell Line, Tumor; Clarithromycin; Drug Synergism; ErbB Receptors; Erythromycin; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Macrolides; Pancreatic Neoplasms; Quinazolines | 2016 |
Analysis of drug treatment outcome in clarithromycin-resistant Mycobacterium avium complex lung disease.
Topics: Aged; Anti-Bacterial Agents; Azithromycin; C-Reactive Protein; Clarithromycin; Drug Resistance, Bacterial; Female; Humans; Lung Diseases; Male; Microbial Sensitivity Tests; Middle Aged; Multivariate Analysis; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Retrospective Studies; Risk Factors; Serum Albumin; Sputum; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
Macrolide antibiotics and the risk of ventricular arrhythmia in older adults.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Arrhythmias, Cardiac; Azithromycin; Clarithromycin; Cohort Studies; Erythromycin; Female; Humans; Logistic Models; Macrolides; Male; Ontario; Propensity Score; Retrospective Studies; Risk Assessment; Risk Factors | 2016 |
Macrolides use and the risk of sudden cardiac death.
Topics: Anti-Bacterial Agents; Arrhythmias, Cardiac; Azithromycin; Clarithromycin; Coronary Artery Disease; Coronary Disease; Death, Sudden, Cardiac; Erythromycin; Humans; Macrolides; Plaque, Atherosclerotic; Risk Factors; Torsades de Pointes | 2016 |
Reduced persistence of the macrolide antibiotics erythromycin, clarithromycin and azithromycin in agricultural soil following several years of exposure in the field.
Topics: Agriculture; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Environmental Monitoring; Environmental Pollution; Erythromycin; Macrolides; Soil; Soil Pollutants; Waste Disposal, Fluid | 2016 |
A combination of silver nanoparticles and visible blue light enhances the antibacterial efficacy of ineffective antibiotics against methicillin-resistant Staphylococcus aureus (MRSA).
Topics: Amoxicillin; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Combined Modality Therapy; Drug Combinations; Drug Synergism; Light; Linezolid; Metal Nanoparticles; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Phototherapy; Silver; Vancomycin | 2016 |
Antimicrobial Susceptibility of Microorganisms Isolated from Periapical Periodontitis Lesions.
Topics: Actinomyces; Amoxicillin; Anti-Bacterial Agents; Azithromycin; Biofilms; Campylobacter; Cefmetazole; Cephalosporins; Ciprofloxacin; Clarithromycin; Clindamycin; Drug Resistance, Bacterial; Fusobacteria; Haemophilus; Humans; Klebsiella; Microbial Sensitivity Tests; Ofloxacin; Periapical Periodontitis; Porphyromonas; Propionibacterium; Staphylococcus hominis; Veillonella | 2016 |
Macrolide Antibiotics Exhibit Cytotoxic Effect under Amino Acid-Depleted Culture Condition by Blocking Autophagy Flux in Head and Neck Squamous Cell Carcinoma Cell Lines.
Topics: Animals; Anti-Bacterial Agents; Autophagy; Azithromycin; Carcinoma, Squamous Cell; Cell Death; Cell Line, Tumor; Clarithromycin; Head and Neck Neoplasms; Humans; Macrolides; Mice | 2016 |
Emergence and molecular characterization of Haemophilus influenzae harbouring mef(A).
Topics: Anti-Bacterial Agents; Azithromycin; Bacterial Proteins; Clarithromycin; Haemophilus Infections; Haemophilus influenzae; Humans; Membrane Transport Proteins; Microbial Sensitivity Tests | 2017 |
Progression and Treatment Outcomes of Lung Disease Caused by Mycobacterium abscessus and Mycobacterium massiliense.
Topics: Aged; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Disease Progression; Female; Humans; Lung Diseases; Male; Microbial Sensitivity Tests; Middle Aged; Mycobacterium Infections, Nontuberculous; Nontuberculous Mycobacteria; Retrospective Studies; Risk Factors; Sputum; Treatment Outcome | 2017 |
PharmGKB summary: Macrolide antibiotic pathway, pharmacokinetics/pharmacodynamics.
Topics: Anti-Bacterial Agents; Azithromycin; Bacteria; Clarithromycin; Erythromycin; Humans; Macrolides; Pharmacogenetics; Signal Transduction | 2017 |
Estimation of amount of selected pharmaceuticals sorbed onto digested sludge from wastewater treatment plant Bratislava-Petržalka.
Topics: Adsorption; Anti-Bacterial Agents; Antidepressive Agents; Azithromycin; Ciprofloxacin; Citalopram; Clarithromycin; Environmental Monitoring; Sewage; Slovakia; Venlafaxine Hydrochloride; Waste Disposal, Fluid; Water Pollutants, Chemical | 2017 |
Effects of clarithromycin, azithromycin and rifampicin on terbutaline-induced sweating in foals.
Topics: Animals; Azithromycin; Clarithromycin; Horses; Rifampin; Sweating; Terbutaline | 2017 |
Therapeutic efficacy of azithromycin, clarithromycin, minocycline and tosufloxacin against macrolide-resistant and macrolide-sensitive Mycoplasma pneumoniae pneumonia in pediatric patients.
Topics: Adolescent; Anti-Bacterial Agents; Azithromycin; Child; Clarithromycin; Drug Resistance, Bacterial; Female; Fluoroquinolones; Humans; Male; Microbial Sensitivity Tests; Minocycline; Mycoplasma pneumoniae; Naphthyridines; Pneumonia, Mycoplasma; Treatment Outcome | 2017 |
Macrolides, Digoxin Toxicity and the Risk of Sudden Death: A Population-Based Study.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Atrial Fibrillation; Azithromycin; Cardiotonic Agents; Case-Control Studies; Cefuroxime; Clarithromycin; Death, Sudden; Digoxin; Drug Interactions; Erythromycin; Female; Heart Failure; Humans; Macrolides; Male; Ontario; Risk Factors | 2017 |
Reduction of non-Betalactam Antibiotics COD by Combined Coagulation and Advanced Oxidation Processes.
Topics: Anti-Bacterial Agents; Azithromycin; Biological Oxygen Demand Analysis; Clarithromycin; Hydrogen Peroxide; Hydrogen-Ion Concentration; Iron; Molecular Structure; Waste Disposal, Fluid | 2016 |
Capillary electrophoresis with capacitively coupled contactless conductivity detection method development and validation for the determination of azithromycin, clarithromycin, and clindamycin.
Topics: Azithromycin; Clarithromycin; Clindamycin; Electric Conductivity; Electrophoresis, Capillary | 2017 |
Distribution of macrolide resistance mechanisms in Bulgarian clinical isolates of Streptococcus pyogenes during the years of 2013-2016.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Azithromycin; Bacterial Proteins; Bulgaria; Child; Child, Preschool; Clarithromycin; Clindamycin; Drug Resistance, Bacterial; Erythromycin; Female; Humans; Infant; Macrolides; Male; Membrane Proteins; Methyltransferases; Microbial Sensitivity Tests; Middle Aged; Multiplex Polymerase Chain Reaction; Streptococcal Infections; Streptococcus pyogenes; Young Adult | 2017 |
Clinical significance of QT-prolonging drug use in patients with MDR-TB or NTM disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Azithromycin; Child; Clarithromycin; Clofazimine; Diarylquinolines; Female; Fluoroquinolones; Follow-Up Studies; Humans; Lost to Follow-Up; Macrolides; Male; Middle Aged; Moxifloxacin; Mycobacterium Infections, Nontuberculous; Mycobacterium tuberculosis; Nitroimidazoles; Nontuberculous Mycobacteria; Oxazoles; Retrospective Studies; Tuberculosis, Multidrug-Resistant; Young Adult | 2017 |
Appraisal of the cardiovascular risks of azithromycin: an observational analysis.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Azithromycin; Cardiovascular Diseases; Clarithromycin; Female; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Retrospective Studies; Risk Factors; Young Adult | 2017 |
Antimicrobial efficacy of drug blended biosynthesized colloidal gold nanoparticles from Justicia glauca against oral pathogens: A nanoantibiotic approach.
Topics: Anti-Bacterial Agents; Antifungal Agents; Azithromycin; Bacteria; Clarithromycin; Drug Antagonism; Fungi; Gold Colloid; Green Chemistry Technology; Justicia; Metal Nanoparticles; Microbial Sensitivity Tests; Microscopy, Electron, Transmission; Mouth; Particle Size; Plant Extracts; Plant Leaves; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; X-Ray Diffraction | 2017 |
Topics: Animals; Anti-Bacterial Agents; Azithromycin; Bridged Bicyclo Compounds, Heterocyclic; Clarithromycin; Diterpenes; Humans; Josamycin; Linezolid; Macrolides; Oomycetes; Oxazolidinones; Phosphorylcholine; Pleuromutilins; Polycyclic Compounds; Pythiosis; Pythium | 2018 |
Trends in the Minimum Inhibitory Concentrations of Erythromycin, Clarithromycin, Azithromycin, Ciprofloxacin, and Trimethoprim/Sulfamethoxazole for Strains of Bordetella pertussis isolated in the Czech Republic in 1967-2015.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Azithromycin; Bordetella pertussis; Child; Child, Preschool; Ciprofloxacin; Clarithromycin; Czech Republic; Erythromycin; Female; Humans; Infant; Male; Microbial Sensitivity Tests; Middle Aged; Trimethoprim, Sulfamethoxazole Drug Combination; Whooping Cough; Young Adult | 2017 |
Prevalence of antibiotic-resistant coliform bacteria, Enterococcus spp. and Staphylococcus spp. in wastewater sewerage biofilm.
Topics: Anti-Bacterial Agents; Azithromycin; Biofilms; Clarithromycin; Enterobacteriaceae; Enterococcus; Prevalence; RNA, Ribosomal, 16S; Slovakia; Staphylococcus; Wastewater | 2018 |
Macrolide Resistance and Its Molecular Genetic Mechanisms in Streptococcus pyogenes Isolated from Children.
Topics: Anti-Bacterial Agents; Azithromycin; Bacterial Proteins; Child; Clarithromycin; Clindamycin; Drug Resistance, Multiple, Bacterial; Ear, Middle; Erythromycin; Female; Gene Expression; Genotype; Humans; Male; Membrane Proteins; Methylation; Microbial Sensitivity Tests; Nasopharynx; Phenotype; Ribosomes; Streptococcal Infections; Streptococcus pyogenes; Vagina | 2016 |
The anti-inflammatory effects of erythromycin, clarithromycin, azithromycin and roxithromycin on histamine-induced otitis media with effusion in guinea pigs.
Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Azithromycin; Clarithromycin; Disease Models, Animal; Ear, Middle; Erythromycin; Guinea Pigs; Histamine; Otitis Media with Effusion; Roxithromycin | 2018 |
Emergence of Resistance to Macrolides and Rifampin in Clinical Isolates of Rhodococcus equi from Foals in Central Kentucky, 1995 to 2017.
Topics: Actinomycetales Infections; Animals; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Drug Resistance, Multiple, Bacterial; Equidae; Erythromycin; Feces; Horses; Kentucky; Microbial Sensitivity Tests; Musculoskeletal Diseases; Prevalence; Respiratory System; Rhodococcus equi; Rifampin; Soft Tissue Infections | 2019 |
Antibiotics in hospital effluents: occurrence, contribution to urban wastewater, removal in a wastewater treatment plant, and environmental risk assessment.
Topics: Anti-Bacterial Agents; Azithromycin; Clarithromycin; Environmental Monitoring; Hospitals; Risk Assessment; Seasons; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical | 2019 |
The Case-Crossover Design for Drug-Drug Interactions: Considerations for Implementation.
Topics: Administrative Claims, Healthcare; Azithromycin; Clarithromycin; Clopidogrel; Cross-Over Studies; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Drug Interactions; Electronic Health Records; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Implementation Science; Models, Statistical; Rhabdomyolysis; Risk Factors; Serotonin and Noradrenaline Reuptake Inhibitors; Treatment Outcome | 2019 |
Lung Tissue Delivery of Virus-Like Particles Mediated by Macrolide Antibiotics.
Topics: Allolevivirus; Animals; Anti-Bacterial Agents; Azithromycin; Capsid Proteins; Clarithromycin; Cytokines; Drug Compounding; Drug Delivery Systems; Escherichia coli; Lung; Macrophages, Alveolar; Mice; Phagocytosis; Phenotype; RAW 264.7 Cells; Tissue Distribution | 2019 |
The differential effect of clarithromycin and azithromycin on induction of macrolide resistance in
Topics: Anti-Bacterial Agents; Azithromycin; Clarithromycin; Drug Resistance, Bacterial; Gene Expression Profiling; Macrolides; Microbial Sensitivity Tests; Mycobacterium abscessus; RNA, Bacterial; RNA, Messenger; Transcriptional Activation | 2019 |
Survival benefit associated with clarithromycin in severe community-acquired pneumonia: A matched comparator study.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Azithromycin; beta-Lactams; Clarithromycin; Cohort Studies; Community-Acquired Infections; Female; Fluoroquinolones; Humans; Macrolides; Male; Middle Aged; Pneumonia, Bacterial; Treatment Outcome | 2020 |
Dissecting
Topics: Anti-Bacterial Agents; Azithromycin; Bacterial Proteins; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Humans; Macrolides; Methyltransferases; Mycobacterium abscessus; Mycobacterium Infections, Nontuberculous | 2020 |
Discontinuation rates attributed to adverse events and treatment outcomes between clarithromycin and azithromycin in Mycobacterium avium complex lung disease: A propensity score analysis.
Topics: Anti-Bacterial Agents; Azithromycin; Clarithromycin; Humans; Lung Diseases; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Propensity Score; Retrospective Studies; Treatment Outcome | 2020 |
Topics: Anti-Bacterial Agents; Antifungal Agents; Antiparasitic Agents; Azithromycin; Clarithromycin; Doxycycline; Humans; Itraconazole; Macrolides; Parasitic Sensitivity Tests; Pythiosis; Pythium; Terbinafine; Tetracyclines; Thailand | 2020 |
Antimicrobial susceptibility patterns of Rhodococcus equi from necropsied foals with rhodococcosis.
Topics: Actinomycetales Infections; Animals; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Drug Resistance, Multiple, Bacterial; Erythromycin; Horse Diseases; Horses; Microbial Sensitivity Tests; Rhodococcus equi | 2020 |
Environmental Risk and Risk of Resistance Selection Due to Antimicrobials' Occurrence in Two Polish Wastewater Treatment Plants and Receiving Surface Water.
Topics: Anti-Infective Agents; Azithromycin; Chromatography, Liquid; Ciprofloxacin; Clarithromycin; Sewage; Sulfamethoxazole; Tandem Mass Spectrometry; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical | 2020 |
A persuasive approach to antimicrobial stewardship in Christchurch hospitals produced a sustained decrease in intravenous clarithromycin dosing and expenditure via a switch to azithromycin orally.
Topics: Administration, Intravenous; Administration, Oral; Anti-Bacterial Agents; Antimicrobial Stewardship; Azithromycin; Clarithromycin; Community-Acquired Infections; Dosage Forms; Guideline Adherence; Hospitals; Humans; New Zealand; Pneumonia | 2020 |
The First Report of Macrolide-Resistant Bordetella pertussis Isolation in Japan.
Topics: Anti-Bacterial Agents; Azithromycin; Bordetella pertussis; Clarithromycin; Drug Resistance, Bacterial; Erythromycin; Genotype; Humans; Infant; Japan; Macrolides; Male; Microbial Sensitivity Tests; Multilocus Sequence Typing; Mutation; RNA, Ribosomal, 23S; Whooping Cough | 2020 |
Airway abundance of
Topics: Adult; Anti-Bacterial Agents; Asthma; Azithromycin; Clarithromycin; Haemophilus Infections; Haemophilus influenzae; Humans; Microbial Sensitivity Tests | 2020 |
Risk of Hospitalization With Hemorrhage Among Older Adults Taking Clarithromycin vs Azithromycin and Direct Oral Anticoagulants.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Dabigatran; Drug Interactions; Factor Xa Inhibitors; Female; Hemorrhage; Hospitalization; Humans; Male; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban | 2020 |
Comparative Study of the Effect of Macrolide Antibiotics Erythromycin, Clarithromycin, and Azithromycin on the ERG1 Gene Expression in H9c2 Cardiomyoblast Cells.
Topics: Animals; Anti-Bacterial Agents; Azithromycin; Carrier Proteins; Cell Proliferation; Cell Survival; Clarithromycin; Erythromycin; Gene Expression; Heart; Macrolides; Membrane Proteins; Myoblasts, Cardiac; Rats | 2020 |
Microplastics as vectors of the antibiotics azithromycin and clarithromycin: Effects towards freshwater microalgae.
Topics: Anti-Bacterial Agents; Azithromycin; Clarithromycin; Ecosystem; Fresh Water; Microalgae; Microplastics; Plastics; Water Pollutants, Chemical | 2021 |
Direct anti-biofilm effects of macrolides on Acinetobacter baumannii: comprehensive and comparative demonstration by a simple assay using microtiter plate combined with peg-lid.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Acyl-Butyrolactones; Agrobacterium tumefaciens; Anti-Bacterial Agents; Azithromycin; Biofilms; Biological Assay; Clarithromycin; Erythromycin; Fidaxomicin; Humans; Ivermectin; Josamycin; Microbial Sensitivity Tests; Microbial Viability; Quorum Sensing; Spiramycin | 2020 |
Clarithromycin use for adjunct surgical prophylaxis before non-elective cesarean deliveries to adapt to azithromycin shortages in COVID-19 pandemic.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Antibiotic Prophylaxis; Azithromycin; Cesarean Section; Clarithromycin; COVID-19; Drug Substitution; Female; Humans; Pandemics; Pregnancy; Prospective Studies; Young Adult | 2020 |
Resumption/efficacy and safety of an azithromycin-containing regimen against Mycobacterium avium complex lung disease in patients who experienced adverse effects with a clarithromycin-containing regimen.
Topics: Anti-Bacterial Agents; Azithromycin; Clarithromycin; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Pneumonia, Bacterial; Retrospective Studies; Treatment Outcome | 2021 |
Are clarithromycin, azithromycin and their analogues effective in the treatment of COVID19?
Topics: Antiviral Agents; Azithromycin; Clarithromycin; COVID-19 Drug Treatment; Humans; RNA, Viral; SARS-CoV-2 | 2021 |
Comparison of drug-susceptibility patterns and gene sequences associated with clarithromycin and azithromycin resistance in
Topics: Anti-Bacterial Agents; Azithromycin; Bacterial Proteins; Clarithromycin; Drug Resistance, Bacterial; Genotype; Humans; Macrolides; Microbial Sensitivity Tests; Mycobacterium abscessus; Mycobacterium Infections, Nontuberculous; Phenotype | 2021 |
Signal of safety due to adverse drug reactions induced by tacrolimus with or without azithromycin.
Topics: Acute Kidney Injury; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Drug-Related Side Effects and Adverse Reactions; Humans; Tacrolimus | 2022 |
Beneficial ex vivo immunomodulatory and clinical effects of clarithromycin in COVID-19.
Topics: Amoxicillin; Anti-Bacterial Agents; Azithromycin; Clarithromycin; COVID-19 Drug Treatment; Cytokines; Humans; Interleukin-2; Macrolides; Retrospective Studies; SARS-CoV-2; Spike Glycoprotein, Coronavirus | 2022 |
Synthesis and biological evaluation of antibacterial activity of novel clarithromycin derivatives incorporating 1,2,3-triazole moieties at the 4''- and 11-OH positions.
Topics: Anti-Bacterial Agents; Azithromycin; Clarithromycin; Humans; Microbial Sensitivity Tests; Molecular Docking Simulation; Molecular Structure; Staphylococcal Infections; Staphylococcus aureus; Structure-Activity Relationship; Triazoles | 2022 |
Antibiotics in the Basque coast (N Spain): Occurrence in waste and receiving waters, and risk assessment (2017-2020).
Topics: Anti-Bacterial Agents; Azithromycin; Ciprofloxacin; Clarithromycin; COVID-19; Ecosystem; Environmental Monitoring; Fluoroquinolones; Humans; Penicillins; Risk Assessment; Spain; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical | 2022 |
Outcomes of Nontuberculous Mycobacterial Keratitis After Clear Corneal Incision Phacoemulsification Surgery: A Case Series of 6 Eyes in South Florida.
Topics: Abscess; Amikacin; Azithromycin; Clarithromycin; Eye Infections, Bacterial; Florida; Humans; Keratitis; Mycobacterium Infections, Nontuberculous; Phacoemulsification | 2022 |
Predicting selection for antimicrobial resistance in UK wastewater and aquatic environments: Ciprofloxacin poses a significant risk.
Topics: Anti-Bacterial Agents; Azithromycin; Ciprofloxacin; Clarithromycin; Drug Resistance, Bacterial; Erythromycin; Humans; United Kingdom; Wastewater; Water Pollutants, Chemical | 2022 |
Determination of the Postexposure Prophylactic Benefit of Oral Azithromycin and Clarithromycin Against Inhalation Anthrax in Cynomolgus Macaques.
Topics: Animals; Anthrax; Anti-Bacterial Agents; Azithromycin; Bacillus anthracis; Clarithromycin; Disease Models, Animal; Levofloxacin; Macaca fascicularis; Respiratory Tract Infections | 2022 |
Risk ranking of macrolide antibiotics - Release levels, resistance formation potential and ecological risk.
Topics: Anti-Bacterial Agents; Azithromycin; Clarithromycin; Erythromycin; Humans; Macrolides | 2023 |
Estimating Sources, Fluxes, and Ecological Risks of Antibiotics in the Wuhan Section of the Yangtze River, China: A Year-Long Investigation.
Topics: Animals; Anti-Bacterial Agents; Azithromycin; China; Clarithromycin; Environmental Monitoring; Risk Assessment; Water; Water Pollutants, Chemical | 2023 |
A Rapid Screening Assay for Clarithromycin-Resistant Mycobacterium avium Complex Using Melting Curve Analysis with Nonfluorescent Labeled Probes.
Topics: Anti-Bacterial Agents; Azithromycin; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Humans; Leprostatic Agents; Lung Diseases; Macrolides; Microbial Sensitivity Tests; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Mycobacterium tuberculosis | 2023 |
Direct toxicity of six antibiotics on soil bacterial communities affected by the addition of bio-adsorbents.
Topics: Amoxicillin; Anti-Bacterial Agents; Azithromycin; Biomass; Ciprofloxacin; Clarithromycin; Soil; Soil Pollutants; Trimethoprim | 2023 |
Antibiotic susceptibility pattern of Portuguese environmental Legionella isolates.
Topics: Anti-Bacterial Agents; Azithromycin; Ciprofloxacin; Clarithromycin; Doxycycline; Fluoroquinolones; Humans; Legionella; Legionella pneumophila; Legionnaires' Disease; Levofloxacin; Microbial Sensitivity Tests; Portugal | 2023 |
[Pollution Characteristics and Risk Assessment of Antibiotics in Beiyun River Basin in Beijing].
Topics: Anti-Bacterial Agents; Azithromycin; Beijing; Clarithromycin; Erythromycin; Lincomycin; Ofloxacin; Risk Assessment; Rivers; Roxithromycin; Sulfapyridine; Tandem Mass Spectrometry | 2023 |
Macrolide and Ketolide Antibiotics Inhibit the Cytotoxic Effect of Trastuzumab Emtansine in HER2-Positive Breast Cancer Cells: Implication of a Potential Drug-ADC Interaction in Cancer Chemotherapy.
Topics: Ado-Trastuzumab Emtansine; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Azithromycin; Breast Neoplasms; Clarithromycin; Female; Humans; Immunoconjugates; Ketolides; Lysosomes; Maytansine; Receptor, ErbB-2; Trastuzumab | 2023 |